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Introduction:  Allosteric effectors of hemoglobin (AEH) represent a class of synthetic 
aromatic aldehydes that transiently form covalent interactions (Schiff-base) with 
hemoglobin (Hb) to form Hb-AEH adduct, preventing the HbS polymerization and 
sickling of red blood cells (RBC). The overall objective of this research was to aid in the 
optimization of novel AEH by understanding their target-site disposition of AEH in 
relevant biological matrices, e.g., HbA solution, whole blood (WB) and human liver 




Methods:  A “universal” HPLC-UV/Vis assay method was developed for the quantitation 
of HbA-AEH adduct for chemically different AEH in HbA solution and in WB. Steady-
state (SS) concentration-dependence and time- dependence HbA binding were 
characterized by a sigmoidal Bmax-model (KD) and a kinetic binding model (kon, koff). The 
Warburg method was used to assess the enzymatic oxidation of selected AEH in HLC. 
WB disposition of 5-HMF (VCU lead, terminated in Phase 2) and VZHE-039 (current top 
candidate, pre-IND) was assessed by measuring their HbA-AEH adduct in WB and 
plasma exposures. 
Results:  All vanillin-derived benzaldehydes exhibit enhanced binding affinity in HbA 
solution, primarily due to their faster kon. Across AEH, i.e., benzaldehydes and 
furaldehydes studied, kon and koff values are strongly (log-log) correlated (r=0.993, n=7), 
suggesting that the molecular modifications of the current AEH scaffold enhance their 
interactions with Hb (as intended), but also (inadvertently) increase their Hb-AEH 
adduct dissociation. 
In HLC, some AEH showed oxidative metabolism (CLint: 5-HMF < TD-7 < INN-
310 < acetaldehyde, prototypical substrate).  Presence of the meta-methoxy group (in 
TD-7) favors ALDH-mediated oxidation, while the ortho-hydroxy group (in VZHE-039) 
protects the aldehyde group/AEH from metabolism. 
In WB, Hb-AEH adduct concentrations for VZHE-039 are sustained in WB for 24 
hrs, confirming its resistance to ALDH metabolism in RBC. A less than proportional 
increase in plasma cmax, but proportional AUC along with prolonged tmax with the initial 
concentration, [VZHE-039]0, were observed for VZHE-039, indicating rate-limiting, but 
ultimately complete dissolution, prior to any HbA binding. The estimated apparent 
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binding affinity (1/KDkinetic’) for VZHE-039 in WB is 23-fold lower than observed in HbA 
solution, primarily due to a 300-fold slower apparent kon’ (Table 1). On the other hand, 
HbA-AEH adduct concentrations for 5-HMF in WB decrease after 1.5 hrs - thus 
providing conclusive evidence of rapid intra-RBC ALDH-mediated metabolism - which 
resulted in an 8-fold lower apparent binding affinity (KD’ of 3.0 mM) from concentration-
dependency study at 1.5 hrs in WB. However, after accounting for first-order 
metabolism in the WB disposition model, the KDkinetic’ for 5-HMF in WB was quite similar 
to that in HbA solution; dissociation of 5-HMF from Hb was slow and determined the 
terminal decline of HbA-AEH adduct in WB (Table 1). 
 
Table 1. Summary for VZHE-039 and 5-HMF 
  Binding in HbA Solution Binding to HbA in WB 
Metabolism in 
HLC 
AEH  KDkinetic kon koff KDkinetic’ kon’ koff’ kmet’ CLintin-vitro Km 






0.10 61 5.8 2.3 0.20 0.46 0 0 NA 
5-HMF 0.28 0.46 0.13 0.20 0.56 0.11 2.2 0.036 >90 
 
 
Conclusions:  WB disposition of AEH is determined by the kinetics of three concurrent 
processes, namely (saturable) Hb binding, (non-saturable) ALDH-mediated metabolism 
in RBC, as well as reversible, first-order PPB/RBC membrane binding. Although the KD 
value for VZHE-039 is 3-fold lower than 5-HMF in HbA solution, both compounds exhibit 
similar apparent KD’ values in WB, albeit due to different mechanisms, namely ALDH-
mediated metabolism for 5-HMF and extensive PPB/RBC membrane binding for VZHE-
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039 – both processes reducing AEH concentrations at the target site, Hb. Concurrent 
PPB/RBC membrane binding for lipophilic benzaldehydes, e.g., VZHE-039, also slows 
down their overall WB HbA adduct formation, but helps sustain them. 
Key molecular features of AEH to enhance HbA binding and reduce intra-RBC 
metabolism have been identified, allowing further rational design of more potent (in WB) 





1.1 Sickle Cell Disease (SCD) 
1.1.1 Prevalence 
Sickle Cell Disease (SCD) is a group of chronic and hereditary blood disorders 
affecting red blood cells (RBC) with the presence of at least one hemoglobin S (HbS) 
allele (Ilesanmi, 2010). SCD is caused by a monogenic mutation, where glutamate is 
replaced by valine (βGlu6 to βVal6) at the amino acid position 6 in the β-chain of HbA to 
give HbS. It is a multi-organ damage disease with high mortality and morbidity (Piel, 
Steinberg, & Rees, 2017). In contrast, people with sickle cell trait in which the person 
only has one abnormal allele of the HbS β chain have very mild symptoms of the 
disease. As a global public health problem, SCD affects approximately 100,000 
Americans, 60,000 Europeans and over 15 million people worldwide (Bender & Hobbs, 
2014). SCD is the most common among those with African heritage, and about 1 out of 
every 365 black or African American births would have the disease. In addition, SCD is 
one of the most prevalent diseases detected through neonatal blood screening (Lane et 
al., 2002). About 300,000 infants born with the abnormality are characterized by HbS 
homozygosity. The number is expected to rise to 400,000 by 2050 (Piel et al., 2017).   
Malaria parasite (plasmodium falciparum) spends part of its life cycle in RBC 
(Bender & Hobbs, 2014; Piel et al., 2017). When malaria parasite is present, the RBCs 
with defective Hb rupture prematurely to prevent its reproduction. People with HbS 
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heterozygotes seem to have increased survival from malaria(Bender & Hobbs, 2014). 
On the other hand, malaria also drives gene selection for red cell disorders including 
SCD. Therefore, higher frequency of SCD is found in areas associated with malaria, 
such as tropical regions like Sub-Saharan Africa and the Middle-East(Bender & Hobbs, 
2014).  
1.1.2 Pathophysiology 
HbA exists as solitary units whenever under oxygenated or deoxygenated 
conditions, whereas HbS molecules aggregate or polymerize under deoxygenated 
conditions leading to sickling of RBC (Bunn & Forget, 1986). The sickling process of 
RBC is due to a point mutation of A into T in the codon of the 6th amino acid of the 
human HBB gene encoding the Hb β‐chain, where GAG switches GAG into GTG, 
resulting in valine replacing glutamate (Bunn & Forget, 1986). In normal Hb (HbA), the 
negatively charged glutamic enforce the solitary integrity of the Hb molecules. 
Substitution of glutamic with the hydrophobic valine leads to aggregation or 
polymerization of the sickle molecules especially at areas of low oxygen pressure (Safo, 
Ahmed, Ghatge, & Boyiri, 2011).   
The hypoxia-driven deoxy-HbS polymerization and the concomitant RBC sickling 
process is made worse by increased levels of the allosteric effector 2,3-DPG and 
perhaps sphingosine phosphate in sickle RBCs (W N Poillon, Kim, Labotka, Hicks, & 
Kark, 1995; William N Poillon & Kim, 1990; Sun et al., 2017, 2016). HbS aggregation is 
thermodynamically unstable, and more HbS molecules will aggregate until reaching a 
critical mass, at which point the addition of any other molecules stabilizes the complex, 
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and finally facilitates the shape change of RBC into dysfunctional sickles or crescent 
moon morphologies impacting HbS O2 delivery activity (Piccin et al., 2019).  The 
progression of polymerization, in addition to 2,3-DPG is also influenced by oxygenation, 
Hb concentration, temperature, pH and saline concentration, etc (W N Poillon et al., 
1995; William N Poillon & Kim, 1990; Sun et al., 2017, 2016). 
The clustered β-chains along the RBC membrane not only damage cytoskeletal 
proteins such as band-3, spectrin and ankyrin, but also promote the deposition of IgG, 
initiate monocyte chemotaxis and lead to early clearance of aged RBC (Piccin et al., 
2019). The lifespan of normal RBC is 120-day. However, the lifespan of sickle RBC is 
no more than 20 days, which is an underlying cause of anemia in people with SCD 
(Piccin et al., 2019).  
Rivera, et al reported endothelin‐1 (ET‐1) activates Ca2+- dependent K+ channel 
(also known as the Gardos channels) (Rivera, 2007). The activation of Gardos channels 
leads to the loss of hypertonic effluent (composed of KCL or KOH) and alkaline, which 
further causes the rapid dehydration of RBCs and favors the hypoxia-induced sickling 
process(Rivera, 2007). Gardos channels play a pivotal role in pathogenesis of SCD 
because a severe and nearly irreversible dehydration can be resulted from a minimal 
activation of Gardos channels (Rivera, 2007). 
Repeated sickling decreases the elasticity of RBC membrane, preventing the stiff 
RBC to easily squeeze through blood vessels, leads to vaso-occlusion and circulation 
impairment, further causing tissue O2 deprivation and organ damages. Sickling of the 
RBC also leads to disruption of the stiff RBC membrane, releasing hemolytic products, 
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such as free Hb, arginase, adenine nucleotides and asymmetric dimethylarginine (Bunn 
& Forget, 1986). Free Hb in the plasma scavenges nitric oxide (NO) by transforming NO 
into nitrate, making this important molecule less bioavailable to the vasculature. NO is 
an important vasodilator to maintain normal vascular tone and inhibit platelet activation. 
NO depletion leads to vasoconstriction and platelet aggregation (Piccin et al., 2019). In 
transforming NO to nitrate, Hb is oxidized into methemoglobin, which readily loses 
heme group, and become unable to bind and transport O2 (Akinsheye & Klings, 2010). 
L-arginine is a source of NO and can be converted to NO by endothelial nitric oxide 
synthase. Patients with SCD tend to be L-arginine deficient due to high levels of 
arginase in plasma from hemolyzed erythrocytes. The released arginase also reduces 
arginine level in the blood, further decreasing NO level in circulation and impairing its 
vasodilation function (Akinsheye & Klings, 2010; Piccin et al., 2019).  
In summary, while SCD is a monogenic disease caused by a single pathogenic 
mutation in normal hemoglobin, its pathophysiology is multifaceted and diverse leading 
to several clinical manifestations. 
1.1.3 Clinical Manifestations 
There are four common genotypes of SCD in the United States. Patients who 
inherit two sickle cell genes (HbSS) have the most severe form of SCD (Bunn & Forget, 
1986). Patients who have HbSC genotype SCD inherit a sickle cell gene from one 
parent, and an abnormal HbC (glutamic acid at the 6th amino acid position replaced by 
lysine) gene from the other parent. Patients carrying HbSC have a milder form of SCD 
compared with those carrying HbSS (Bunn & Forget, 1986). There are two different 
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types of β thalassemia gene, “β0” or “β+”. Patients carrying β0 thalassemia gene have 
more severe symptoms of SCD than those carrying β+ thalassemia gene. Similar to 
patients carrying HbSC, those with HbS-β+ thalassemia have milder symptoms of SCD 
(Bunn & Forget, 1986). Patients who have HbAS genotype SCD carry one normal Hb 
gene from one parent, and a sickle cell gene from the other parent, which is also called 
sickle cell trait (SCT). Patients who carry SCT live a normal life and have no any 
symptom of SCD. But there is a chance that they might pass the trait or the disease on 
to their children (Bunn & Forget, 1986). 
SCD symptoms are characterized by chronic hemolytic anemia. Patients might 
manifest weakness and fatigue. Symptoms of jaundice or cholelithiasis may also be 
observed (Piel et al., 2017). Patients with SCD have a higher chance for infection 
(Booth, Inusa, & Obaro, 2010). Normal splenic functions include storing B cells, which 
produce antibodies, filtering the blood, removing damaged or old RBCs, and helping to 
clear encapsulated bacteria. However, in patients with SCD, blood flowing to the spleen 
is impeded because of obstruction by sickle cells compromising its function. In the first 
few years of life, patients with SCD have loss of function of the spleen (asplenia), 
resulting in increased susceptibility to infections with encapsulated bacteria, such as 
pneumococcus, haemophilus influenzae type b and meningococcus serogroup B, etc 
(Tamouza et al., 2002).  
Another remarkable clinical manifestation of patients with SCD is pain, a warning 
sign that is associated with vaso-occlusive events, acute or chronic complications(Bunn 
& Forget, 1986). Acute complications of SCD include acute-occlusive crisis, acute 
anemia, acute splenic sequestration, acute chest syndrome, priapism, acute renal 
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failure, fever and infection, thrombosis, stroke, hepatobiliary or ocular complications, or 
multisystem organ failure (Bunn & Forget, 1986). Chronic complications of SCD include 
chronic pain (greater than 3 months, particularly neuropathic in origin), avascular 
necrosis, leg ulcers (more common in male and older patients), renal complications 
(such as proteinuria or renal papillary necrosis),  pulmonary complications (such as 
pulmonary hypertension, obstructive sleep apnea or asthma), ophthalmologic 
complications, cholecystitis, vitamin D deficiency and fertility, etc (Bunn & Forget, 1986). 
1.1.4 Hemoglobin (Hb) 
Hb is a polyfunctional protein in RBC. The functions of Hb include O2 transport, 
catalytic reaction, nitric oxide metabolism, metabolic reprogramming, pH regulation and 
maintaining redox balance(Ahmed, Ghatge, & Safo, 2020). The X-ray crystallography 
structure of Hb was first elucidated by Max Perutz, who won a noble prize for this 
achievement(Bragg & Perutz, 1952). Hb is an allosteric tetramer protein, composed of 
two α- and β- globin chains(Ahmed et al., 2020; Bragg & Perutz, 1952). Each globin-
chain contains an iron-heme group that is capable of binding to one O2.  Hb functions 
between two conformational states - the high-affinity R-state, which binds oxygen 
(oxygenated Hb) and the low-affinity T-state which contains no oxygen (deoxygenated 
Hb) (Bunn & Forget, 1986). The high-affinity R-state consists of an ensemble of high-O2 
affinity states, including the classical R, RR2, R3, RR3 (Safo et al. 2004; Oder et al. 
2016; Ahmed et al., 2020). The O2 binding to Hb is a cooperative process, where O2 
binding to the hemes destabilize the α1 β2 interface, resulting in a allosteric transition 
from the T-state to the R-state, facilitating increase binding affinity of oxygen to all 
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hemes (Ahmed et al., 2020). This cooperative binding allows a more efficient release of 
O2 to tissue with a small decrease of partial pressure of O2.  
HbA, normal adult hemoglobin, is found to account for about 90% of total Hb in 
healthy RBC (Bunn & Forget, 1986). HbA functions normally in sensing metabolic 
activity and modulating O2 binding accordingly. However, when abnormal mutation 
happened within the α1 β2 interface, O2 binding affinity of Hb is usually altered (Thom, 
Dickson, Gell, & Weiss, 2013).  
1.2 Therapeutic Strategies for SCD  
Four medications with different mechanisms have been approved by F.D.A. for 
the treatment of SCD, including hydroxyurea (HU), voxelotor, crizanlizumab and L-
glutamine. Other strategies such as pain management, blood transfusion and infection 
prevention, etc. are also applied to alleviate the symptoms and improve the outcomes of 
patients with SCD. 
1.2.1 Hydroxyurea (Pharmacological Reactivation of Hemoglobin F (HbF)) 
HU has been used for the treatment of SCD for over two decades. HU was 
originally developed as a chemotherapeutic agent for myeloproliferative disorders. HU 
was later found to be effective for patients with SCD by significantly reducing the 
frequency of pain episodes, acute chest syndromes, hospitalization and the need for 
blood transfusion in most cases possibly due to increased fetal Hb (HbF) level 
(Charache et al., 1995; Cokic et al., 2003).  
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HbF is composed of two α and two γ subunits and produced from 10 to 12 weeks 
of gestation by erythroid precursor cells(Bunn & Forget, 1986). HbF is dominant during 
neonate (about 50% to 95%), but slowly declines through the first six months after birth. 
HbF (two α and two γ subunits) is replaced by corresponding HbA (two α and two β 
subunits) by 6 to 12 months after birth. After 12 months, only about 1% HbF remains 
except for individuals with diseases involving red blood cells.  HbA is the dominant Hb 
present throughout life. Different from the β subunit of HbA, the ᵞ subunit of HbF has 
either glycine or alanine at position 136. Both of these amino acids are nonpolar and 
neutral, that make HbF exhibit higher affinity for oxygen compared to HbA (Kaufman & 
Lappin, 2019).  
The levels of HbF increased by HU vary between 10% to 50% in patients with 
SCD depending on genotype and populations (Cokic et al., 2003; Nader et al., 2018). 
The cells containing HbF are called F cells. The effects of HbF on SCD symptoms 
depend on the HbF level in each RBC. HU not only improves the deformability of sickle 
RBC by increasing the F cells number, decreasing the production and polymerization of 
HbS, but also increasing the water contents and mean corpuscular volume (MCV) of 
RBC (Piccin et al., 2019). Cokic et al reported that HbF induced by HU is via NO-
dependent activation of soluble guanylyl cyclase (Cokic et al., 2003). The increased 
release of NO by HU improves the blood flow via vasodilation effect. HU also enhances 
blood rheology by increasing deformability of RBC and hematocrit. In addition, HU 
reduces the adhesiveness of circulating cells to endothelium by decreasing 
phosphatidylserine density on microparticles in RBC, and attenuating neutrophils (Piccin 
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et al., 2019). HU has been shown to reduce frequency of pain episodes, acute chest 
syndromes, needs for transfusion and hospitalization (Piccin et al., 2019). 
HU is offered to infants 9 months of age and older, children, adolescents and 
adults with SCD, regardless of the clinical severity based on the clinical study. HU is 
also considered for patients with HbSC and HbSβ+ thalassemia with recurrent sickle cell 
complications (Scott, Hillery, Brown, Misiewicz, & Labotka, 1996; Ware & Aygun, 2009). 
An initial dose of 10-15 mg/kg/day is used for infants younger than one-year-old with 
good creatinine clearance (CrCL > 60 mL/min). 20mg/kg/day is used as an initial dose 
for children one year of age or older with good creatinine clearance (CrCL > 60 mL/min). 
Adult may start HU on 15 to 20 mg/kg/day. The commercially available dosage forms 
are capsules, new formulation Siklos and compounded oral suspension. For dosing 
convenience, the given dose can be rounded off to the nearest 2.5 mg/kg. HU is 
excreted renally. Individuals with CrCL less than 60 mL/min or end-stage kidney 
disease exhibit higher HU exposure due to decreased renal clearance. These patients 
need to be initiate with half of HU starting dose and titrate up with smaller increments. 
The initial dose is calculated based on weight. The dose is increased approximately 
every 8 weeks by 5mg/kg daily to a maximal dose of 35 mg/kg/day or 2500 mg daily. 
The maximal tolerated dose should be maintained if not able to reach 35 mg/kg/day 
(“Disease-modifying therapies for prevention of vaso-occlusive pain in sickle cell 
disease. UpToDate, Inc. Accessed June-06,” 2020).  
The treatment goal is to have HbF level greater than 20%, and HbF levels should 
be monitored every two or three months. The complete blood count and reticulocyte 
count should be monitored every four weeks while dose is titrated up. Other lab values 
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such as platelet, RBC, MCV, HbF quantitative, renal and liver panels are also monitored. 
The common adverse effects from HU are gastrointestinal upset and darkening of nail 
beds or skin. Some patients also see symptoms of neuropenia, thrombocytopenia, 
anemia, hair thinning, teratogenicity and fertility. Bone marrow suppression is the major 
dose-limiting toxicity for HU(Ware & Aygun, 2009). HU treatment should be stopped if 
Hb level is less than 8 g/dL off transfusion, or absolute neutrophil count is less than 
2000/μL, or platelet count is less than 8000/μL, or target reticulocyte count is less than 
80,000 to 100,000/μL. The treatment is restarted at the same dose if recovery occurs 
within a week or at a lower tolerated dose (“Disease-modifying therapies for prevention 
of vaso-occlusive pain in sickle cell disease. UpToDate, Inc. Accessed June-06,” 2020). 
1.2.2 Voxelotor (GBT-440, Anti-Sickling Agent) 
Voxelotor (GBT-440) is another anti-sickling drug for the treatment of SCD. 
Voxelotor is an allosteric modifier of Hb by increasing its O2 affinity(Han, Saraf, & 
Gordeuk, 2020). GBT-440 binds to α chain of Hb and shifts the O2 equilibrium curve 
(OEC) to the left that increases the affinity of HbS for O2. This allosteric property prevent 
polymerization of HbS and  leads to inhibition of RBC sickling(Blair, 2020b; Han et al., 
2020). Voxelotor has shown to decrease RBC sickling and hemolytic biomarkers in 
clinical trials, but lack of long-term studies on its prevention of vaso-occlusion and 
decreasing frequency of pain crises and hospitalizations(Vichinsky et al., 2019).  
Voxelotor was approved by F.D.A. in November 2019 and indicated for individuals, 
whose age is equal to or greater than 12 years old with continuous pain episodes 
resulted from vaso-occlusive events despite appropriately HU dosing, or who cannot 
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tolerate HU due to severe adverse effects or any other reason(Blair, 2020b). Voxelotor 
is recommended to be administered as a single oral dose: 1500 mg once daily.  
Voxelotor can be administered together with HU. As for patients with severe liver 
impairment, the daily dose of voxelotor is reduced to 1000 mg once daily, since 
voxelotor is extensively metabolized by CYP3A4 in the liver(Blair, 2020b; Metcalf et al., 
2017). Voxelotor is both a substrate and an inhibitor of CYP3A4, and therefore, should 
be avoided to administer together with CYP3A4 inducers or inhibitors(Blair, 2020b; 
Metcalf et al., 2017). If voxelotor is concomitantly administered with other CYP3A4 
inhibitors such as fluconazole, the daily dose is supposed to be cut to 1000 mg once 
daily, too. Conversely, the daily dose of voxelotor should be increased if it is 
simultaneously taken with CYP3A4 inducers up to 2500 mg. Liver function and Hb level 
should be monitored during voxelotor administration. The common adverse effects from 
voxelotor include gastrointestinal upset such as nausea, diarrhea and abdominal pain. 
Rash, hypersensitivity and headache are also observed in some cases(Blair, 2020b; 
Metcalf et al., 2017). 
1.2.3 Crizanlizumab (Anti-Adhesion Agent) 
Crizanlizumab is a humanized IgG2 kappa monoclonal antibody(Ataga et al., 
2017). SCD pathophysiology involves adhesive interactions among RBC, endothelial 
cells and neutrophils facilitating following vaso-occlusive events(Ataga et al., 2017).  
The activation of endothelial cells recruits neutrophils, and directs them to roll on 
endothelial selectins, a family of cell adhesion molecules expressed on activated 
endothelial cells or platelets(Man et al., 2020). The selectins further induce the adhesion 
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of neutrophils to activated endothelial cells and platelets. Then adherent neutrophils 
mediate the capture of circulating RBC through a series of signaling transduction 
reactions (Ley, 2001). Crizanlizumab is a selectin blocker (Ataga et al., 2017; Blair, 
2020a; Man et al., 2020). crizanlizumab binds to P-selectin, blocks its interactions with 
corresponding ligands including P-selectin glycoprotein ligand 1 on the surface of the 
activated endothelium and platelets, then finally inhibits adhesive interactions between 
RBC, endothelial cells, platelets and neutrophils (Man et al., 2020). Crizanlizumab was 
approved by F.D.A. in November 2019.  It is recommended to be used for patients 16 
years and older with SCD, who have frequent or severe pain episodes derived from 
vaso-occlusive crisis and unresponsive to L-glutamine, hydroxyurea, or both(Blair, 
2020a). Crizanlizumab can also be taken together with hydroxyurea. According to the 
clinical study, crizanlizumab is recommended to be given at 5 mg/kg by intravenous 
infusion over 30 minutes once every 2 weeks for 2 doses (at week 0 and week 2), and 
then followed by 5 mg/kg once every 4 weeks thereafter(Blair, 2020a). The common 
adverse effects associated with crizanlizumab treatments include infusion site reactions, 
infusion related reactions, arthralgia or myalgia, abnormal platelet aggregation, 
headache, pruritis or nausea (Ataga et al., 2017).  
1.2.4 L-Glutamine (Modulator of Oxidative Stress) 
L-Glutamine is a conditionally essential amino acid and is synthesized in the 
body.   The exact mechanism of L-glutamine in patients with SCD is unknown. As a 
precursor of nicotinamide adenine dinucleotide, L-glutamine may involve increasing 
nicotinamide adenine dinucleotide, enhancing availability of reduced glutathione and 
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improving defense against oxidative stress in RBC (Cox, Hart, Kirkham, & Stotesbury, 
2020; Niihara et al., 2014). L-glutamine was approved by F.D.A. in 2017 for SCD 
children and adults with continuous pain episodes resulting from vaso-occlusive events 
despite appropriately HU dosing, or who cannot tolerate hydroxyurea due to severe 
adverse effects or any other reason(Cox et al., 2020; Niihara et al., 2014). L-glutamine 
can be taken with or without HU. L-glutamine is preferred for patients who can tolerate 
oral medication and be able to comply with twice-daily regimen. L-glutamine is given 
based on body weight. If patients with SCD are less than 30 kg, L-glutamine is given 5 g 
( 1 packet ) by mouth  twice daily; If patients with SCD are between 30 and 65 kg, L-
glutamine is given  10 g ( 2 packets ) by mouth  twice daily; If patients with SCD are 
greater than 65 kg, L-glutamine is given  15 g ( 3 packets ) by mouth  twice daily. More 
data is required to demonstrate the long-term efficacy and safety of L-glutamine. L-
glutamine is pretty safe and common adverse effects are gastrointestinal side effects 
and headache(Cox et al., 2020; Niihara et al., 2014). 
1.2.5 Pain Management (NSAIDs, Opioids) 
For patients with SCD, pain is complicated and impacted by more than just vaso-
occlusive events. Firstly, individuals with SCD should minimize or avoid specific pain 
triggers such as cold temperature, overexertion, dehydration, hormonal changes due to 
menses and respiratory exposures, for example, smoking- or air pollution-induced 
asthma exacerbation. Taking care of general health with regular exercises, nutritional 
food, sleep hygiene and stress reduction also contribute to alleviation of chronic pain in 
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patients with SCD. It is reported that about a third of patients with SCD self-medicate 
with cannabinoids to alleviate pains(Roberts et al., 2018).  
Pain management is individualized based on the underlying causes, duration, 
intensity and patients or their clinician’s concerns. Corresponding strategies should be 
applied to cope with underlying varied causes of pain. For example, patients with acute 
vaso-occlusive pain can be treated with nonsteroidal anti-inflammatory drugs 
(NSAIDs)(Roberts et al., 2018). Chronic pain associated with SCD may involve 
hyperalgesia and central sensitization. Some patients may not prefer chronic 
medications for pain management, however, patients who have severe pain on the 
majority of days may need daily opioids, such as long-acting oral morphine or 
oxycodone, etc(Roberts et al., 2018). Opioid treatment is efficacious to alleviate pains in 
SCD, but it also increases the risk of addiction and adverse effects such as respiratory 
suppression, gastrointestinal upset, developmental or hormonal changes, etc (Roberts 
et al., 2018).  
As an opioid receptor agonist, N-methyl-D-aspartate (NMDA) receptor antagonist 
and monoamine re-uptake inhibitor, methadone may have advantages over opioids with 
less addiction (Roberts et al., 2018). In addition, methadone is effective for patients with 
neuropathic pain due to NMDA antagonism (Smith & Alsalman, 2013). But methadone 
increases the risk of arrhythmia such as QTc interval prolongation (Upadhya et al., 
2013). Electrocardiogram should be monitored during methadone treatment. Regular 
transfusions may be efficacious for individuals with refractory or chronic pain 
unresponsive to above-mentioned analgesics via lowering the percentage of HbS and 
preventing following vaso-occlusive events (Piccin et al., 2019; Uwaezuoke et al., 2018). 
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Disease-modifying medications, such as HU and crizanlizumab, are also beneficial for 
pain management in patients with SCD (Ataga et al., 2017; Piccin et al., 2019).  
1.2.6 Blood Transfusion 
Blood transfusion is applied in patients with SCD to lower the amount of HbS to 
less than 30% in the body (Wahl & Quirolo, 2009). Blood transfusion is given every 3 to 
4 weeks for chronic indications, such as patients with severe or recurrent acute chest 
syndrome or patients with recurrent priapism to debilitate chronic pain, and to reduce 
risks of stroke, transient ischemic attacks and chronic organ failures (Wahl & Quirolo, 
2009).  Blood transfusion is also applied in acute conditions such as severe anemia and 
splenic sequestration. Blood transfusion is not routinely used to prevent pain. But 
patients with frequent acute or chronic pain episodes despite appropriate disease-
modifying treatments may benefit from six months duration of regular blood transfusion 
(Wahl & Quirolo, 2009). The risk of blood transfusion includes iron overload, 
alloimmunization, hyperviscosity, viral transmission and volume overload, etc (Wahl & 
Quirolo, 2009). Iron chelation agents including deferasirox, deferoxamine or deferiprone 
can be administered to treat iron overload derived from blood transfusion (Wahl & 
Quirolo, 2009). 
1.2.7 Infection Prevention  
Patients with SCD have increased susceptibility to infections with encapsulated 
bacteria and are benefit from updated immunizations with pneumococcal vaccine, 
Haemophilus Influenzae type b vaccine, meningococcal conjugate vaccine or 
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meningococcal serogroup B vaccine (Overturf, 1999). Penicillin V potassium (Penicillin 
VK) should be administered in the first five years of age in those carrying sickle cell 
HbSS or HBSβ0 thalassemia (Overturf, 1999; Sobota, Sabharwal, Fonebi, & Steinberg, 
2015). Penicillin treatment is usually discontinued at age five to complete vaccination 
series and to prevent higher rates of penicillin-resistant organisms in older children. 
Patients with splenectomy or invasive pneumococcal infection may need continuous 
penicillin prophylaxis beyond age 5 (Overturf, 1999; Sobota et al., 2015). The dosing of 
penicillin VK is based on age. Infants between 0 to 3 months administer 62.5 mg 
penicillin VK by mouth, twice daily; children less than 3 years old administer 125 mg 
penicillin VK by mouth, twice daily; Children between 3 and 5 years old administer 250 
mg penicillin VK by mouth, twice daily (Booth et al., 2010; Sobota et al., 2015).  Other 
therapeutic options include amoxicillin 20 mg/kg/day orally or bicillin 600 K units via IM 
every 4 weeks (Booth et al., 2010; Sobota et al., 2015).   
1.3 Allosteric Effectors of Hb (AEH) 
1.3.1 Mechanism of Action (MOA) of AEH 
Allosteric effectors of Hb (AEH) represents a class of synthetic small molecules 
with aldehyde as their main functional group. Aldehyde group of AEH reversibly binds to 
N-terminal of α-chain of Hb via a transiently-covalent imine linkage (Schiff-base HbA-
AEH adduct)(Ahmed et al., 2020). Several classes of these aromatic aldehydes bind 
and stabilize the R-state Hb, increasing the protein affinity for oxygen to which prevent 
HbS polymerization and concomitantly inhibit RBC sickling(Ahmed et al., 2020). For 
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example, 5-HMF (a furaldehyde) was under clinical investigation for treatment of SCD, 
however, terminated at Phase 2 clinical trial due to lack of efficacy presumably by 
extensive metabolism at target site (Oder, Safo, Abdulmalik, & Kato, 2016). The most 
predominant metabolites of 5-HMF in human was found to be 5-hydroxymethyl-2-furoic 
acid (HMFA), an inactive product formed by ALDH enzyme (Obied, 2010; Parikh, 2013). 
GBT-440 (a benzaldehydes), on the other hand, was successfully made to market for 
the treatment of SCD(Blair, 2020b). 
Besides the primary MOA on increasing O2-affinity of Hb for 5-HMF and GBT-440, 
some of the novel synthesized AEH also elicit a second O2-independent MOA that 
directly destabilize the polymerization of HbS (Oder, Safo, Abdulmalik, & Kato, 2016; 
Ahmed 2020).     Certain structure feature contributes to this second MOA. An ortho-
positioned methoxypyridine substitution relatives to the aldehyde group on the 
benzaldehyde ring allows the compound to make interaction with a surface-located αF-
helix that leads to destabilization of the HbS polymers (Oder et al., 2016). The αF-helix 
is involved in polymer stabilization and SCD patients with a rare mutation 
αAsn78→αLys78 on the F-helix show significantly fewer sickling episodes with improved 
clinical phenotype (Burchall & Maxwell, 2010; Rhoda et al., 1983). 
1.3.2 Clinical Findings of Voxelotor (GBT-440) 
As discussed in the section of therapeutic strategies of SCD, GBT-440 targets on 
Hb to increase its O2 binding affinity, resulting in inhibition of HbS polymerization and 
RBC sickling. GBT-440 belongs to the AEH family. The following physicochemical 
properties of GBT-440 were collected from Scifinder (Web-based, CAS). GBT-440 is a 
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small (MW = 337) lipophilic aromatic aldehyde (LogD7 = 4.07) (Figure 1.1). The pKa of 
GBT-440 is predicted to be 3.46 from the pyridine group and 7.67 from the phenol group. 
At physiological relevant pH of blood (pH 7.4), majority of GBT-440 are in neutral 
species. GBT-440 is sparingly soluble in aqueous phase, where the solubility is 
predicted to be 0.029 mM at pH 7 and 25 °C. 
Total of 18 clinical trials of GBT-440 were found on the ClinicalTrail.gov website. 
10 complete studies covered the regular Phase I to III studies, as well as special 
populations including pediatric, renal impairment, hepatic impairment or idiopathic 
pulmonary fibrosis (IPF) patients (“ClinicalTrials.gov.,” 2020). Drug interactions of GBT-
440 with caffeine, S-warfarin, omeprazole, or midazolam was also tested among 24 
healthy precipitants(“ClinicalTrials.gov.,” 2020). 2 clinical trials on effect of GBT-440 on 
hypoxemia in healthy volunteers and IPF patients were terminated (“ClinicalTrials.gov.,” 
2020). 6 clinical trials are still ongoing, where the majority are faced to pediatric 
population (3 studies), 1 study on the tolerability of higher dose of GBT-440 (>1500 mg), 
1 study on assessment of long-term treatment with GBT-440, and 1 new study on 
actigraphy improvement with GBT-440 (“ClinicalTrials.gov.,” 2020). 
1.3.2.1. Clinical Pharmacokinetics (PK) 
GBT-440 followed dose-proportional PK in single ascending does SAD and 
multiple ascending dose (MAD) studies within tested strength (<2800 mg) 
(Hutchaleelaha et al., 2019). Absorption is rapid with plasma level peaked at around 2 – 
4 hrs (median) when dose < 2000 mg (Hutchaleelaha et al., 2019). tmax in RBC was 
observed between 6 – 24 hrs (median) (Hutchaleelaha et al., 2019). AUC and cmax in 
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plasma, RBC, and WB (WB) proportionally increased with increasing dose (100 – 2800 
mg) (Hutchaleelaha et al., 2019). Plasma and RBC concentrations at SS were 
proportional to the increasing of dose (300, 600, 900 mg), indicating no auto-induction 
of enzyme within 118 days. In SCD patients, GBT-440 followed dose-proportional PK as 
well (500 – 1500 mg) (Hutchaleelaha et al., 2019). Inter-subject variability (%CV) for 
AUC∞ and cmax was below 22% for healthy volunteers receiving dose < 1000 mg, but 
between 22% - 36% with 2000 and 2800 mg(Hutchaleelaha et al., 2019). In SCD 
patients, %CV were below 28% in WB, but slightly higher in plasma (~35%)(Multi-
Discipline Review of Voxelotor, 2019). Dissolution may explain the larger variability at 
higher dose and delayed tmax (7 hrs) at 2800 mg(Hutchaleelaha et al., 2019). Low-fat 
breakfast showed no significant effect on GBT-440 absorption, where a high-fat meal 
increased AUC with 42% and cmax with 45%(Hutchaleelaha et al., 2019; Multi-Discipline 
Review of Voxelotor, 2019). GBT-440 is recommended to be taken with or without food 
according to the F.D.A. label.  
Steady-state was achieved at 15 days in healthy volunteers and the exposure 
was accumulated 6-fold approximately(Hutchaleelaha et al., 2019). In SCD patients, 
steady-state was reached by day 8 and around 3-fold accumulation was observed(Multi-
Discipline Review of Voxelotor, 2019). The dosing interval was the same as once daily 
across studies. The terminal decline in plasma, WB, and RBC are parallel. The terminal 
half-life in healthy volunteers was around 61 – 85 hrs, while in SCD patients was shorter 
with approximately 36 hrs, which probably due to low Hb level of SCD 




GBT-440 was highly bound to plasma protein (99.8%) in a dose-independent 
manner(Multi-Discipline Review of Voxelotor, 2019). RBC/plasma ratio calculated by 
AUC∞ were reported to range from 67:1 to 111:1 from phase I study(Hutchaleelaha et 
al., 2019). Though PPB is high, it is expected to be low affinity and high capacity, while 
Hb binding of GBT-440 is expected to be high affinity and low capacity (saturable 
binding). This High Hb binding affinity is believed to drive GBT-440 into RBC, resulting 
in a high RBC/plasma ratio. In SCD patients, blood-to-plasma ratio was reported as 15-
17 from the multi-disciplines review report of F.D.A.. The primary research data on how 
the blood-to-plasma ratio was calculated is not available, which may help to explain the 
large discrepancy on RBC partitioning of GBT-440 between healthy volunteers and 
patients.  Low Hb level in SCD patients may contribute to the lower RBC partitioning. 
Regardless, the WB disposition of GBT-440 is toward RBC rather than stay in plasma.  
In the mass balance study with a single dose of 400 mg GBT-440, 63% was 
recovered in feces including 33% as the parent compound form, indicating GBT-440 
was not well absorbed in gut or eliminate through biliary excretion(Multi-Discipline 
Review of Voxelotor, 2019). 35% (metabolites and parent compound) was recovered in 
urine, where only 0.08% excreted unchanged, indicating renal elimination for parent 
compound is negligible and the majority of GBT-440 was metabolized before excretion 
via kidney(Multi-Discipline Review of Voxelotor, 2019). Absolute oral bioavailability was 
not tested, however, from the results of its mass balance study, where majority of the 
drug was excreted unchanged in feces and only 0.08% unchanged in urine, oral 
bioavailability of GBT-440 is predicted to be low to moderate.  
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GBT-440 is metabolized primarily by CYP450, UGT, and SULT enzymes. When 
GBT-440 was co-administrated with CYP3A4 inhibitor, midazolam to healthy volunteers, 
the exposure was increased by around 75%(Multi-Discipline Review of Voxelotor, 2019). 
A PBPK model based on in-vitro metabolism and ADME studies predicted an increase 
of exposure by 73% - 100% with concomitant administration of fluconazole (moderate 
CYP3A/CYP2C9, strong CYP2C19)(Multi-Discipline Review of Voxelotor, 2019). Daily 
dose of GBT-440 is recommended to be reduced to 1000 mg when co-administrated 
with strong CYP3A4 inhibitor or fluconazole(Multi-Discipline Review of Voxelotor, 2019). 
Part of results on GBT440 on pediatric population was published in an abstract in 
a meeting of European hematology association at 2018.  6 children received single 
dose of 600 mg GBT-440 capsule, and 25 adolescents received 900 mg daily for up to 
24 weeks(Washington et al., 2018). WB and plasma concentration were collected up to 
15 days after single dose and 24 weeks for multiple dose administration. Authors 
applied a two-compartmental PK model for data analysis, and concluded as similar PK 
exposure among adolescents and adults (Washington et al., 2018). Authors also 
mentioned higher PK exposure was observed in children than adolescents(Washington 
et al., 2018). F.D.A. approved the use of GBT-440 for adolescent at the same dose 
regimen as adult (1500 mg QD). The original data supported this dosing regimen in 
adolescents has not been published yet. Regarding children, no dosing regimen was 
recommended from F.D.A., but an ongoing clinical trial on children may provide 
essential information for the approval of the use of GBT-440 in children.  
The clinical results on 16 renal impairment subjects (900 mg) are consistent to 
the findings in mass balance study, that the renal elimination of GBT-440 is a minor 
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pathway. The geometric mean of AUC0-24 and cmax in WB with renal impairment were 80% 
and 84% compared to healthy volunteers(Blair, 2020b; Multi-Discipline Review of 
Voxelotor, 2019). AUC0-24 and cmax in plasma with severe renal impairment was 60% 
and 56% compared to healthy volunteers(Multi-Discipline Review of Voxelotor, 2019). 
The lower exposure of GBT-440 in severe renal impairment subjects may due to the 
lower albumin level in plasma, which increased the unbound fraction of GBT-440 for 
hepatic metabolism. Anemia caused by severe renal impairment may also further 
increase the free GBT-440 from Hb binding for hepatic metabolism.  No dose 
adjustment is required for GBT-440 from F.D.A. for subjects with severe renal 
impairment. 
GBT-440 was studied in mild (Child-Pugh A, n = 7), moderate (Child-Pugh B, n = 
7) and severe (Child-Pugh C, n = 7) hepatic impairment subjects, as well as normal 
subjects (n = 7)(Han et al., 2020). The geometric mean ratio of the dose normalized 
AUC∞ for mild, moderate or severe hepatic impairment group to normal group were 1.14, 
1.15, and 1.90 respectively(Multi-Discipline Review of Voxelotor, 2019). F.D.A. 
recommended no dose adjustment for mild and moderate hepatic impairment, but 
reduced to 1000 mg of GBT-440 for severe hepatic impairment patients.  
1.3.2.2. Clinical Pharmacodynamics (PD) 
In the Phase I/II study (Clinical trial: GBT440-001), the primary PD endpoints at 
steady-state were p50 and p20 shift (the pO2 at 50% and 20% of Hb saturated with O2) 
and the percentage modified Hb derived from oxygen-equilibrium curve(Howard et al., 
2019; Hutchaleelaha et al., 2019). The secondary PD measurements were changes in 
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bilirubin, lactate dehydrogenase, reticulocyte counts, which were biomarkers of 
hemolysis. GBT-440 showed dose-dependent p50 and p20 decrease, indicating 
enhanced O2 binding affinity of Hb(Howard et al., 2019; Hutchaleelaha et al., 2019). 
Additionally, all hemolysis biomarkers also showed does-dependent decrease(Howard 
et al., 2019; Hutchaleelaha et al., 2019). The incidences of adverse events (AEs) were 
mild to moderate and were comparable among three arms (300, 600, 900 mg). 900 mg 
was selected for Phase III study, and a higher dose 1500 mg was designed intended to 
achieve higher efficacy.  
In the Phase III study (Clinical trial: GBT440-031), the primary PD endpoints 
were the proportion of patients achieving the change of Hb level ≥ 1 g/dL from week 24 
to baseline(Vichinsky et al., 2019). 59% of the patients (n =74) with 900 mg achieved 
the primary Hb response, while 38% in 900 mg (n = 79) and 9% in placebo (n = 76), 
regardless of HU use or anemia severity at baseline(Vichinsky et al., 2019). The 
adjusted mean changes in Hb level from week 24 to baseline was 1.1 g/dL, 0.6 g/dL, 
and -0.1 g/dL for 1500 mg, 900 mg of GBT-440 and placebo, respectively(Vichinsky et 
al., 2019).  Literature indicated an increase of Hb level is associated to decrease of 
multiorgan failure and death(Vichinsky et al., 2019). Actual effect of GBT-440 on 
morbidity and mortality among patients were not evaluated, however, a long-term 
follow-up studies are planned next(Vichinsky et al., 2019). GBT-440 reduced in 
incidences of hemolysis, indicated by the significantly decreased of bilirubin level and 
increased of the percentage of reticulocytes in 1500 mg group from week 24 to 
baseline(Vichinsky et al., 2019). Lactate dehydrogenase level and reticulocyte count 
also showed numerically but no significant decrease in 1500 mg group(Vichinsky et al., 
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2019). The incidences of acute vaso-occlusive crises were not significantly difference 
among three groups, where the percentages of participants who received blood 
transfusions during clinical trials are similar among treatment and placebo 
groups(Vichinsky et al., 2019).  Long-term effect of GBT-440 on frequency of SCD 
related complications including vaso-occlusive were planned for a Phase III extensive 
clinical trial (NCT035573882)(“ClinicalTrials.gov.,” 2020). In summary, GBT-440 showed 
a rapid directly pharmacological effect on increasing Hb level and decreasing hemolysis 
within 2 weeks and sustain to 24 weeks. The long-term effect of GBT-440 on 
improvement of vaso-occlusive crises and other SCD related complications are needed. 
The percentage of participants who reported serious AEs were low and similar among 
treatment and placebo groups(Vichinsky et al., 2019). To maximize the therapeutic 




1.4 Relevant Metabolic Enzymes  
1.4.1 Aldehyde Dehydrogenase (ALDH) 
Aldehydes are highly reactive electrophilic compounds, involved in many 
physiological and therapeutic effects, as well as cytotoxic, genotoxic, and mutagenic or 
carcinogenic problems(Vasillou, Pappa, & Estey, 2004).  Aldehydes are primarily 
detoxified through phase I enzymatic reactions.  One of the most important pathways is 
through oxidative metabolism by ALDH.  
In ALDH superfamily, sixteen genes have been identified, among which the class 
1 (ALDH-1) and class 2 (ALDH-2) are most abundantly expressed and well-
studied(Yoshida, Rzhetsky, Hsu, & Chang, 1998). Both ALDH-1 and ALDH-2 are 
homotetramers (Liu et al., 1997). ALDH-1 is mainly located in cytosol, and widely 
expressed in various tissue including liver and RBC (Vasillou et al., 2004). ALDH-2 is a 
mitochondrial enzyme, and widely expressed in various tissue with highest levels found 
in liver (Vasillou et al., 2004). AEH with the functional aldehyde group is expected to 
subject to ALDH-1 metabolism on the RBC target site. ALDH-1 in both RBC and human 
liver cytosol (HLC) share similar physical, chemical, and kinetic properties. HLC is 
selected as the biomatrix to screen ALDH-mediated metabolism for AEH(Ryzlak & 
Pietruszko, 1987).  ALDH mentioned in this research specifically referred to ALDH-1.  
The oxidation of aldehyde to the corresponding carboxylic acid by ALDH requires 
the presence of cofactor nicotinamide adenine dinucleotide (NAD+)(Liu et al., 1997). In-
vitro study showed that ALDH can oxidize a broad spectrum of both aliphatic and 
aromatic aldehydes with different binding affinities (Km)(Vasillou et al., 2004). This 
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cytosolic enzyme shows high binding affinity on retinal (Km < 0.1 μM) and acetaldehyde 
(Km < 100 μM), two prototypical substrates of ALDH(Vasillou et al., 2004). Binding 
affinity of ALDH of aromatic aldehydes are vary for substrate with different 
structures(Marchitti, Brocker, Stagos, & Vasiliou, 2008; Vasillou et al., 2004).  
1.4.2 Other Metabolic Enzymes for Aldehydes 
As discussed earlier, AEH may subject to ALDH-mediated metabolism, and HLC 
is selected as the biomatrix for the study. A typical method to characterize ALDH activity 
on a substrate is to measure NADH, the reduced form of the cofactor NAD+(Liu et al., 
1997; Marchitti et al., 2008; Vasillou et al., 2004). In HLC, other oxidative and reductive 
enzymes may also react with aldehydes with or without co-factor NAD+, including 
aldehyde oxidase (AO) and alcohol dehydrogenase (ADH)(Marchitti et al., 2008).  
AO is  a molybdenum cofactor-containing soluble enzyme, located in liver and 
other tissues, but not in RBC(Marchitti et al., 2008). AO catalyzes the oxidation of a 
broad substrate with low-specificity, including aromatic azaheterocycles and various 
aldehydes, such as benzaldehyde, retinal, pyridoxal, and vanillin (Wroczyński & 
Wierzchowski, 2000). AO has several cofactor binding sites, including iron-sulfur protein 
(2Fe-2S clusters), flavin adenine dinucleotide (FAD), and molybdopterin cofactor 
(MoCo)(Parikh, 2013). The reaction involves converting electron accepter (O2 or 
electron accepters) and water molecules (H2O) to hydrogen peroxide (H2O2), while an 
aldehyde is converted to carboxylic acid(“Uniport.org. Accessed June-01,” 2020). In-
vitro study showed the Km of AO on benzaldehyde to be 5 μM and 45 μM in the 
presence of 2,6-dichlorophenol indophenol and ferricyanide as electron acceptors, 
27 
 
respectively(Foti et al., 2016). In HLC system, without addition of electron acceptor, the 
oxidation of AO on aromatic aldehydes may have limited influence on characterization 
of ALDH-mediated metabolism for AEH.  
ADH is a dimeric-enzyme that catalyze the interconversion of alcohols and their 
corresponding aldehydes(Obied, 2010). There are seven different ADH isozymes in 
human, where three belongs to class I (ADH-1), one to class II (ADH-2), one to class III 
(ADH-3), one to class IV (ADH-7) and one to class V (ADH-6)(“Uniport.org. Accessed 
June-01,” 2020). ADH-1 and ADH-2 are cytosolic enzyme primarily expressed in liver, 
while ADH-3 is present in liver and other tissues(Obied, 2010). ADH can metabolize 
primary, secondary, and tertiary alcohols that are primarily aliphatic and to a lesser 
degree of cyclic(Obied, 2010). Ethanol is a known substrate of ADH with Km of low 
millimolar range (0.05 – 4 mM for class 1, and 30 mM for class II, IV, V)(Obied, 2010). 
Benzaldehyde is not a substrate to ADH, while the alcohol group on furan ring (e.g. 5-
HMF) has been reported to be metabolized by ADH(Obied, 2010).  In-vitro studies 
showed that in the presence of the ADH inhibitor, i.e., methylpyrazine, the oxidation of 
5-HMF was reduced in HLC(Obied, 2010). Co-factor NAD+ is required for oxidation of 
alcohols and NADH is required for reduction of aldehydes(Jelski, Zalewski, & 
Szmitkowski, 2008). ADH is present in HLC but not in RBC, which may complex the 
extrapolation of ALDH-mediated metabolism of AEH in HLC to RBC. 
Other Non-CYP450 enzymes may involve in aldehyde metabolism, including 
aldo-keto reductase (AKR) and short chain dehydrogenase/reductase (SDR)(Marchitti 
et al., 2008). AKR is present in HLC and lysosome, but need NADPH as cofactor to 
reduce aldehydes(“Uniport.org. Accessed June-01,” 2020). SDR catalyzes the reduction 
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of retinal in presence of NADPH(“Uniport.org. Accessed June-01,” 2020). Therefore, 
these enzymes will not affect the characterization of ALDH-mediated metabolism of 
AEH in HLC through measurement of NADH. 
1.4.3 Cytochrome P450 (CYP450) 
A broad spectrum of substrates can be catalyzed by CYP450 (Manikandan & 
Nagini, 2017). Many aromatic drugs covering wide therapeutic area have been 
approved to be substrates of CYP450, such as anti-virus (Darunavir, CYP3A4), anti-
histamine (Meclizine, CYP2D6), anesthetic (Ropivacaine, CYP1A2, CYP2B6, CYP3A4) 
drugs(“Drugbank.ca. Accessed June-07,” 2020). However, the specificity of CYP450 on 
aromatic aldehydes has not been systemically studied. AEH, as xenobiotic aromatic 
aldehyde, may become substrates of CYP450 in liver, where CYP450 may serve as 
important elimination pathway for AEH, but may also decrease oral bioavailability from 
first-past metabolism. AEH may also be inhibitor or inducer of CYP450, which will 
influence the elimination of other drugs that are mainly eliminated through CYP450. 
Human CYP450 are membrane-bound enzyme system found on endoplasmic 
reticulum (ER) and mitochondrion of cells that play a pivotal role in detoxification of 
xenobiotics, cellular metabolism and homeostasis(Manikandan & Nagini, 2017). 
CYP450 are hemoproteins with 400-500 amino acid residues(Manikandan & Nagini, 
2017). The typical monooxygenation reaction of CYP-450 is via incorporation of one 
oxygen into substrate (Scheme 1.1) (Manikandan & Nagini, 2017). 




Energy is required in this reaction supplied by the transfer of electrons from 
NADPH through FAD (Manikandan & Nagini, 2017). CYP450 are widely expressed in 
various tissue, mainly in liver. The classification of CYP450 based on major substrate 
class and the functions of CYP450 gene families are listed in table 1.1 and 1.2 
(Manikandan & Nagini, 2017).  
 Some CYP450 families can be inhibited by various xenobiotics, which is 
essential in therapeutic area since CYP450 are the major enzymes in metabolism of 
many drugs. The inhibition can be classified as reversible and irreversible (mechanism-
based) inhibitions. Competitive inhibitor reversibly binds to the same binding site as 
other substrate, which decreases the apparent binding affinity, characterized by Km’ of 
the substrate but does not influence the maximum rate of metabolism (vmax’). Non-
competitive inhibitor reversibly binds to allosteric site of enzyme, which reduces the vmax’ 
but has the same Km’ as no inhibitor presence. Uncompetitive inhibitor reversibly binds 
to enzyme-substrate complex, which decreases the vmax’ and increases Km’. 
Mechanism-based inhibitor covalently binds to enzyme, which reduces the amount of 
active enzyme to other substrate resulting in reduced vmax’. For the market drugs acting 
as CYP450 inhibitors, most are competitive inhibitors, which means, the elimination of 
the victim drug is reduced in presence of these inhibitor (perpetrator drugs), a lower 
dose of victim drug is needed to prevent toxic accumulation of drug in 
body(“FDA.gov/drugs/drug-interactions-labeling [online]. Accessed June-07,” 2020). 
Some prototypical CYP450 substrates serve as probes to test inhibitors in drug-drug 
interaction studies, for example, midazolam (CYP3A4), warfarin (CYP2C9), omeprazole 
(CYP2C19), and caffeine (CYP1A2), metoprolol (CYP2D6), and rosiglitazone 
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(CYP2C8)(“FDA.gov/drugs/drug-interactions-labeling [online]. Accessed June-07,” 
2020).  
Some CYP450 can also be induced by drugs through transcription factors, such 
as aryl hydrocarbon receptor (AhR) for CYP1A1, CYP1A2, and CYP1B1, pregnane 
nuclear receptor (PXR) for CYP3A, constitutive androstane receptor (CAR) for 
CYP2B(Manikandan & Nagini, 2017). Unlike inhibition effect that can be seen rapidly 
after inhibitor is onboard, induction of enzyme is much slower through modification of 
gene, followed by the level change of mRNA and the production of CYP450 enzymes. 
When CYP450 is induced, the corresponding substrate concentration is reduced, in 
order to achieve the same therapeutic effect, a larger dose of victim drug is needed to 





Table 1.1. Classification of CYP450 based on major substrate class. 
Class of Substrates  CYP450 Enzymes 
Sterols  
1B1, 7A1, 7B1, 8B1, 11A1, 11B1, 11B2, 17A1, 19A1, 
21A2, 27A1, 39A1, 46A1, 51A1 
Xenobiotics  
1A1, 1A2, 2A6, 2A13, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 
2E1, 2F1, 3A4, 3A5, 3A7 
Fatty acids  2J2, 4A11, 4B1, 4F12 
Eicosanoids  4F2, 4F3, 4F8, 5A1, 8A1 
Vitamins  2R1, 24A1, 26A1, 26B1, 26C1, 27B1 
Unknown  
2A7, 2S1, 2U1, 2W1, 3A43, 4A22, 4F11, 4F22, 4V2, 
4X1, 4Z1, 20A1, 27C1 
 
 
Table 1.2. Functions of CYP450 gene families. 
CYP450 Family  Functions 
CYP1-4  Biotransformation of xenobiotics, chemicals and drugs 
CYPs 5 and 8  Thromboxane and prostacyclin biosynthesis 
CYPs 11, 17, 19, and 21  
Hydroxylations required for the biosynthesis of bile 
acids, activated vitamin D3, and cholesterol 






2. HYPOTHESES, SPECIFIC AIMS, AND SIGNICANCE 
2.1. Hypotheses 
Allosteric effectors of hemoglobin (AEH) represent a class of synthetic aromatic 
aldehydes for the development of therapeutic use in Sickle Cell Disease (SCD). AEH 
have been shown in-vitro and in-vivo to bind to Hb in a transiently-covalent manner, 
increasing oxygen binding affinity of Hb and decreasing hypoxia-induced sickle Hb (HbS) 
polymerization(Oder et al., 2016). The main objectives of this research are 1). To 
understand the primary mechanism of action (MOA) of the AEHs, by fully characterizing 
concentration- and time-dependent profiles of selected AEH binding to Hb. Compounds 
with large structural and functional diversity were selected for structure-activity 
relationship (SAR) study. 2). To investigate their ALDH susceptibility; and 3). To 
integrate the underlying disposition mechanisms of WB (WB) using quantitative kinetic 
models. Therefore, the hypotheses of this research are as follows: 
1) AEH exhibit concentration- and time-dependent binding to Hb. Due to the 
absence of metabolic enzymes in HbA solution, all AEH are expected to achieve 
steady-state and sustain Hb-AEH adduct level in HbA solution. Specific structural 
modifications of AEH affect their Hb binding affinity and binding kinetics. 
2) Since the primary mechanism of action (MOA) involves aldehyde functional 
group of AEH and ALDH is known to be present in red blood cell (RBC), AEH 
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can undergo ALDH-medicated metabolism. Specific structural modifications of 
AEH can reduce ALDH-medicated metabolism at target site (RBC). 
3) Since human liver cytosol (HLC) and RBC share the same isoform of ALDH-1 
enzyme. In-vitro metabolic findings in HLC are expected to be translatable to in-
vitro RBC metabolism for AEH. 
4) AEH bind to Hb in a concentration- and time-dependent manner in WB. Several 
processes including plasma protein binding (PPB), red blood cell membrane 
binding/crossing, ALDH-mediated metabolism in RBC, may affect their WB 
binding kinetics and decrease apparent binding affinity in WB.  
5) AEH with no evidence of in-vitro ALDH-mediated metabolism can achieve 
steady-state and sustain Hb-AEH adduct levels in WB. Whereas AEH that 
undergoes in-vitro ALDH-mediated metabolism, the Hb-AEH adduct levels in WB 
will decrease after a peak and steady-state cannot be achieved. 
2.2. Specific Aims 
To address the objectives and hypotheses listed in section 2.1, the following specific 
aims are proposed: 
Specific Aim 1: Characterize, assess and compare concentration- and time-
dependent Hb binding of AEHs in HbA solution. 
1) Develop and validate a universal LC-UV assay method to quantitate Hb-AEH 
adduct in HbA solution.  
2) Investigate in-vitro time- and SS concentration-dependent Hb binding of selected 
AEH in HbA solution with optimized experimental conditions.  
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3) Develop quantitative kinetic and SS models to fit experimental data and obtain 
relevant parameters. Characterize and compare the HbA binding profiles among 
different AEH, and select AEH with high HbA binding affinity and fast binding 
kinetic for further testing in WB. 
4) Conduct SAR studies on Hb binding affinity and binding kinetics of AEH to 
provide information on molecular design for future drug development.   
Specific Aim 2: Characterize, assess and compare in-vitro metabolism of AEH in 
human liver cytosol (HLC)  
1) Verify ALDH-enzyme activity in HLC using the prototypical substate, 
acetaldehyde. Monitor the UV/Vis absorption interference of AEH on 
measurement of co-factor of NADH formation.  
2) Characterize in-vitro metabolism of AEH in HLC, assess and compare ALDH-
mediated metabolism among selected AEH.  
3) Select AEH that are resistant to the ALDH-mediated metabolism in HLC for 
further testing in WB disposition studies.  
Specific Aim 3: Characterize the in-vitro WB disposition of the selected AEH. 
1) Develop and validate a universal LC-UV assay method to quantitate Hb-AEH 
adduct in WB.  
2) Develop and validate a LC-UV assay method to quantitate the selected AEH in 
plasma. 
3) Characterize in-vitro WB disposition of selected AEH and compare to its binding 
in HbA solution.  
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4) Characterize and compare Hb-AEH adduct binding profiles of selected AEH with 
5-HMF in WB.  
5) Develop quantitative PK/PD model to characterize HbA-AEH adduct binding 
kinetics and to integrate the underlying WB disposition mechanisms of selected 
AEH. 
2.3.  Significance 
SCD is characterized primarily by a chronic, severe hemolytic anemia, leading to 
vascular occlusion, tissue infection, painful “crises” and, eventually, and chronic organ 
damage(Piel et al., 2017). Both life-quality and life-span are extensively affected by this 
chronic disease. On the average, life expectancy of SCD patients is reduced by about 
30 years(Bunn & Forget, 1986). Based on a 2017 review, approximately 100,000 people 
live with SCD in the United States, and 300,000 babies are born with SCD per year 
worldwide(Piel et al., 2017).  
Common clinical management includes administration of analgesics and blood 
transfusions for symptom relief. Four F.D.A.-approved drug treatment options are 
available for SCD, including hydroxyurea, voxelotor (GBT-440), crizanlizumab and L-
glutamine. Noticeably, voxelotor is an AEH that targets Hb and prevents hypoxia-
induced HbS polymerization and RBC sickling by increasing O2 binding affinity of Hb 
(Vichinsky et al., 2019). Nonetheless, F.D.A. approval of voxelotor for SCD was based on 
significantly increased Hb levels and reduced hemolysis in patients, considered to be 
clinically relevant, rather than pertinent long-term clinical outcomes(Multi-Discipline Review 
of Voxelotor, 2019; Vichinsky et al., 2019). Moreover, as the first approved therapy 
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targeting the Hb in SCD, Voxelotor is very costly. Global Blood, the company 
discovered voxelotor, set a list price of $10,417 a month for the drug. To give health 
provider multiple choices of AEH, and reduce the current high cost of the only approved 
AEH, and aid in future development of potentially more effective AEH drug candidates 
with better PK/PD properties, several in-vitro studies on screening novel synthetic AEH 
were conducted in this research. 
AEH has been studied over 30 years. Prior to voxelotor clinical trials, the VCU lead 
compound, 5-HMF successfully passed Phase I study, but failed at Phase II due to poor 
PK properties. Our group has discovered a new class of novel AEH with the same MOA 
of O2-dependent anti-sickling activity as 5-HMF and voxelotor.  Some of these 
compounds exhibit an additional mechanism of anti-sickling activity by directly 
destabilizing HbS polymerization. This novel oxygen-independent anti-sickling MOA is 
due to the compounds interacting with the surface-located F-helix (Abdlumalik, D67, 
920–928 (2011)). Crystal structures of these novel AEH have been published to explain 
their MOA on atomic level (Oder et al., 2016; Pagare et al., 2018). Despite these studies, 
no systematic studies have been performed on their in-vitro time- and SS concentration-
dependent binding with the primary target Hb, as well as their in-vitro ALDH-mediated 
metabolism. This is the first study to fully characterize and understand kinetic binding of 
AEH to Hb, and discover the underlying SAR, which is beneficial for guiding future 
molecular design.  It is also essential to assess the role of ALDH-enzyme to in-vitro 
metabolism of selected AEH, which when combined with the Hb binding study can 
provide early screening for selecting promising AEH candidates for further development.  
In this research, we use experimentally and quantitatively modeling approach to 
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understand AEH primary binding to Hb, metabolic stability in HLC and the disposition 





3. IN-VITRO SS CONCENTRATION- AND TIME-DEPENDENCY OF HBA-AEH 
ADDUCT FORMATION IN HBA SOLUTION 
3.1 Introduction 
As discussed in Chapter 1 of the introduction section, AEH bind “transiently 
covalently” via Schiff-base reaction with α globin chains of Hb in RBC that formed Hb-
AEH adduct to increase O2 - affinity of Hb, decrease polymerization of HbS and inhibit 
RBC sickling.  The Schiff-base reaction has been reported to be a concentration- and 
time-dependent binding based on the previous studies with 5-HMF (Obied, 2010; Parikh, 
2013). 5-HMF binding to Hb in HbA and HbS solutions has been studied using an 
HPLC-UV/Vis ultrafiltration assay to determine free 5-HMF concentration, which 
decreased in a concentration- and time-dependent manner in Hb solution (Obied, 2010; 
Parikh, 2013).  Endogenous moiety, e.g. glucose, has also been reported to bind to Hb 
via Schiff-base reaction in a concentration- and time-dependent manner (Ge & Lee, 
1997). The formed Schiff-base further undergoes Amadori rearrangement to form 
HbA1C, which is used widely in clinic as a surrogate endpoint and diagnose for diabetes. 
Unlike 5-HMF, where dissociation from Hb is slower than association to Hb, glucose is 
found to be 1,000 times slower in associating to Hb than dissociating, followed by 
Amadori rearrangement (Ge & Lee, 1997; Parikh, 2013).  
Isolated HbA solution instead of HbS is normally the matrix used for 
characterizing AEH binding to Hb because of easy accessibility. HbS differs from 
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normal HbA by only a single base substitution (mutation) of the (polar) β6-glutamic acid 
by the neutral amino acid, valine (Bunn & Forget, 1986). The overall fold of both HbA 
and HbS structures are identical with only minor localized structural differences at the 
βVal6 mutation site (Safo et al., 2011). AEH is known to bind to the N-terminal Val1 
nitrogen on α-subunits of the Hb molecule, which is identical in HbA and HbS. It is 
expected therefore that the binding kinetics of AEH to HbA and HbS are similar. 
Previous results on 5-HMF support this hypothesis, where the estimated binding 
affinities are almost identical (KD HbS = 0.13 mM (17%); KD HbA= 0.18 mM (4%)) with only 
slight intrinsic kinetic differences between HbA and HbS solution (kon = 0.27 ± 0.03% 
and 0.83 ± 0.13% mM-1hr-1, respectively, and koff= 0.05 ± 0.01% and 0.1 ± 0.04% hr-1, 
respectively).   
Various analytical methods has been reported for 5-HMF quantification in both 
non-biological and biological matrices (Abdulmalik et al., 2005; Driffield et al., 2005; 
Menez et al., 1984; Michail et al., 2007; Obied, 2010; Standefer & Eaton, 1983). More 
recently, LC-MS/MS was reported for quantification of 5-HMF in biological matrices, with 
the advantages of improved detection limit, not having to deal with absorption 
interference compared to UV detection, and identification of multiple interest of analytes 
in complex system (Hardt-Stremayr et al., 2012; Lin et al., 2008; Zhang et al., 2012).  
However, besides the high cost involved in LC-MS system, it also requires more tedious 
sample preparation processes.   
In this study, we aimed to characterize the binding kinetics of AEH to Hb, either 
via quantification of AEH or Hb / Hb-AEH adduct. Since Hb solution is a relatively clean 
matrix with little UV/Vis absorption interference after ultrafiltration process, our previous 
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lab members developed an HPLC-UV/Vis assay method on 5-HMF (reference assay 
method). This involves, first reacting 5-HMF with Hb and passing through a filter with a 
cutoff 10 kD, and then determining free 5-HMF concentration using with a C18 column. 
Unfortunately, this ultrafiltration method is not applicable to compounds with high non-
specific membrane binding on filter, including lipophilic AEH, e.g. INN-312, a 
benzaldehyde (Parikh, 2013). Unlike 5-HMF (cLogP = - 0.1), most of the AEH selected 
in this research are lipophilic compounds (cLogP =1.3 - 3.5) that are expected to highly 
bind to the filer membrane. Therefore, the previous reference assay method is not 
suitable for novel selected lipophilic AEH, necessitating the development of a new 
analytical method.   
A novel “universal" assay method was designed that allows measurement of Hb-
AEH adduct of chemically different AEH, rather than individual AEH molecule, thus 
allowing its use across a series of AEH (furaldehydes and benzaldehydes).  This 
method involves a weak cation-exchange HPLC-UV/Vis assay to separate HbA-AEH 
adduct from free Hb.  Similar analytical methods have been used to readily separate 
and quantify various Hb from RBC lysates, as well as for qualitative screening of Hb 
variants, with the benefits of high efficiency and little sample preparation time (Kutlar, 
Kutlar, Wilson, Headlee, & Huisman, 1984; Ou, C.-N., & Rognerud, 1997; Ou, Buffone, 
& Reimer, 1983). Cation-exchange HPLC has also been used for  kinetic analysis of 
glycated Hb, aspirin-acetylated Hb and acetaldehyde Hb-adducts (Itala, Seppa, 
Turpeinen, & Sillanaukee, 1995; Turpeinen, Stenman, & Roine, 1989). The separation 
of Hb variants and Hb-adducts is based on their different isoelectric point (pI), as well as 
the different pH and ion concentrations of mobile phases. In our assay, AEH modified 
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Hb (Schiff-base Hb-AEH Adduct) decrease the pI of Hb, i.e. becomes more anionic than 
the free Hb, which allows the separation from free Hb (Adducts, Zaugg, Walder, & Klotz, 
1977). 
A library of ten structurally different AEH  (5-HMF, 2,5-DMF, vanillin, TD-8, TD-9, 
TD-7, INN-310, PP-14, VZHE-039, and GBT-440, Figure 3.1) were selected for their 
HbA binding kinetic characterization, based on their varying in-vitro functional and anti-
sickling effects. WB obtained from SCD patients were incubated with each AEH 
separately for 2 hrs, where the % Hb-AEH adduct formation and % sickling inhibition 
were measured (Abdulmalik, 2018). All tested AEH (n = 8) showed concentration-
dependent HbS adduct formation (Figure 3.2). Three AEH (VZHE-039, PP-14, and INN-
310) were chosen for their potently modifying HbS (100% HbS-AEH adduct) at 2 mM 
(Pagare et al., 2018). Three isomers (TD-7, TD-8, TD-9) were chosen because of their 
different HbS binding profiles(Deshpande et al., 2018), which may due to different 
primary target (Hb) binding affinity and/or binding kinetics, as well as ALDH-mediated 
metabolism that reduced AEH concentrations in RBC. Vanillin, the parent compound of 
the eight chosen benzaldehydes, was included as negative control. GBT-440 (voxelotor), 
currently approved for the treatment of SCD was chosen as the positive clinical 
reference (Han et al., 2020; Multi-Discipline Review of Voxelotor, 2019). Two 
furaldehydes, i.e., 5-HMF and 2,5-DMF were included to cover VCU lead compound 
and enlarge structural variability for SAR study (Xu et al., 2017).  
The functional/biological results described above for the 10 selected in WB were 
lack of kinetic binding information. In addition, the WB environment cannot distinguish 
the underlying mechanisms that result in different Hb binding profiles, which include Hb 
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binding kinetic, ALDH-mediated metabolism, PPB, and/or RBC membrane 
binding/partitioning. This chapter is aimed to study AEH binding to the primary target, 
i.e., Hb, to characterize their binding kinetics. SS concentration-dependency studies 
were designed to estimate the primary binding affinity and capacity, as well as time-
dependency studies for characterization of kinetic reactions via the estimation of the 





Figure 3.1. Structure of selected AEH. 
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Figure 3.2. AEH selection:  in-vitro concentration-dependency of HbS-AEH adduct 
formation in SCD WB at 2 hrs. Smooth lines connected the experimental data 






3.2.1 Materials and Reagents 
1. NERL® high purity water (Fisher Scientific, Nazareth, PA) 
2. Bis-tris (Sigma-Aldrich, St.Louis, MO) (209.24 g/mol) 
3. Potassium cyanide (Sigma-Aldrich, St.Louis, MO) (KCN, 65.12 g/mol) 
4. Sodium chloride (Sigma-Aldrich, St.Louis, MO) (NaCl, 58.44 g/mol) 
5. HbA solution (isolated and concentrated by Dr. Martin Safo’s lab, Department 
of Medicinal Chemistry, VCU) (12.60 g/dL) 
6. AFSC Hemo Control (Cat. No. 5331) (Helena laboratories, Beaumont, TX) 
7. Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
8. Hydrochloric acid, ACS 37% (Sigma-Aldrich, Milwaukee, WI) (HCl ,36.46 
g/mol) 
9. Sodium cyanoborohydride (sigma-aldrich, St.Louis, MO) (NaBH3CN, 62.84 
g/mol) 
10.  Sodium borohydride (sigma-aldrich, St.Louis, MO) (NaBH4, 37.84 g/mol) 
11. 5-Hydroxymethyl-2-furfural (5-HMF) (Sigma, St. Louis, MO) (126.11 g/mol) 
12. 2,5-Furandicarboxaldehyde (2,5-DMF) (Sigma-Aldrich, Milwaukee, WI) 
(124.09 g/mol) 
13. TD-7 (provided by Dr. Martin Safo, Dr. Yan Zhang, Department of Medicinal 
Chemistry, VCU) (273 g/mol) 
14. TD-8 (provided by Dr. Martin Safo, Dr. Yan Zhang, Department of Medicinal 
Chemistry, VCU) (273 g/mol) 
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15. TD-9 (provided by Dr. Martin Safo, Dr. Yan Zhang, Department of Medicinal 
Chemistry, VCU) (273 g/mol) 
16. INN-310 (provided by Dr. Martin Safo, Dr. Yan Zhang, Department of 
Medicinal Chemistry, VCU) (243 g/mol) 
17. VZHE-039 (provided by Dr. Martin Safo, Dr. Yan Zhang, Department of 
Medicinal Chemistry, VCU) (259 g/mol) 
18.  Vanillin ReagentPlus® 99% (Sigma, St. Louis, MO) (152.15 g/mol) 
19.  PP-14 (provided by Dr. Martin Safo, Dr. Yan Zhang, Department of Medicinal 
Chemistry, VCU) (287 g/mol) 
20.  GBT-440 (Voxelotor, 337.37 g/mol) (MedChemExpress, NJ) 
21. Dimethyl sulfoxide (DMSO), ≥ 99.9%, A.C.S. Reagent (Sigma-Aldrich, 
Milwaukee, WI) (78.13 g/mol) 






1. 96-well deep plate (Thermo Scientific, Nazareth, PA) 
2. Incubator (Thermo Fisher Scientific Inc., Pittsburgh PA) 
3. ABL800 FLEX blood gas analyzer (Radiometer America, Inc., Westlake, OH) 
4. HPLC Water 2695 (Waters, Milford, MA) 
5. Photodiode array detector 2996 (Waters, Milford, MA) 
6. Poly CATA weak cation-exchange column, 30 mm x 4.6 mm (PolyLC, Inc., 
Columbia, MD)  
7. Supelco® Pre-column Filter 0.2 μm (Sigma-Aldrich, St.Louis, MO)  
8. Durapore® membrane filter, 0.22 μm (Sigma-Aldrich, St.Louis, MO) 
9. 9 mm autosampler Insert (VWR, West Chester, PA) 
10. 9 mm autosampler Insert (Thermo Fisher Scientific Inc., Pittsburgh PA) 
11. 9 mm autosampler vail (Waters, Milford, MA) 
12. 9 mm autosampler vail cap (Thermo Fisher Scientific Inc., Pittsburgh PA) 
13. Vacuum filtration apparatus (assembled, department of MedChem, VCU) 
14. Empower 2 software (Waters, Milford, MA) 
15. Scientist®, version 3.0 (Micromath Software) 
16. pH Meter (Fisher Scientific, Pittsburgh, PA) 
17. Vortex (Vortex-Genie, VWR, West Chester, PA). 
18. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
19. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA). 
20. 30 – 300 µL multichannel pipette (Fisher Scientific, Hanover Park, IL) 
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21. 3-25 µL positive displacement pipette and corresponding pipette tips (Rainin 
Instruments, Oakland, CA). 
22. 10-100 µL and 100-1000 µL VWR pipettes and corresponding pipette tips 





3.2.3 Preparation of Solutions 
1. HbA solution 
Concentrations of purified isolated human HbA solution were determined by 
using automated blood gas analyzer (Radiometer America, Inc., Westlake, OH). HbA 
stock solution was then diluted with HPLC grade water to achieve the designed 
experimental nominal concentrations (0.2 or 0.1 mM).  
 
2. NaBH3CN and NaBH4 solution (stopping solution)  
10 mg NaBH3CN was dissolved into 3 mL of water to make 50 mM NaBH3CN 
solution. 10 mg of NaBH4 was dissolved into 5 mL of water to make 50 mM NaBH4 
solution. NaBH3CN/NaBH4 mixture (1:1 v/v) stock solution was freshly made every day 
to stop the Schiff-base reaction and reduce unreacted aldehydes for kinetic 
measurement of HbA-AEH adduct (Deshpande et al., 2018). 50 μL was added to each 
sample collection tube and kept on ice ready for use. 
 
3. AEH solution 
AEH was dissolved in DMSO to make 100 mM stock solution. Different volume of 
stock solution was added to 96-well plate to achieve designed final initial nominal 
concentration of AEH ([AEH]0) in the 96-well. Necessary pilot studies for some AEH 
were performed to determine [AEH]0 range for definitive studies. Final concentrations of 




4. Mobile phases 
Buffer A (20 mM Bis-Tris, 2 mM KCN, pH 6.5) and buffer B (20 mM Bis-Tris,2 
mM KCN, 200 mM NaCl, pH 6.6) were prepared with HPLC grade water, and adjusted 
pH with HCl. 8.37 g Bis-Tris, 0.26 g KCN were dissolved in 2000 mL water to make 
Buffer A. 8.37 g Bis-Tris, 0.26 g KCN, and 23.38 g NaCl were dissolved in 2000 mL 
water to make Buffer B. Both mobile phases were filtered through a membrane filter 




3.2.4 Sample Preparation and Experimental Design  
3.2.4.1 Sample Preparation 
For each AEH, varying [AEH]0 were added to HbA solution (0.2 mM or 0.1 mM) in 
a 96-well plate and incubated at 37 ºC along with mild shaking.  After AEH addition, 
aliquots were taken at different time intervals until SS achieved. NaBH3CN/NaBH4 was 
added to and well mixed with aliquots (V:V = 1:1) to terminate the Schiff-base reaction, 
fixate the Hb-adduct and reduce the free reactive aldehydes from the mixture 
(Deshpande et al., 2018).  Samples were immediately frozen and kept at -80 ºC. For 
HPLC analysis, samples were thawed on ice, well mixed and then transferred to HPLC 
vails. Samples were kept at 4 ºC during HPLC analysis.  
3.2.4.2 Pilot Experimental Design for SS Concentration- and Time-Dependency of 
HbA-AEH Adduct Formation in HbA Solution 
Pilot studies were performed to optimize [AEH]0 range and sampling schedule for 
definitive studies, as well as to provide information of initial parameter estimates for SS 
concentration- and time-dependency modeling. Two SS concentration-dependent 
models, which are hyperbolic and sigmoidal Bmax-model were compared based on their 
goodness-of-fit for 5-HMF, TD-7 and VZHE-039.  
Concentrations and sampling schedule for each AEH were designed either from 
visual inspection of the previous in-vitro SCD WB binding studies of AEH (Figure 3.2), 
the known HbA binding kinetics of other AEH, or literatures.  For example, 12% of HbS-
AEH adduct was observed when 2 mM of [vanillin]0 incubated with WB from SCD 
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patients for 2 hrs (Figure 3.2). When compared among tested AEH, vanillin appeared to 
behave more like a less potent and a slow kinetic AEH, like 5-HMF (28% HbS 
modification). Therefore, 0.44 – 5.8 mM of vanillin were studied up to 27 hrs based on 
the study design of 5-HMF (Parikh, 2013).  
In-vitro studies showed that 1 mM and 2 mM of [VZHE-039]0 resulted in 60% and 
100% of HbS modification in WB, respectively (Figure 3.2).  Concentration- and time-
dependency binding suggested that VZHE-039 may be similar to TD-7, with fast and 
potent Hb binding (Deshpande et al., 2018). Therefore, a concentration range of 0.01 
mM to 1 mM was chosen for VZHE-039, and aliquots were collected every 6 mins at 
early time points to capture its fast kinetics at earlier reaction time, followed by every 
half to one hour till 3.5 hrs. 
Due to the lack of in-vitro Hb binding data on GBT-440, a large concentration 
range of 0.1 – 12.5 mM was designed with few aliquots collection (0.03, 0.5, 1, 3 hrs). 
3.2.4.3 Definitive Experimental Design for SS Concentration- and Time-
Dependency of HbA-AEH adduct Formation in HbA Solution 
Based on the pilot studies, preliminary data, literatures and rational designs 
(Deshpande et al., 2018; Parikh, 2013), the final [AEH]0 range and sampling schedule 
were designed to cover the full SS concentration- and time-dependent HbA binding 
profiles of AEH (Table 3.1).  
For example,  free concentrations of 5-HMF in presence of HbA has been found 
to decline and approached equilibrium within 24-30 hrs, with a binding affinity of 0.25 
mM (Parikh, 2013). Therefore, 5-HMF was designed to cover concentration range from 
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0.06 to 4 mM with aliquots collection up to 24 hrs. 2,5-DMF, another furaldehyde, 
showed enhanced in-vitro apparent binding affinity than 5-HMF in WB (Figure 3.2); 
therefore, lower concentrations (0.025, 0.05, 0.1 mM) were designed compared to 5-
HMF. 
Since 100% HbA modification was not achieved with 5.8 mM of vanillin from pilot 
study, higher [vanillin]0 up to 20 mM (about 10-fold higher than the estimated KD = 1.7 
mM from its pilot study) was designed in the definitive study.  
TD-7, TD-8, and TD-9 are isomers, however major difference in their ability to 
induce Hb-AEH adduct formation in SCD blood have been reported (Figure 3.1) 
(Deshpande et al., 2018). At 2 mM, TD-7 showed 66% HbS modification, whereas TD-8 
and TD-9 only showed 18% and 43%, respectively, in WB. Therefore, more condense 
sampling were scheduled up to 5 hrs for TD-7 and covered lower [TD-7]0. In contrast, 
aliquots were collected up to 24 and 27 hrs for TD-8 and TD-9, respectively and higher 
[TD-8]0 and [TD-9]0 (2 and 4 mM) were studied. In-vitro HbS binding kinetics of INN-310 
in WB was more like TD-7 than other AEH; therefore, similar concentration and time-
dependency study were designed for both compounds (Table 3.1) (Deshpande et al., 
2018). 
In-vitro studies showed that 1 mM and 2 mM of PP-14 resulted in 44.4% and 
90.8%  of inhibition of cell sickling, respectively (Safo et al., 2019). PP-14 may behave 
more like fast and potent binding compound, such as TD-7. Therefore, concentration 
range of 0.02 mM to 2 mM were chosen, and aliquots were collected up to 4 hrs, 
according to the experimental design of TD-7. 
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Unlike other AEH where their kinetic profiles can be characterized with 0.2 mM 
HbA, VZHE-039 achieved SS fast (< 6 mins). Therefore, 0.1 mM of HbA was used for 
VZHE-039 in definitive study to slow down the overall kinetics. Condense sampling 
schedule (every 3 mins) was designed in order to capture the kinetics at early reaction 
time to optimize parameter estimates.  
According to the pilot study of GBT-440, SS was observed to be achieved almost 
instantaneously. High GBT-440 concentrations show possible secondary reactions with 
evidence of new peaks observed on chromatogram after long incubation time, as well 
as a decrease of the primary HbA-adduct concentration after 2 mins. Therefore, the 
primary HbA-AEH adduct was assumed to achieve SS by 2 mins. Since the kinetic 
study is not achievable under the current experimental method, only the SS 
concentration-dependency definitive study was designed. According to its pilot study, 





Table 3.1. Definitive experimental design for SS concentration- and time-
dependency of HbA-AEH adduct formation in HbA solution. 
AEH 
 [AEH]0 Time Point [HbA]0 
[mM] [hr] [mM] 
5-HMF 0.063, 0.13, 0.25, 0.5, 1, 2, 4 




0.025, 0.05, 0.1, 0.25, 0.5, 1, 2, 
4, 8 




0.44, 0.74, 1.5, 2, 3, 3.5, 4.4, 5, 
6, 7, 11, 21 
0.05, 0.5, 1, 2, 3, 4.5, 8.5, 
27 
0.2 
TD-8 0.1, 0.2, 0.4, 1, 2, 4 0.05, 0.5, 1, 2, 4, 6, 24 0.2 
TD-9 0.1, 0.2, 0.4, 1, 2, 4 0.05, 0.5, 1, 4.5, 5, 6, 24, 27 0.2 
TD-7 
0.025, 0.05, 0.1, 0.2, 0.4, 0.8, 
1.6 
0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 
0.8, 1, 1.1, 2.1, 5.1 
0.2 
PP-14 
0.05, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 
0.6, 1, 2 
0.025, 0.1, 0.15, 0.2, 0.25, 
0.35, 0.45, 0.55, 0.65, 1, 4 
0.2 
INN-310 
0.027, 0.046, 0.09, 0.11, 0.18, 
0.36, 0.57, 1, 2, 3, 5 
0.03, 0.1, 0.2, 0.3, 0.4, 1, 
1.5, 2, 4, 6 
0.2 
VZHE-039 
0.026, 0.04, 0.06, 0.083, 0.12, 
0.25, 0.3, 0.4 
0.025, 0.05, 0.1, 0.15, 0.2, 
0.25, 0.3, 0.35, 0.4 
0.1 
GBT-440 
0.02, 0.04, 0.06, 0.08, 0.1, 0.12, 
0.14, 0.16, 0.2, 0.4, 0.5, 0.65, 
0.8, 0.9, 1, 1.7, 3.3, 6.5, 12.5 
0.03 0.2 
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3.2.5 HPLC-UV/Vis Conditions 
HbA and HbA-AEH adduct concentrations were quantitated by HPLC-UV/vis 
with a weak cation-exchange column (PolyCATA, 30 mm x 4.6 mm) and a detection 
wavelength of 410 nm.  A precolumn filter (Supelco®, 2.0 μm) was used to protect 
column. A linear gradient wash was applied with buffer A (20 mM Bis-Tris, 2 mM KCN, 
pH 6.5) and buffer B (20 mM Bis-Tris,2 mM KCN, 200 mM NaCl, pH 6.6) over 20 
minutes with flow rate of 1.5 mL/min (Table 3.2).    
 
Table 3.2. HPLC conditions for HbA and HbA-AEH adduct quantification in HbA 
solution. 
LC System Waters 2695 separation model 
Detector Waters 2996 PDA  
Analytical Column  Poly CATA weak cation-exchange column, 30 mm x 4.6 mm  







Flow Rate 1.5 mL/min 
Injection Volume 10 μL 
Mobile Phases 
A (20 mM Bis-Tris, 2 mM 
KCN, pH 6.5) 
B (20 mM Bis-Tris, 2 mM 
KCN, 200 mM NaCl, pH 6.6) 
0 min 100 0 
10 min 60 40 
15 min 0 100 
16 min 100 0 





3.2.6 Partial Validation of HPLC-UV/Vis Assay Method  
3.2.6.1 Selectivity and Representative Chromatograms 
Assay selectivity was assessed with water/stopping solution (V:V = 1:1) in 
presence of 2%DMSO as control. A mixture of Hb variants, including HbF, HbA, HbS, 
HbC (Helena Laboratories, Beaumont, TX) was qualitatively assessed in order to 
confirm the separation of Hb according to their different isoelectric point (pI). The 
separation of HbA-AEH adduct and HbA mixture were monitored for all AEH.  
3.2.6.2 UV Spectra of HbA and HbA-AEH Adduct 
A 3D capture from (200 nm to 600 nm) was set up on a PDA detector to compare 
the UV spectrum properties of HbA and HbA-AEH adduct.  Detection wavelength was 
optimized for HbA and HbA-AEH adduct quantification. Molar absorptivity (extinction 
coefficient ε) of HbA and HbA-AEH adduct at the detection wavelength (410 nm) were 
compared using Lambert-Beer’s law (Equation 3.1), in order to determine if HbA 
calibration curve can be used for the quantification of HbA-AEH adduct.  
 
∆A = ε * l * ∆C       ---- Equation 3.1 
∆A: change of absorbance measured by PDA detector  
ε: experimental molar extinction coefficient of HbA, HbA-AEH adduct 
l: pathlength that automatically corrected by Empower 2 software 




Three HbA calibration curves (0.003 - 0.4 mM) were prepared in water and 
followed by a 2-fold dilution with stopping solution in presence of 2%DMSO for the 
assay validation. The peak area was used for quantification. Linearity was assessed 
using linear regression with 1/y weighting factor applied in order to cover large [AEH]0 
range (133-fold). Sensitivity (slope), accuracy (DNF = (Predicted concentration – 
Nominal concentration) / Nominal concentration) and precision (RSD = SD / Mean) were 
evaluated. eLOQ was estimated as the lowest observed nominal concentration which 
has acceptable of %DFN and %RSD, corrected by the dilution factor. Concentrations 
below eLOQ were not included in the data set. 
3.2.6.4 Mass Balance 
Mass balance was assessed by adding HbA-AEH adduct and HbA 
concentrations quantified from HbA calibration curves, and compared to the [HbA]0.  
3.2.6.5 Comparison to the Reference Assay Method using 5-HMF 
In order to further validate this “universal” assay method, the SS concentration-
dependency study data of 5-HMF collected from the previous validated reference assay 
method were revisited and remodeled using a Sigmoidal Bmax-model (Parikh, 2013).  
Binding affinity (KD) was estimated using calculated bound 5-HMF molar concentrations 
against [5-HMF]0 in the reference assay method, and compared to the KD estimated 




3.2.7 Data Analysis and Modeling 
3.2.7.1. Data Analysis 
The HbA-AEH adduct peak well separated from free HbA peak for all tested AEH 
(Figure 3.3 – 3.5 in Section 3.3.1.1). Peak area was consistently integrated using 
Gaussian skim method, since the separation between HbA-AEH adduct and HbA peak 
at low [AEH]0 did not allow valley-to-valley integration. HbA-AEH adduct peak area was 
corrected from the baseline measurement by subtraction from the peak area at the 
same retention time in absence of AEH (control sample). HbA-AEH adduct and HbA 
exhibited the same molar absorptivity at 410 nm (Figure 3.6 in Section 3.3.1.2). Since 
no reference chemical compound for Hb-AEH adduct is available, HbA calibration curve 
was used for HbA-AEH adduct quantification.  
Experimental data obtained at SS were used in concentration-dependent 
modeling to determine binding affinity. For each AEH, equilibrium time was observed 
from time-dependent HbA binding, where HbA-AEH adduct concentration stopped 
increasing and remained the same with time. HbA-AEH adduct concentrations above 
eLOQ (0.006 mM) were all included in the data set, except special cases listed below 
which violated the assumptions of models (Section 3.2.7.2 and 3.2.7.3). 1). HbA-AEH 
adduct concentrations decrease after SS. In SS concentration-dependency study, 2,5-
DMF showed a major mass balance lost at high [2,5-DMF]0; therefore, data were 
excluded when [2,5-DMF]0 > 0.5 mM, where the HbA-AEH adduct concentrations 
decreased. 2). For kinetic studies, sub-set data were used for parameter estimation for 
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5-HMF, 2,5-DMF, vanillin, and PP-14, which excluded the data showed the loss of HbA-
AEH adduct along time.   
The AEH SS concentration- and time-dependent data were modeled by a 
Sigmoidal-Bmax model and a simple 1:1 saturable binding model (simple kinetic binding 
model), respectively, described in the following sections 3.2.7.2 and 3.2.7.3. 
3.2.7.2. Modeling of SS Concentration-Dependency of HbA-AEH Adduct 
Formation and HbA Loss  
The SS (at equilibrium) concentration-dependency HbA-AEH adduct data of 5-
HMF, TD-7 and VZHE-039 were firstly modeled using the saturable hyperbolic model 
(Equation 3.2) according to the previous study on 5-HMF (Parikh, 2013). 
 
[𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]∞ =  
𝑩𝒎𝒂𝒙∗ [𝑨𝑬𝑯]𝟎
𝑲𝑫+ [𝑨𝑬𝑯]𝟎
                                                                  ----  Equation 3.2 
Bmax: Maximal AEH-HbA adduct formed/AEH bound 
KD: Equilibrium dissociation constant 
[HbA-AEH adduct] ∞: HbA-AEH adduct concentration at SS 
[AEH]0: Nominal initial concentration of AEH 
 
Scientist® (version 3.0) was used for nonlinear-regression. Initial estimates of 
Bmax and KD were obtained from the visual inspection of the experimental data. Final 
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parameters were optimized based on the goodness-of-fit of model determined by r2, 
residuals, sum of squared observations, model selection criterion, and precision of 
parameter estimation (COV). 1/y weighted factor was applied to cover the large [AEH]0 
range. 
 Due to imprecision of the parameter estimates for novel AEH (large COV of KD 
estimates for TD-7 (28%) and VZHE-039 (43%)), a simple sigmoidal Bmax-model was 
applied by introducing a Hill coefficient (n) to account for the potential cooperative 
binding of AEH (Equation 3.3). Accordingly, a reversed sigmoidal Bmax-model was 
applied to fit SS HbA concentrations (Equation 3.4). 
 





𝒏                                                                 ----  Equation 3.3 





𝒏                                                 ----  Equation 3.4 
 
Goodness-of-fit from both hyperbolic and sigmoidal models were compared for 
all three tested AEH (5-HMF, TD-7 and VZHE-039), which covered both furaldehydes 
and benzaldehydes, as well as less, medium and potent binding affinities. The 
sigmoidal model provided better parameter estimates with improved r2 and COV. 
Therefore, for other AEH, SS concentration-dependent experimental data were fit by 
sigmoidal model only.  
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3.2.7.3. Modeling of Time-dependency of HbA-AEH Adduct Formation 
A simple kinetic binding model was established based on the MOA of AEH 
(Scheme 3.1).  Association of AEH to Hb is characterized by a second-order rate 




Assumptions built in this simple kinetic binding model are: 1). one AEH molecule 
reversibly binds to one HbA molecule (1:1); 2). HbA-AEH adduct is the primary and the 
only modified Hb formed in the system, where no parallel/sequential reactions 
happened. 3). AEH, HbA and HbA-AEH adduct are stable in the sample system within 
incubation time.  
The rate of change in HbA-AEH adduct, AEH concentrations at any time, “t” was 
described by the differential equations listed below (Equations 3.5), where [AEH], [HbA], 
and [HbA-AEH adduct] are concentrations of unbound AEH, unmodified HbA, and HbA-
AEH adduct at time t, respectively. 
 
𝒅[𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]
𝒅𝒕
= (𝒌𝒐𝒏 ∗ [𝑨𝑬𝑯] ∗ [𝑯𝒃𝑨]) −  (𝒌𝒐𝒇𝒇 ∗ [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕])  
𝒅[𝑨𝑬𝑯]
𝒅𝒕
= (𝒌𝒐𝒇𝒇 ∗  [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]) −  (𝒌𝒐𝒏 ∗  [𝑨𝑬𝑯] ∗ [𝑯𝒃𝑨])  
----- Equations 3.5 






HbA are present in the mixture as either free HbA or HbA-AEH adduct form 
(Equation 3.6).  
 
[𝑯𝒃𝑨] = [𝑯𝒃𝑨]𝟎 −  [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]     ----- Equation 3.6 
 
Initial conditions were fixed (listed below), where [AEH]0, [HbA]0, and [HbA-AEH 
adduct]0 are concentrations of unbound AEH, free HbA, and HbA-AEH adduct at time 0, 
respectively. 
 
 [𝐇𝐛𝐀]𝟎 = 𝟎. 𝟐 𝐦𝐌 (𝐨𝐫 𝟎. 𝟏 𝐦𝐌 𝐟𝐨𝐫 𝐕𝐙𝐇𝐄 − 𝟎𝟑𝟗) 
 [𝐀𝐄𝐇]𝟎 = 𝐍𝐨𝐦𝐢𝐧𝐚𝐥 𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧  𝐨𝐟 𝐀𝐄𝐇, 𝐚𝐭 𝐭𝐢𝐦𝐞 𝟎  
 [𝐇𝐛𝐀 − 𝐀𝐄𝐇 𝐚𝐝𝐝𝐮𝐜𝐭]𝟎 = 𝟎                 
 
Scientist® (version 3.0) was used for nonlinear-regression. Initial estimates were 
obtained from pilot studies or rational design of the definitive studies. Final parameters 
were optimized based on the goodness-of-fit determined by r2, residuals, sum of 
squared observations, model selection criterion, precision of parameter estimation 




To help interpret the primary model parameters (kon and koff), the following 
secondary model parameters were calculated as shown below (Equations 3.7): 
 
𝑲𝑫 =  
𝒌𝒐𝒇𝒇
𝒌𝒐𝒏
                     
𝒌𝒂𝒔𝒔 =  𝒌𝒐𝒏 ∗  [𝑯𝒃𝑨]𝟎 
𝒌𝒅𝒊𝒔𝒔 =  𝒌𝒐𝒇𝒇        
𝒌𝒆𝒒 =  𝒌𝒂𝒔𝒔 +  𝒌𝒅𝒊𝒔𝒔                               ----        Equations 3.7 
 
 The dissociation equilibrium constant, KD, was used as a measure of AEH affinity 
for Hb, while the (first-order) association (kass), dissociation (kdiss) and equilibrium rate 
constants allow the calculation of half-lives (t1/2 = ln 2 / k) for these processes - 
assuming first-order conditions (keq), i.e., [AEH]0 are lower than KD.  Finally, kass and keq 
depend on [HbA]0, which are quite diluted in our HbA binding experiments (0.2 or 0.1 
mM to slow down kinetic reactions), and were therefore extrapolated to the 
physiological HbA concentrations (2.0 mM) in WB described in Chapter 5. 
3.2.7.4. Sensitivity Analysis for the Simple Kinetic Binding Model 
In order to better understand the simple kinetic binding model, sensitivity 
analyses were performed to provide information for the experimental design and initial 
parameter estimates. Initial estimates on kon (0.25 hr-1*mM-1), koff (0.05 hr-1), and [HbA]0  
(0.125mM) were obtained from the previous studies for 5-HMF (Parikh, 2013). Four 
65 
 
scenarios were designed by changing [HbA]0 (0.025mM to 0.625 mM, 25-fold), koff (0.01 
hr-1 to 0.25 hr-1 , 25-fold), kon (0.05 hr-1*mM-1 to 1.25 hr-1*mM-1, 25-fold), or 
proportionally changing on koff and kon (0.01 hr-1 /0.05 hr-1*mM-1 to 0.25 hr-1 / 1.25 hr-
1*mM-1, 25-fold). Model sensitivity analyses were performed to assess how the change 
of kon, koff, and [HbA]0 affected the overall time-dependent and SS concentration-
dependent binding for AEH, characterized by t1/2eq, KD, as well as HbA-AEH adduct 
concentrations at equilibrium ([HbA-AEH adduct] ∞). Fold-change calculated by dividing 
the largest number by the smallest value obtained using parameter values from upper 
limit (UL) and lower limit (LL). If results from UL were smaller than results from LL, the 





3.3.1. Partial Validation of HPLC-UV/Vis Assay Method  
3.3.1.1. Selectivity and Representative Chromatograms 
A chromatogram of water/stopping solution in the presence of 2% DMSO showed 
no peak (Figure B.3.1 in Appendix B), while 0.1 mM HbA showed a single peak (Figure 
3.3).  Hb variants separated from each other, eluted in the order of HbF (pI = 6.90), HbA 
(pI = 6.95), HbS (pI = 7.09) and HbC (pI = 7.40) (Figure B.3.2 in Appendix B) (Bunn & 
Forget, 1986).  AEH binding to Hb is expected to decrease the pI of protein, which 
allows its separation from free Hb.  For each tested AEH, regardless of their different 
physicochemical properties (e.g., cLogP of 5-HMF = -0.1, TD-7 = 1.3), HbA-AEH adduct 
peak was separated and eluted prior to the HbA peak on chromatogram (Figure 3.4 – 
3.6, other representative chromatogram listed in Appendix B Figure B.3.3 – B.3.10).  
3.3.1.2. UV Spectra of HbA and HbA-AEH Adduct 
HbA and HbA-AEH adduct show similar UV/Vis spectra (Figure 3.7). λ was 
determined as 410 nm, which is close to λmax and is consistent with the λ used in the 
previous studies (Deshpande et al., 2018). The estimated extinction coefficients at 410 
nm were 2.9 and 2.8 AU*mM-1cm-1, for HbA and HbA-AEH adduct, respectively.  









Figure 3.4. Representative chromatogram of HbA-AEH adduct and HbA 





Figure 3.5. Representative chromatogram of HbA-AEH adduct and HbA 
separation for 8 mM of 5-HMF in HbA solution (0.2 mM) at 8 hrs. 
 
 
Figure 3.6. Representative chromatogram of HbA-AEH adduct and HbA 





Figure 3.7. Representative UV spectra (λ = 200 – 600 nm) of HbA-AEH adduct and 








HbA calibration curves (0.0015 – 0.2 mM) were linear (1/y weighted) with r2 of 
0.999 and slope of 1.1 * 108 (Figure 3.8). 0.0015 mM showed acceptable precision 
(%RSD = 6%) and accuracy (%DFN = 9%). After corrected by the 2-fold dilution factor, 
eLOQ for HbA and HbA-AEH adduct quantification in HbA solution is 0.003 mM. Overall, 
HbA calibration curves (n = 3) showed acceptable precision (%RSD of 4%-15%) and 
accuracy (%DFN of -20% to 4.5%).  
 
Figure 3.8. Representative calibration curve of HbA in water/stopping solution 
(V:V = 1:1) in presence of 2%DMSO. 1/y weighted linear regression (line) was fit to 







































3.3.1.4. Mass Balance 
At SS, free HbA concentrations decreased as [AEH]0 increased, concurrently 
HbA-AEH adduct concentrations increased as more of free AEH were able to bind to 
and saturate the HbA binding sites (Figure 3.9 – 3.10). For most AEH, HbA 
concentrations decreased to zero at the saturable condition, except GBT-440, where 50% 
of free HbA still remained (Figure 3.9 – 3.10). Mass balance (i.e., HbA + HbA-AEH 
adduct relative to [HbA]0) for all tested AEH were above 83% except for high [AEH]0. 
There is a trend of the loss of mass balance at high [AEH]0 and/or long incubation times 
(Figure 3.9, and Figure B.3.11 – B.3.18 in Appendix B). Two extreme examples are 
vanillin and 2,5-DMF, where vanillin only achieved a maximum of 70% HbA modification, 
and 2,5-DMF showed almost completely lost mass balance (9%) at 8 mM for 24 hrs 
reaction time (Figure B.3.11 – B.3.19 in Appendix B). Some AEH, namely 5-HMF, 2,5-
DMF, vanillin, PP-14, and GBT-440 showed additional peaks eluted prior to HbA-AEH 
adduct peak especially at high [AEH]0 and/or long reaction time - indicating additional 
parallel/sequential reactions.   
In the SS concentration-dependency study, binding affinity was estimated based 
on the primary HbA-AEH adduct concentrations quantified by HbA calibration curves. 
The mass balance lost at high [AEH]0 were incorporated by Bmax estimation. In kinetic 
studies, selected data were included for parameter estimation, where the loss of HbA-
AEH adduct along time were excluded. Though some mass balance were lost at high 
[AEH]0, for the research purposes of this study, this assay method is still valid for 
characterizing SS concentration- and time-dependent profiles of the primary HbA-AEH 
adduct.   
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Figure 3.9. Mass balance assessment for VZHE-039 in HbA solution for 0.4 hr. The 
sigmoidal Bmax-model and the reverse sigmoidal Bmax-model (lines) were fit with 
for HbA-AEH adduct and HbA (symbols), respectively. Linear regression (dashed 




































Figure 3.10. Mass balance assessment for GBT-440 in HbA solution for 0.03 hr. 
The sigmoidal Bmax-model and the reverse sigmoidal Bmax-model (lines) were fit 
with for HbA-AEH adduct and HbA (symbols), respectively. Linear regression 



































3.3.1.5. Comparison to the Previous Reference Assay Method using 5-HMF 
The binding estimates obtained from both the previous reference assay and the 
current “universal” assay method using the same Sigmoidal Bmax-model are statistically 
the same (Table 3.3), validating the prospective use of the current “universal” assay 
method.  
 
Table 3.3. Comparison of the final parameter estimates of SS concentration-
dependency of HbA-AEH adduct formation for 5-HMF by the sigmoidal Bmax-
model, using two different HPLC-UV/Vis assay methods. Data were presented as 
PE estimate with (COV).  
  Reference Method "Universal" Method 
r2 0.994 0.998 
Bmax / HbA0 0.74 (10%) 1.0 (6%) 
KD 0.28 (17%) 0.37 (16%) 




3.3.2. Sensitivity Analysis for the Simple Kinetic Binding Model 
HbA solution provides an environment that is absent of any metabolic AEH 
degradation, allowing that equilibrium (SS) of AEH binding to HbA is achieved. Both 
association and dissociation rate determine the time it takes to achieve SS. The 
association rate is driven by both AEH and HbA concentrations, as well as the second-
order association rate constant (kon). When AEH concentrations are lower than KD, 
[HbA]0 multiplied by kon is the apparent first-order association rate constant as since Hb 
concentrations remain close to [HbA]0.  The dissociation rate is driven by Hb-AEH 
adduct concentration and the first-order dissociation rate constant (koff).  The overall 
equilibration rate depends on both association and dissociation rates; under first-order 
condition, i.e., AEH concentrations below KD, the equilibration rate is the sum of 
apparent first-order association rate constant (kon*[HbA]0) and first-order dissociation 
rate constant, koff. 
Therefore, when AEH is below KD, increasing [HbA]0, kon, or koff resulted in 
shorter equilibrium half-lives (t1/2eq) (Figure 3.11 – 13). Compared to the change of kon 
and [HbA]0, t1/2eq is more sensitive to the change koff (Table 3.4). When both kon and koff 
increase, t1/2eq also is shortened inverse-proportionally (Table 3.4). However, when AEH 
concentrations exceed KD, the association rate is sped up by the higher concentration of 
AEH. Therefore, t1/2eq remains the same with increasing [HbA]0 and kon. Since koff is a 
first-order rate constant, which is not affected by AEH concentrations, t1/2eq remains 
sensitive to the change of koff (Table 3.4).  
Once the reaction achieves equilibrium, the HbA-AEH adduct∞ at a given [AEH]0 
and [HbA]0 is determined are by both kon and koff. Larger kon and/or smaller koff results in 
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larger HbA-AEH adduct∞ (Figure 3.15 – 16). The maximum of HbA-AEH adduct∞ (Bmax) 
achieved depends on the initially available concentration of HbA ([HbA]0) in the system.  
Therefore, increasing [HbA]0 leads to higher HbA-AEH adduct∞, while KD remains the 
same (Figure 3.14). On the other hand, the change of kon and koff do not affect Bmax, but 
move KD into different directions (Figure 3.15 - 16). Larger koff values result in larger KD 
(i.e., lower binding affinity), while larger kon values result in smaller KD (i.e., higher 
binding affinity). When kon and koff are changed the same, KD remains the same (Figure 
3.17). 
In summary, t1/2eq (= ln(2)/(kon*[HbA]0)), HbA-AEH adduct∞ or Bmax (= 
[HbA]0*[AEH]0/((koff/kon)+[AEH]0)), KD (=kon/koff) are determined by both kon and koff 
together. With our current experimental design, where serial HbA-AEH adduct 
concentrations were measured until SS, and kon and koff estimated from the simple 
binding model, their final estimates are expected and were indeed found to be highly 
correlated. To help reduce this correlation, [AEH]0 were selected, based on pilot 
experiments, to cover a concentration range about 10-fold below and above the 
expected KD. In addition, the serial sampling schedule was designed to cover both the 
ascending portion and the SS plateau of the time-dependent HbA-AEH adduct curve. 
The entire time-dependency HbA-AEH adduct dataset (or subset) across [AEH]0 were 
used to fit by the simple kinetic binding model to obtain estimates for the primary model 





Table 3.4. Assessment of outcome metrics from sensitivity analysis for the simple 
kinetic binding model. Data are presented as fold-change calculated by dividing 
the largest number by the smallest value obtained using parameter values from 
upper limit (UL) and lower limit (LL). If results from UL were smaller than results 
from LL, the fold-change is expressed as a negative number. 
AEH0 : KD = 1 : 10 
 Fold-change Bmax t1/2eq KD 
[HbA]0 25 25 -3 0 
kon 25 0 -3 -25 
koff 25 0 -6 25 
kon / koff 25 0 -25 0 
AEH0 : KD = 50 : 1 
 Fold-change Bmax t1/2eq KD 
[HbA]0 25 25 0 0 
kon 25 0 0 -25 
koff 25 0 -13 25 




Figure 3.11. Simulation of time-dependent HbA-AEH adduct formation using the 
simple kinetic binding model by changing [HbA]0 (25-fold). ([AEH]0 = 0.13 mM, KD 
= 0.2 mM) 
 
Figure 3.12. Simulation of time-dependent HbA-AEH adduct formation using the 





























































Figure 3.13. Simulation of time-dependent HbA-AEH adduct formation using the 



































Figure 3.14. Simulation of SS concentration-dependency of HbA-AEH adduct 
formation using the simple kinetic binding model by changing [HbA]0 (25-fold).  
 
 
Figure 3.15. Simulation of SS concentration-dependency of HbA-AEH adduct 

































































Figure 3.16. Simulation of SS concentration-dependency of HbA-AEH adduct 
formation using the simple kinetic binding model by changing koff (25-fold).    
 
 
Figure 3.17. Simulation of SS concentration-dependency of HbA-AEH adduct 
formation using the simple kinetic binding model by changing koff and kon 


























































koff:kon = 0.25 : 1.25
koff:kon = 0.05 : 0.25
koff:kon = 0.025 : 0.125
koff:kon = 0.01 : 0.05
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3.3.3. Pilot Study of SS Concentration- and Time-Dependency of HbA-AEH 
Adduct in Formation HbA Solution 
The hyperbolic-Bmax-model was used from previous study for 5-HMF by fitting the 
calculated bound 5-HMF against free 5-HMF concentrations in HbA solution mixture 
(Parikh, 2013). This hyperbolic model was also chosen to fit the HbA-AEH adduct 
concentration against nominal AEH concentrations for 5-HMF, TD-7 and VZHE-039 
first. However, the hyperbolic Bmax-model resulted in large imprecision (large COV) on 
point estimates, especially for TD-7 and VZHE-039 (Table 3.5). Steeper slopes were 
observed for VZHE-039 and TD-7 than for 5-HMF. Therefore, another parameter, i.e., 
Hill coefficient (n), was introduced to account for the potential cooperative binding of 
AEH to Hb molecules. The sigmoidal Bmax-model fitted the experimental better with 
more precise point estimates and better r2 for all three tested AEH (Table 3.5). 
Therefore, sigmoidal Bmax-model was used to fit SS concentration-dependency studies 





Table 3.5. Comparison of the final parameter estimates of SS concentration-
dependency of HbA-AEH adduct formation for 5-HMF, TD-7, and VZHE-039, using 
the sigmoidal Bmax-model and hyperbolic Bmax-model. Data are presented as PE 
with (COV).  
 5-HMF TD-7 VZHE-039 
Sigmoidal Hyperbolic Sigmoidal Hyperbolic Sigmoidal Hyperbolic 
r2 0.998 0.988 0.997 0.989 0.980 0.974 
Bmax/ 
HbA0 
1.0 (6%) 1.1 (7%) 0.085 (5%) 1.4 (11%) 0.085 (18%) 1.1 (16%) 
KD 0.37 (16%) 0.58 (23%) 0.19 (10%) 0.38 (28%) 0.17 (37%) 0.24 (43%) 
n 1.1 (10%) 1.0 1.8 (15%) 1.0 1.5 (39%) 1.0 
 
Though the pilot study design for VZHE-039 using 0.2 mM HbA solution does not 
use optimized experimental conditions, it still provided useful information for the initial 
parameter estimates (KD = 0.17 (37%) mM; kon  = 22 (14%) hr-1 mM-1, and koff = 3.0 
(18%) hr-1) for definitive study. VZHE-039 achieved SS in presence of 0.2 mM of [HbA]0 
within the first time point (6 mins), indicating that the originally designed experimental 
conditions missed most of the ascending portion of the reaction kinetics (Figure 3.18). 
According to the nature of a bimolecular reaction, their association rate depends on kon, 
[HbA]0 and [AEH]0 concentrations. Since we aimed to cover both low and high 
concentration of AEH around the KD, decreasing [VZHE-039]0 to prolong the kinetic 
reaction time is not an optimal experimental design (Figure 3.18). Rather, lowering 




Figure 3.18. Pilot study of SS concentration- and time-dependency of HbA-AEH 
adduct formation for VZHE-039 in HbA solution (0.2 mM). The hyperbolic Bmax-
model and sigmoidal Bmax-model (lines) were fit to the SS concentration-
dependency of HbA-AEH adduct (symbols), while the simple kinetic binding 



























































The initial concentrations selected for vanillin ([vanillin]0) successfully covered 
the low and ascending portion of the sigmoidal curve, but may miss the plateau (Figure 
3.19). Higher [vanillin]0 (>5.8 mM) were designed for definitive study to capture the 
saturation portion to estimate Bmax more precisely. The sigmoidal Bmax -model fits the 
data well with acceptable goodness-of-fit (r2 = 0.999). Point estimates for KD, Bmax and 
n were 2.2 mM (COV = 8%), 0.16 (5%) mM, 1.4 (7%), respectively, and were used as 
initial parameter estimates for the definitive study. The time-dependency experimental 
design captured both the ascending and plateau phase of the kinetic curves (Figure 
3.19). The simple kinetic binding model fitted the data well with acceptable goodness-
of-fit (r2 = 0.963). Point estimates for kon and koff were 0.19 (12%) hr-1mM-1, and 0.43 





Figure 3.19. Pilot study of SS concentration- and time-dependency of HbA-AEH 
adduct formation for vanillin in HbA solution (0.2 mM). The sigmoidal Bmax-model 
and the simple kinetic binding model (lines) were fit to the SS concentration- and 
































































The initial concentrations selected for GBT-440 ([GBT-440]0) covered the 
plateau and the sigmoidal portion of SS concentration-dependency curve, but missed 
the [GBT-440]0 below KD (Figure 3.20). Lower [GBT-440]0 (< 0.1 mM) were added for 
definitive study to capture the low and ascending portions of the curve and better 
estimate n. The sigmoidal Bmax -model fitted the data well with acceptable goodness-of-
fit (r2 = 0.998). Point estimates for KD, Bmax and n were 0.10 mM (COV = 5%), 0.13 (2%) 
mM, 3.6 (27%), respectively, and were used as initial parameter estimates for the 
definitive study. In time-dependency study, HbA-AEH adduct concentrations decreased 
after 2 mins for most of GBT-440 concentrations, indicating the binding kinetics was too 





Figure 3.20. Pilot study of SS concentration- and time-dependency of HbA-AEH 
adduct formation for GBT-440 in HbA solution (0.2 mM). The sigmoidal Bmax-
model (line) was fit to the SS concentration- dependency of HbA-AEH adduct 





























3.3.4. Definitive Study of SS Concentration- and Time-Dependency of HbA-AEH 
Adduct Formation in HbA Solution 
3.3.4.1 Definitive Study of SS Concentration-Dependency of HbA-AEH Adduct 
Formation in HbA solution 
All AEH showed the expected saturable concentration-dependent HbA binding, 
where HbA-AEH adduct concentrations ultimately achieved SS under the experimental 
conditions - except 2,5-DMF (Figure 3.21).  The entire [HbA]0 was modified by AEH, 
resulting in saturation, except for GBT-440, where only about 50% HbA were modified 
to the HbA adduct and the remaining 50% were not. Bmax/HbA0 values were close to 1, 
except for vanillin, INN-310 and GBT-440 (Table 3.6). Consistently positive values for n 
in SS binding indicate allosteric effects, supported by X-ray crystallography studies, 
where two AEH molecules (e.g., TD-7) were observed binding to the N-terminal Val1 of 





































Figure 3.21. Definitive study of SS concentration-dependency of HbA-AEH adduct 
formation for the selected AEH in HbA solution (0.2 mM). The sigmoidal Bmax-









































Table 3.6. Final parameter estimates of SS concentration-dependency of HbA-
AEH adduct formation in HbA solution using sigmoidal Bmax-model. Data are 
presented as PE with (COV).  
  r2 Bmax /HbA0 KD  n 
 [mM]   
5-HMF 0.998 1.0 (6%) 0.37 (16%) 1.1 (10%) 
2,5-DMF 0.997 1.0 (15%) 0.19 (25%) 1.7(21%) 
Vanillin 0.990 0.70 (7%) 1.7 (16%) 1.9 (24%) 
TD-8 0.997 0.90 (8%) 0.58 (19%) 1.4(17%) 
TD-9 0.999 0.90 (3%) 0.25 (7%) 2.0 (12%) 
TD-7 0.997 0.85 (5%) 0.19 (10%) 1.8 (15%) 
INN-310 0.976 0.70 (8%) 0.19 (21%) 2.4 (20%) 
PP-14 0.988 0.80 (6%) 0.16 (13%) 2.8 (30%) 
VZHE-039 0.986 0.80 (14%) 0.10 (24%) 1.9 (34%) 





Compared to 5-HMF (VCU lead compound), 2,5-DMF showed a 2-fold enhanced 
binding affinity (smaller KD), possibly due to its additional aldehyde group on the furan 
ring (Figure 3.22).  Compared to the parent compound, vanillin, all benzaldehyde 
derivatives exhibited enhanced HbA binding affinity, indicating that the additional 
pyridinyl-methoxy side chain increases HbA binding affinity/interactions, as supported 
by X-ray crystallography findings (Figure 3.21)(Deshpande et al., 2018).  In addition, the 
positions of methoxy group and/or the pyridinyl-methoxy group on the benzene ring 
determine KD (TD-7<TD-9<TD-8) (Figure 3.23).   
 
Figure 3.22. Definitive study of SS concentration-dependency of HbA-AEH adduct 
formation for 5-HMF and 2,5-DMF in HbA solution (0.2 mM). The sigmoidal Bmax-
































Figure 3.23. Definitive study of SS concentration-dependency of HbA -AEH 
adduct formation for TD isomers, as well as 5-HMF and vanillin in HbA solution. 
The sigmoidal Bmax-model (lines) was fit to the experimental data (symbols). 
 
 
Similar to 2,5-DMF and TD-7, a group of AEH showed enhanced binding affinity 
over 5-HMF as well, namely, INN-310, PP-14, VZHE-039, and GBT-440 (Figure 3.24). 
INN-310 share the same meta-positioned methoxy group on benzene ring as in TD-7, 
where the only difference is the hydroxy group on pyridine ring, which resulted in 
identical binding affinity estimates (KD = 0.19 mM). PP-14, VZHE-039 and GBT-440 
shared the same ortho-positioned-hydroxy group on benzene ring and exhibited high 


































Figure 3.24. Definitive study of SS concentration-dependency of HbA -AEH 
adduct formation for high affinity AEH, as well as 5-HMF and Vanillin in HbA 





































3.3.4.2 Definitive Study of Time-dependency of HbA-AEH adduct Formation in 
HbA Solution 
All AEH showed time-dependent HbA-AEH adduct formation under designed 
experimental conditions (Figure 3.25 – 3.27).  Increasing initial AEH concentrations 
([AEH]0) led to a more rapid achievement of HbA adduct equilibrium, as well as 
increased HbA-AEH adduct∞ concentrations - as expected from the sensitivity analysis 
discussed in section 3.3.2.  The simple kinetic binding model adequately described the 
observed data across a wide range of AEH0 concentrations and time points (Figure 3.25 
– 3.27, Table 3.7) and resulted in similar KD estimates compared to the KD obtained 




Table 3.7. Final parameter estimates of time -dependency of HbA-AEH adduct 
formation in HbA solution, using the simple kinetic binding model. Data are 
presented as PE with (COV). 
  r2 kon koff KD t1/2eq  
    [mM-1*hr-1] [hr-1] [mM] [hr] 
5-HMF  0.934 0.46 (11%) 0.13 (25%) 0.28 3.1 
2,5-DMF 0.980 0.54 (6%) 0.065 (14%) 0.12 4.5 
Vanillin 0.956 0.16 (13%) 0.69 (16%) 4.3 0.96 
TD-8 0.935 0.18 (10%) 0.10 (26%) 0.55 5.0 
TD-9  0.979 0.76 (8%) 0.18 (15%) 0.23 2.1 
TD-7  0.992 9.8 (5%) 1.5 (9%) 0.15 0.20 
PP-14 0.958 16 (12%) 2.2 (19%) 0.14 0.13 
INN310 0.897 5.0 (11%) 0.70 (25%) 0.14 0.41 




Table 3.8. Comparison of the final KD and KDkinetic estimates from SS 
concentration- and time-dependency of HbA-AEH adduct formation in HbA 
solution, using sigmoidal Bmax-model and simple kinetic binding model, 
respectively. Data are presented as PE with (COV). 
  KD KDKinetic 
 [mM] [mM] 
5-HMF  0.37 (16%) 0.28 (36%) 
2,5-DMF 0.19 (25%) 0.12 (20%) 
Vanillin 1.7 (16%) 4.3 (29%) 
TD-8 0.58 (19%) 0.55 (36%) 
TD-9 0.25 (7%) 0.23 (23%) 
TD-7 0.19 (10%) 0.15 (14%) 
INN-310 0.19 (21%) 0.14 (31%) 
PP-14 0.16 (13%) 0.10 (36%) 
VZHE-39 0.10 (24%) 0.10 (22%) 






The tested AEH achieved equilibrium on different time scales (Figure 3.25 – 
3.27). At low [AEH]0 - assuming first-order conditions - 5-HMF, TD-8, and TD-9 
equilibrated slowly with HbA, in 12 – 20 hrs, with an equilibrations half-life of 3.1, 5.0, 
2.1 hrs, respectively (Figure 3.25). The slow equilibration rates were caused by their 
small kon and koff rate constants (Table 3.7).  TD-7, being an isomer with TD-8 and TD-9, 
exhibited significantly more rapid equilibration in less than 1 hr due to its large kon and 
koff values (Figure 3.26).  The three TD isomers differ by either the position of the 
methoxy moiety or the methoxypyridine moiety on the benzene ring (Figure 3.1). TD-7 
has a meta-located methoxy group relative to the aldehyde, while TD-9 has the methoxy 
group located at the para position on the benzene ring.  TD-8 differs from TD-9 by the 
position of the methoxypyridine moiety, which is located para and ortho to the aldehyde 
moiety, respectively. These structural differences appear to determine their binding 
kinetics to HbA. VZHE-039, which is structurally similar to TD-7, but with an ortho-
positioned hydroxyl group instead of meta-positioned methoxy group relative to the 
aldehyde moiety, showed the fastest binding kinetics, achieving equilibrium in less than 
half an hour (Figure 3.27).  PP-14 and INN-310, which showed slightly lower binding 
affinity (large KD) than VZHE-039, exhibited slower overall binding kinetics than VZHE-
039. GBT-440, on the other hand, showed the same binding affinity as VZHE-039 in the 
SS concentration-dependency study, but very fast reaction kinetics which could not be 




Figure 3.25. Definitive study of time-dependency of HbA-AEH adduct formation 
for 5-HMF in HbA solution (0.2 mM). The simple kinetic model (lines) was fit to the 


































Figure 3.26. Definitive study of time-dependency of HbA-AEH adduct formation 
for TD-7 in HbA solution (0.2 mM). The simple kinetic model (lines) was fit to the 


































Figure 3.27. Definitive study of time-dependency of HbA-AEH adduct formation 
for VZHE-039 in HbA solution (0.1 mM). The simple kinetic model (lines) was fit to 





































Vanillin - without a bulky side-chain available for supplemental HbA interactions 
besides the Schiff base binding - exhibits a small kon and relatively large koff, resulting in 
poor HbA affinity (KD) (Table 3.7).  Compared to the parent compound, vanillin, the 
addition of a methoxy-pyridine side chain to the benzene ring, in general, leads to a 
(desirable) increase of kon.  However, TD-7, PP-14 and VZHE-039 also show, to a 
lesser extent, an (undesirable) increase of koff (Table 3.7).  
All AEH across furaldehydes and benzaldehydes, except vanillin and 2,5 - DMF, 
showed a strong correlation (r = 0.993, n=7) between their kon and koff values (Figure 
3.28). The two furaldehydes, 2,5-DMF and 5-HMFdiffers from each by the former having 
an additional aldehyde moiety at the 2-position. The two exhibited similar kon values, but 
2,5-DMF has a 2-fold smaller koff relative to 5-HMF. The previously discussed SS 
concentration-dependency studies showed that most of the studied AEHs (except GBT-
440, vanillin, 2,5-DMF) achieved more than 80% of HbA modification at full HbA 
saturation. However, vanillin and 2,5-DMF showed a significant loss of mass balance, 
especially at high [AEH]0 (Figure B.3.11 – 2.12 in Appendix B); along with the observed 
additional peaks on chromatograms for both vanillin and 2,5-DMF, this indicates other 
parallel/sequential reactions may happen beyond the primary HbA-AEH adduct 
formation. These might explain why vanillin and 2,5-DMF are outliners in the coloration 
of kon and koff. 
The strong correlation between kon and koff with most of the AEHs indicates that 
the current molecular design strategy did enhance interaction with Hb (as intended), but 
also enhanced dissociation from Hb, albeit inadvertently. This strong correlation also 
indicates proportional changes of kon and koff in the same direction, resulting in a less 
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than 5-fold improvement of KD from the top candidate VZHE-039, relative to the 
previous lead compound (5-HMF). However, the overall Hb binding kinetics of VZHE-
039 is more rapid than 5-HMF, as reflected by a more than 50-fold shorter t1/2eq under 
the current experimental conditions, due to the increase of both kon and koff.  
 
Figure 3.28. Log-log correlation of kon and koff for AEH. A power equation (dashed 
line) was fit to the experimental data (blue circle symbols), except for two 






























3.4 Discussion and Conclusions 
Previous X-ray crystallography studies showed that two AEH molecules (e.g., TD-
7) bind to each α-chain of Hb molecule (2:1 stoichiometry) (Deshpande et al., 2018). In 
our SS concentration-dependency studies, a sigmoidal Bmax-model was applied to 
incorporate the possibility of cooperative binding by Hill coefficient, n. All AEH resulted 
in n >1, which matched the 2:1 binding phenomenon observed in X-ray crystallography 
studies. 
In the SS concentration-dependency studies, major losses of mass balance were 
observed at saturable conditions with long incubation times for some AEH, namely 2,5-
DMF, vanillin, and GBT-440. Unidentified new peaks were also observed, eluting at an 
earlier time on the chromatograms for all three AEH, which indicates that besides the 
primary HbA-AEH adduct formation, other “unidentified Hb adducts (UHbA-adducts)” 
are formed in Hb mixtures. Since the increase of HbA-adducts parallels the decrease of 
the primary HbA-AEH adduct, a sequential conversion of primary HbA-AEH adduct to 
UHbA-adducts may occur. 
A similar process, glycation may provide some hints, where glucose first reversibly 
binds to Hb via Schiff-base reaction, followed by irreversible rearrangement to form 
HbA1C (Ge & Lee, 1997).  However, the loss of the primary HbA-AEH adduct may also 
be due to parallel conversion from free Hb directly to HbA-adducts. For example, GBT-
440 is also believed to bind to β-chain of Hb when high [GBT-440]0 is present in Hb 
solution (Abdulmalik, 2018). Binding to other sides of Hb may change the conformation 
of Hb in different way, which further decrease pI of UHbA-adducts protein (early elution) 
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compared to the free HbA and the primary HbA-AEH adduct. 2,5-DMF and vanillin are 
also the outliners in the coloration relationship of kon and koff, where the potential UHbA-
adducts may play a role. 
For the time-dependency studies, a simple kinetic binding model (1:1 binding) was 
used because of its good model selection criteria, indicating an acceptable fit of the 
experimental data, resulting in reliable final point estimates for kon and koff (Table 3.7 in 
Section 3.4.4.2). The different assumptions on AEH to Hb binding ratio between SS 
concentration- and time- dependent models resulted in slightly different final estimates 
for KD (Table 4.8 in Section 3.4.4.2). However, after accounting for the coefficient of 
variance (COV%), i.e., imprecision, of the final estimates, these differences between KD 
and KDkinetic estimates are considered negligible - indirectly confirming the proper use of 
both models for Hb binding affinity and binding kinetic characterization.  
The crystal structures of some AEH in complex with liganded Hb have been 
elucidated, which can provide some insight into the differences in the binding affinity of 
the AEHs to Hb. Consistent with TD-7 showing the lowest KD (highest binding affinity) 
among the three isomers, TD-7 (0.19 mM), TD-8 (0.58 mM) and TD-9 (0.25 mM), the 
electron density of bound TD-8 and TD-9 was found to be very weak and sparse 
compared to TD-7, suggesting weaker interactions of TD-8 and TD-9  with Hb than TD-
7 (Deshpande et al., 2018). INN-310 (SAJ-310) also showed strong binding density like 
TD-7; however, it appears to make more interactions with Hb than TD-7, explaining a 
slightly higher affinity to HbA of INN-310 (0.14 mM) than TD-7 (0.19 mM). 
TD-7 and VZHE-039 share the same methylhydroxyl group on the pyridine ring. 
However, TD-7 differs from VZHE-039, with the former having a meta-positioned 
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methoxy group while the latter has an ortho-hydroxyl group. The methylhydroxyl group 
on the pyridine ring is expected to make interactions with the surface-located αF-helix to 
directly weaken polymer interactions.  The F-helix is implicated in polymer stabilization 
through hydrogen-bonding interactions with other polymer strands (Cretegny & 
Edelstein, 1993). Consistent with this idea, natural mutations, e.g.  αAsn78→Lys (Hb 
Stanleyville) that abrogate these interactions, lead to increased solubility/less “sickling” 
of deoxy HbS hetero tetramers, mitigating the severity of SCD (Cretegny & Edelstein, 
1993). Interestingly, while the methylhydroxyl of VZHE-039 makes the predicted 
interactions with the F-helix that of TD-7 does not; rather rotating away from the F-helix 
(Ahmed et al., 2020). This unique F-helix interaction may help explain why VZHE-039 
binds with the highest affinity among the benzaldehydes (Ahmed et al., 2020). 
Consistently, VZHE-039 showed the lowest KD (0.1 mM), i.e., VZHE-039 < INN-310 
<TD-7 < TD-9 < TD-8 < vanillin. We also note that VZHE-039 interactions with αF-helix 
has resulted in a secondary O2-independent anti-sickling activity in addition to the 
primary O2-dependent anti-sickling activity, which may show clinical benefits over other 
aromatic aldehydes (Ahmed et al., 2020; Oder et al., 2016; Pagare et al., 2018). 
A difference between our novel AEH and the SCD-approved GBT-440 with respect 
to their HbA binding is their binding ratio to Hb molecules: GBT-440 binds to the HbA 
molecule with 1:1 ratio, as suggested by X-ray studies where its bulky pyrazole 
substituent precluded a second molecule to bind to the opposite α-chain of Hb tetramer; 
this is in contrast with the observed 2:1 stoichiometry for other AEH.  In SS 
concentration-dependency studies with GBT-440, 50% natural HbA remains unmodified 
under saturable conditions, whereas for all other AEH, all the entire initial HbA was 
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modified to form the HbA-AEH adduct (although, as discussed above, a few AEH 
showed evidence of incomplete mass balance and  unknown chromatography peaks, 
suggesting other, as yet-unknown HBA adducts 
The “universal” HPLC-UV/Vis assay method used to quantitate HbA-AEH adduct 
employed indirect validation by HbA (rather than HbA-AEH adduct) calibration curves, 
where the tetrameric structure of HbA were measured.  Our novel AEH bind to both 
sides of α-chains of Hb, leading to 100% HbA tetramer modification. On the other hand, 
for GBT-440, because only one side of α-chain is bound, but the other side remains in 
its unbound natural form, i.e., only 50% of HbA tetramer is modified 
kon and koff are highly correlated among most of novel AEH, which indicates the 
current molecular design strategy led to enhanced association, by design, but also 
enhance dissociation, albeit unintentionally. Several reasons may explain the 
undesirable increasing of koff, 1). The stability of side chains of AEH binding with HbA; 
2). The electric density of imine carbon and nitrogen that affect hydrolysis process of 
Schiff-base; 3). The kinetic feature of Schiff-base reaction. 
For example, to explain the kinetic difference between 5-HMF and TD-7 (kon = 
0.46 and 9.8 hr-1mM-1, koff = 0.13 and 1.5 hr-1, respectively), crystal structures were 
compared. A pair of 5-HMF or TD-7 molecules form Schiff-base interactions with the N-
terminal αVal1 nitrogen of the two α-subunits in a symmetry-related fashion (Ahmed et 
al., 2020). The additional interactions for 5-HMF involves a strong and intricate network 
of water-mediated and direct hydrogen bonds (Ahmed et al., 2020).  On the other hand, 
in TD-7, the additional interactions to the proteins are predominantly hydrophobic and 
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weak hydrogen bonds, which may be unstable in water environment to facilitate the 
dissociation of AEH from Hb (Ahmed et al., 2020). 
The Schiff-base hydrolysis reaction of the HbA-AEH adduct may be facilitated 
with the increasing electropositive and electronegative nature of the imine carbon and 
nitrogen, respectively (Scheme 3.2). A computational approach using Mulliken charge 
analysis (Software: Gaussian 09) was applied to calculate the electric density of Schiff-
base formed by AEH. Compared to INN-310 and TD-7, the intramolecular hydrogen 
bond of PP-14 and VZHE-039 increased the electronegativity of the nitrogen atom (-
0.37 for INN-310 and TD-7, -0.54 for PP-14 and VZHE-039) and the electropositivity of 
the carbon atom (0.071 for INN-310 and TD-7, 0.198 for PP-14 and VZHE-039) of the 
Schiff-base, which is favorable for the decomposition of the Schiff base (koff: VZHE-039 > 
PP-14 > TD-7 > INN-310) (Abdulmalik, 2018). 
The reversible “transient covalent” Schiff-base reaction involves intermediates 
(Kallen, 1971).  The kinetic features between the formation and hydrolysis of Schiff-
base may be determined by any of steps shown in Scheme 3.2. koff used in our kinetic 
model is an overall rate constant that includes all the steps of Schiff-base hydrolysis and 
is ultimately determined by the rate-limiting part in the Schiff-base hydrolysis reaction 
steps. To explain the overall increasing of koff for tested AEH and design novel AEH with 





In summary, we report for the first time the validation and application of a weak 
cation-exchange HPLC-UV/Vis assay (Universal Method) for ten diverse anti-sickling 
aromatic aldehydes, which provided insight into the binding kinetics of aromatic 
aldehydes interactions with HbA. Key molecular features to enhance Hb binding have 
been identified, allowing rational design of potentially more effective drug candidates for 
druggability evaluation. A top candidate, namely VZHE-039, is selected based on its 
fastest binding kinetics among tested AEH and the most potent binding affinity that 
comparable to the clinical reference, GBT-440. 
In addition to its rapid and high-affinity HbA binding, VZHE-039 has a secondary 
O2-independent anti-sickling MOA, which may provide clinical advantages. However, 
one of the major potential drawbacks of aromatic aldehydes is their potentially poor PK 
properties due to extensive and rapid metabolic oxidation of the aldehyde moiety into 
the corresponding inactive functional metabolites by ALDH, which is abundantly present 
in RBC, their site of action. Therefore, the stability of novel AEH in presence of ALDH 







4. IN-VITRO METABOLISM OF AEH IN HUMAN LIVER CYTOSOL (HLC) 
4.1.  Introduction 
In-vitro metabolic studies are common approach to identify relative essential 
metabolic pathways at early stages of drug development. Compared to in-vivo approach, 
in-vitro metabolic study has the advantages of cost- and time-effectiveness, easy 
experimental procedures, protection of experimental animals, and avoiding the problem 
of inter-species differences. Several enzyme systems are commonly used in studying 
in-vitro metabolism, including recombinant enzymes, sub-cellular fractions, hepatocytes, 
and tissue slides (Ekins, Ring, Grace, Mcrobie-belle, & Wrighton, 2001). Depending on 
the relative metabolic pathways of research interests, choosing the correct in-vitro 
enzyme system is essential. For example, since human liver is the major elimination 
organ for most small molecule drugs, and nearly 80% such therapeutic drugs are 
metabolized by CYP450 enzymes, microsome becomes the most widely used for in-
vitro metabolism studies(Manikandan & Nagini, 2017). Microsome contains enzymes on 
endoplasmic reticulum, such as CYP450 enzymes, flavin-monooxygenases, 
glucuronosyltransferases, monoamine oxidase (Jia & Lliu, 2007). However, as an 
artificial sub-cellular fraction, microsome often faces the problem of capacity limitations 
(Foster et al., 2010).   The use of recombined enzyme is good for studying a specific 
enzyme isoform but limited by its deficiency of extrapolation to in-vivo clearance. Human 
liver cytosol (HLC) contains soluble metabolic enzymes, including sulfotransferases, 
methyltransferase, aldehyde dehydrogenase (ALDH), aldehyde oxidase, alcohol 
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dehydrogenase (ADH) and so on (Jia & Lliu, 2007).  Human liver S9 is the supernatant 
fraction obtained from liver homogenate by centrifuging at 9000 g for 20 minutes in a 
suitable medium, which contain both microsomal and cytosolic fractions that are 
commonly used to study sulfation, methylation, glucuronidation. Like other sub-cellular 
enzyme systems, HLS9 shares the same limitation of the lack of intact cell structure that 
accounts for cell membrane permeability and co-factors.  Hepatocytes and liver slices 
are the in-vitro systems that most closely mimic  in-vivo metabolism, including the intact 
cell environment and necessary co-factors that account for potential of hydrolysis, 
oxidation, reduction, and glucuronidation (Jia & Lliu, 2007).  Some major drawbacks for 
use of hepatocyte and liver slices are stability problem of the enzymatic activities, cell 
viability, and labor extensive (Jia & Lliu, 2007). None of in-vitro enzyme system is thus 
prefect but a system matched to the research interests provides the most needed 
information.  
ALDH is a primary enzyme that oxidizes varying endogenous and exogenous 
aldehydes to carboxylic acids using the co-factor NAD+. Human ALDH enzymes are 
involved in essential detoxified pathways and widely expressed in various tissues 
(Mezey, Rawles, Rhodes, & Potter, 1987; O’Brien, Siraki, & Shangari, 2005). Substrate 
specificity of ALDH is broad, covering a large variety of aldehydes, such as retinal, 
acetaldehyde, aromatic and aliphatic aldehydes (O’Brien et al., 2005). Previous in-vitro 
and in-vivo studies showed that some allosteric effectors of Hb (AEH) exhibit anti-
sickling activities, e.g. furaldehydes (example is 5-HMF) and benzaldehydes (INN-312), 
but are subjected to ALDH – mediated metabolism, rendering these molecules less 
desirable for development to treat sickle cell disease (SCD) (Obied, 2010; Parikh, 2013). 
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Novel synthetic AEH selected in this research are benzaldehydes that structurally share 
similar aromatic and pyridine ring with the previously studied anti-sickling 
benzaldehydes, i.e., INN-compounds. Like the INN compounds, these compounds, are 
also suspected to undergo ALDH-mediated metabolism. Liver is the major organ for 
detoxification of aldehydes by the most abundant metabolizing enzyme ALDH (O’Brien 
et al., 2005).  Both cytosolic ALDH-1 and mitochondrial ALDH-2, two major isoforms of 
ALDH are expressed in liver (O’Brien et al., 2005). ALDH-1 is also expressed in RBC, 
and was found to have similar physical, chemical, and kinetic properties as the ALDH-1 
in HLC (Mezey et al., 1987). ALDH-1 in both RBC and HLC show high affinity for 
aldehydes, low affinity to cofactor NAD+, and is strongly inhibited by disulfiram (Inoue, 
Nishimukai, & Yamasawa, 1979). In order to study the potential stability of AEH in 
presence of ALDH, HLC is chosen as the enzyme matrix to screen their metabolic 
efficiency.  
UV/Vis spectrophotometry is a commonly used analytical method for metabolic 
reactions, which has the advantages of low-cost, easy-sample preparation, and time-
effectiveness. To characterize metabolic reactions, several approaches are being used, 
including monitoring the depletion of substrate, the formation of product or co-factor 
consumption. Depending on the physicochemical properties of substrate and product, 
consumption of co-factor may be used to monitor enzyme activities. For example, if both 
the substrate and product share similar UV spectrum features and no detection 
wavelength can be optimized to separate product from substrate, monitoring the co-
factor consumption can be a good alternative way if substrate and product have limited 
interference at the detection wavelength of co-factor. To better conduct in-vitro 
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metabolic reactions using sub-cellular system like HLC, the concentration of 
corresponding co-factor (e.g. ALDH enzyme with NAD+ as the cofactor) need to be 
optimized. Enough concentration of co-factor is needed to be added into system to 
avoid the early completion of the metabolic reaction due to the deficiency of co-factor.  
A typical metabolic model to quantitatively characterize enzyme activity is 
Michaelis-Menten (MM) kinetics (Equation 4.2). Initial reaction rate (vi) is obtained as 
the slope from concentration (products or cofactor) -time dependent progress curve. 
When [S] << km, vi is proportional to the increase of substrate concentrations (apparent 
first-order kinetics). When [S] >>km, vi becomes independent of substrate 
concentrations due to the saturation of metabolic enzyme (apparent zero order kinetics). 
Intrinsic clearance (CLint) describes the ability of the organ to remove drug in the 
absence of flow limitations and binding to cells or proteins in the blood.  CLint can be 
estimated from the ratio of maximum reaction rate to binding affinity (vmax / Km), which is 
equal to the slope of the apparent first-order kinetics (when [S] << km). CLint is commonly 
used to compare the enzyme specificity to substrates. The larger the CLint is, the more 
efficient is the enzyme to clearing this specific substrate, in absence of other factors, 
including PPB and blood flow. It is also useful to allow extrapolation of in-vitro data to in-
vivo metabolism.  
AEH, characterized by aromatic aldehyde may be subject to ALDH-mediated 
metabolic degradation in red blood cells (RBC), limiting their duration of action. The 
main objective of this chapter is to screen their ALDH susceptibility in early developing 
phase. a UV/Vis spectrophotometric assay method was used to assess the oxidation of 
5-HMF, 2,5-DMF, TD isomers, INN-310, and VZHE-039 in HLC by monitoring the 
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reduction of the cofactor (NAD+) of ALDH. Their metabolic kinetic properties to ALDH 
enzyme were then characterized by MM kinetics or a linear apparent first-order kinetics. 
Structure features that protect the aldehyde group of AEH from ALDH enzyme 




4.2.  Methods 
4.2.1. Materials and Reagents 
1. Tris-HCl buffer 1 M, pH 7.5 (Fisher Scientific, Pittsburgh, PA). 
2. Tris Base (Sigma, St. Louis, MO) (121 g/mol) 
3. Co-factor - β-Nicotinamide adenine dinucleotide hydrate (NAD+) from yeast 
(Sigma, St.Louis, MO) (663 g/mol) 
4. β-Nicotinamide adenine dinucleotide, reduced dipotassium salt (NADH) 
(Sigma, St.Louis, MO) (742 g/mol) 
5. Ethanol 200 proof, 99.5% (Sigma-Aldrich, Milwaukee, WI) (46 g/mol) 
6. Acetaldehyde, ACS 99% (Sigma-Aldrich, Milwaukee, WI) (44 g/mol) 
7. HCl, ACS 37% (Sigma-Aldrich, Milwaukee, WI) (36 g/mol) 
8. 5-Hydroxymethyl-2-furfural (5-HMF) (Sigma, St. Louis, MO) (126 g/mol) 
9. 2,5-Furandicarboxaldehyde (2,5-DMF) (Sigma-Aldrich, Milwaukee, WI) (124 
g/mol) 
10. TD-7-HCl (provided by Dr. Martin Safo, Department of Medicinal Chemistry, 
VCU) (309 g/mol) 
11. TD-8-HCl (provided by Dr. Martin Safo, Department of Medicinal Chemistry, 
VCU) (309 g/mol) 
12. TD-9-HCl (provided by Dr. Martin Safo, Department of Medicinal Chemistry, 
VCU) (309 g/mol) 
13. INN-310 (provided by Dr. Martin Safo, Department of Medicinal Chemistry, 
VCU) (243 g/mol) 
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14. VZHE-039-HCl (provided by Dr. Martin Safo, Department of Medicinal 
Chemistry, VCU) (331 g/mol) 
15.  Vanillin ReagentPlus® 99% (Sigma, St. Louis, MO) (152 g/mol) 
16. Dimethyl sulfoxide (DMSO), ≥ 99.9%, A.C.S. Reagent (Sigma-Aldrich, 
Milwaukee, WI) (78 g/mol) 
17. Human Liver cytosol, 10 mg protein/mL, mixed gender, pool size 50 






1. Synergy™ 2 multi-mode microplate reader (BioTek, Winooski, VT). 
2. Greiner® UV-Star 96-well plate (Sigma, St.Louis, MO) 
3. Falcon® assay plate, 96-well plate (VWR, West Chester, PA). 
4. SciFinder® (CAS software, 2010). 
5. MarvinSketch, version 17.9 (ChemAxon software, 2017) 
6. Scientist®, version 3.0 (Micromath Softwar) 
7. pH Meter (Fisher Scientific, Pittsburgh, PA) 
8. Vortex (Vortex-Genie, VWR, West Chester, PA). 
9. Balance (Fisher Scientific A 250, Pittsburgh, PA). 
10. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA). 
11. 30 – 300 µL multichannel pipette (Fisher Scientific, Hanover Park, IL) 
12. 3-25 µL positive displacement pipette and corresponding pipette tips (Rainin 
Instruments, Oakland, CA). 
13. 10-100 µL and 100-1000 µL VWR pipettes and corresponding pipette tips 





4.2.3. Sample Preparation and Experimental Design 
1. 0.5 M Tris-HCl, pH 7.5 
60.57 g of Tris Base was dissolved in 800 mL sterile deionized (DI) water, 
and the pH adjusted to 7.5 with HCl with stirring. The Tris-HCl solution was then 
made up to 1000 mL with sterile DI water and filtered with sterile-filter.  
2. NAD+ solution 
11.2 mM stock solution was freshly made every day for oxidative 
metabolism experiments. 22.3 mg NAD+ was dissolved in 3 mL of 0.5 M Tris-HCl 
buffer (pH 7.5). 25 μL of 11.2 mM stock solution was added to each well of 96-
reaction plate to obtain a final in-well concentration of 1.4 mM (200 μL). 
3. NADH solution 
3.2 mM stock solution was freshly made every day for reductive 
metabolism experiments. 11.9 mg NAD+ was dissolved in 5 mL of 0.5 M Tris-HCl 
buffer (pH 7.5). 25 μL of 3.2 mM stock solution was added to each well of 96-
reaction plate to obtain a final in-well concentration of 0.4 mM (200 μL). 
4. Human liver cytosol (HLC) solution 
1.6 mg/mL stock solution was made with 160 μL of 10 mg/mL. HLC added 
to 840 μL of Tris buffer on ice. 25 μL was transferred to each well of 96-reaction 
plate to obtain a final in-well concentration of 0.2 mg/mL (200 μL). 
5. 0.5% DMSO in Tris buffer 
0.5 mL DMSO was added to 100 mL of Tris buffer. The co-factor NAD+ 
and NADH, and the HLC solutions were prepared with 0.5% DMSO in Tris buffer.  
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6. Substrate solution 
Most AEH (5-HMF, 2,5-DMF; salt form of TD-7, TD-8, TD-9 and VZHE-
039) were dissolved in Tris buffer with no co-solvent present. INN-310, which is 
insoluble in Tris buffer, was then dissolved with 0.5% DMSO as co-solvent. The 
concentration range for acetaldehyde and ethanol were selected based on 
previously reported Km values to cover the full MM kinetics (Parikh, 2013). For 5-
HMF, concentrations were studied up to 90 mM, which was approached to the 
UV/Vis detection limit (3 AU). For other novel AEH (2,5-DMF, TDs, INN-310, 
VZHE-039), concentrations were studied up to the solubility limit (Table 4.2). 
Solubility of AEH was estimated from their UV/Vis absorption at λmax, when 




4.2.4. UV/Vis Spectrophotometric (Warburg) Measurement Procedure 
Enzymatic reaction in HLC was characterized spectrophotometrically by 
monitoring by the formation or depletion of co-factor (NADH) at 340 nm (λmax) using a 
Synergy® 2 Multi-Mode Microplate reader. The absorbance of NADH was then 
converted to the corresponding concentrations using Lamber-Beer’s law (Equation 4.1), 
followed by in-well volume (200 μL) correction to obtain the amount generated or 
depleted during oxidative metabolism or reductive metabolism. 
 
∆A = ε * l * ∆C ----------------------------------------------------------- Equation 4.1 
∆A: change of absorbance measured by the microplate reader 
ε: experimental molar extinction coefficient of NADH at 340 nm 
l: pathlength of the solution in well 
∆C: change of NADH concentration 
 
The baseline absorbance at 340 nm from each AEH were captured in the micro-
well in the absence of HLC. The change of absorbance was corrected from the 





4.2.5. Validation of ALDH and ADH Activity in HLC 
Prototypical substrates of ALDH and ADH, i.e., acetaldehyde and ethanol 
respectively, were used to verify enzyme activities for each batch of HLC. Varying 
substrates concentrations were selected based on previous studies to capture full MM 
kinetics (Parikh, 2013). Kinetic parameters (Km, vmax, and CLintin-vitro) were estimated 
using a modified MM model and compared with literature reported values, to verify the 
enzyme activities of HLC for the AEH metabolism studies. 
4.2.6. Optimization of Experimental Conditions 
The concentrations of enzyme, co-factor and substrate determine the overall 
metabolic rate. To capture proper metabolic profile for kinetic parameter estimates 
within the reasonable reaction time frame, 0.2 mg/mL HLC and 1.4 mM NDA+ were 
selected based on previous studies for oxidative metabolism of AEH (Parikh, 2013). 
0.4 mM of NADH was used for reductive metabolism studies of AEH, which was 
optimized based on calibration curve and the UV/Vis detection limit.  
The concentration range of each substrate (AEH) was optimized according to 
the solubility and baseline interference of AEH. Before conducting the metabolism 
studies in HLC, UV spectrum properties (200 – 500 nm) of AEH were characterized 
first to estimate their interference at the detection wavelength (340 nm) and to 
determine their solubility in Tris buffer. Maximum absorbance wavelength (λmax) and 
the corresponding extinction coefficient (ε) were estimated. Solubility of AEH was 
assessed by observed their absorption deviation from Lambert-Beer’ law at λmax. ε340nm 
of AEH was characterized to assess their interference to NADH absorption.  
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Since INN-310 is insoluble in Tris buffer, DMSO was used as a co-solvent. The 
inhibition effect of DMSO to ALDH enzyme was studied using acetaldehyde with 2% or 
0.5% DMSO. We finally chose 0.5% over 2% DMSO, since 2% DMSO completely 
abolished ALDH enzyme activities in HLC.   
The interference of two types of plates, i.e., Greiner® UV-Star 96-well plate and 
Falcon® assay plate. ε340nm of NADH, kinetic parameters estimated from oxidative 
metabolism of acetaldehyde and ethanol in HLC were compared to assess the 
potential interference of the plates. 
4.2.7. Oxidative and Reductive Metabolism of AEH in HLC 
A mixture of co-factor (1.4 mM NAD+ for AEH oxidative metabolism and 0.4 mM 
NADH for reductive metabolism) and varying concentrations of AEH substrate were 
added to a 96-well plate and allowed to equilibrate for 15 mins at 37 °C. The metabolic 
reaction was initiated by addition of 0.2 mg /mL HLC. All concentrations listed above 
are final concentrations in well. Enzymatic reaction was measured by monitoring NADH 
spectrophotometrically at 340 nm (max) with constant slow plate shaking. Each 
experimental run was performed in triplicates.  
  Progress curve of NADH formation (oxidative reaction) or depletion (reductive 
reaction) were captured over 10 mins. Initial reaction rates (vi) were estimated as the 
initial linear slope from NADH progress curve, which are the zero-order rates of 
metabolism for the respective substrate concentrations. The vi values were then plotted 
against initial substrate concentrations ([AEH]0) to assess enzyme kinetics. Michaelis-
Menten (MM) curves were fitted by a modified MM model (Equation 4.2). Non-linear 
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regression approach (Scientist® software, version 3.0) was used to estimate kinetic 
parameters. Goodness-of-fit was assessed by r2, residuals, correlation matrix, and 
coefficient of variant (COV) of parameters.  
 
𝒗 = 𝒗𝟎 +
𝒗𝒎𝒂𝒙 ∗[𝑺]
𝑲𝒎+ [𝑺]
        ---- Equation 4.2 
v: initial metabolic reaction rate  
v0: baseline enzymatic activity (in absence of exogenous substrate) 
vmax: maximal rate of metabolism 
Km: MM affinity constant 
S: initial substrate concentration 
 
In-vitro metabolic efficiency, also known as intrinsic clearance (CLintin-vitro) was 
calculated based on the primary kinetic parameters (Equation 4.3) estimated from MM 
curve. For AEH, where only first-order enzyme kinetics were observed, CLintin-vitro was 
estimated as the slope from the non-saturable enzyme reaction phase. 
 𝑪𝑳𝒊𝒏𝒕
𝒊𝒏−𝒗𝒊𝒕𝒓𝒐 =  
𝒗𝒎𝒂𝒙
𝑲𝒎




4.3.1. Calibration of UV/Vis Spectrophotometer 
Since AEH and its corresponding carboxylic acid share similar UV spectrum 
properties, the formation of the reduced form of co-factor (NADH) was monitored over 
time instead of the product (carboxylic acid) or substrate (AEH). In this enzymatic 
reaction, when one molar of substate is converted to product, concurrently, one molar of 
co-factor (NAD+) is reduced to NADH. Therefore, by monitoring the formation of NADH, 
the oxidative metabolism of AEH can be characterized. Vice versa, by monitoring the 
depletion of NADH, the reductive metabolism can be characterized.  
The Lambert-Beer’s law is used to convert UV/Vis absorbance of NADH to molar 
concentrations (Equation 4.1). Literature reported the extinction coefficient of NADH at 
340 nm (εNADH) is 6.22 mM-1cm-1, while NAD+ with a significantly less absorbance (εNAD 
= 0.04 mM-1cm-1) (Horecker & Kornberg, 1948; Inoue et al., 1979). In order to determine 
the experimental molar absorptivity of NADH, calibration curves of NADH (0.01 – 0.5 
mM) were characterized at 340 nm. A 1/y weighted linear regression was applied to put 
more weighting on lower concentrations, which is the testing concentration range of the 
NADH used in the experimental set up for AEH metabolism studies.  Lambert-Beer’s 
law was used to estimate εNADH as the slope of the calibration curve. All tested NADH 
calibration curves were comparable using the two different 96-well plates (Greiner® UV-
Star and Falcon® assay plate), where εNADH ranged from 4.99 to 5.31 mM-1cm-1 (Figure 
4.1). The experimental molar absorptivity values (4.99 - 5.31 mM-1cm-1) were slightly 
lower than the literature reported values (6.22 mM-1cm-1) (Horecker & Kornberg, 1948; 
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Inoue et al., 1979), likely due to differences in experimental conditions and/or 
procedures. For example, the literature reported value was obtained by using a DU 
quartz spectrophotometer and 1.0 cm cells with Corex D windows, while we used the 
SynergyTM 2 multi-mode microplate reader and 96-well plates (Horecker & Kornberg, 
1948).  
 
Figure 4.1. Representative calibration curve of NADH at λ of 340 nm. 
 
  

































4.3.2. Selectivity of Assay Technique 
Since the absorbance of NADH was used to monitor the enzymatic reaction, 
assay selectivity at 340 nm was studied to assess other potential interfering factors, 
including the 96-well plate, Tris buffer, NAD+ and AEH. Empty plates show no notable 
absorption at 340 nm. As mentioned in section 4.3.1, both two type of plates show 
comparable εNADH at 340 nm, i.e., Greiner® UV-Star (5.16, 5.33 mM-1cm-1) and Falcon® 
assay plate (4.99 mM-1cm-1). Tris buffer shows no absorption at 340 nm. 1.4 mM NAD+ 
shows some baseline absorbance. Among the 7 tested AEH (5-HMF, 2,5-DMF, TD-7, 
TD-8, TD-9, INN-310, VZHE-039), molar absorptivity of NAD+ ranged from 0.1 to 0.2 
mM-1 cm-1, which was considered as low interference compared to NADH (εNADH = 4.99 
- 5.33 mM-1cm-1).  
The majority of the interference at 340 nm came from the benzaldehydes (Table 
4.1). Vanillin, the parent compound of the benzaldehydes showed more than 3-fold 
higher molar absorptivity (16.9 mM-1cm-1) than NADH at 340 nm. Therefore, its oxidative 
metabolic reaction in HLC could not be characterized by monitoring co-factor using this 
UV/Vis spectrophotometric assay. All other benzaldehydes, structurally characterized 
with an additional pyridine ring, showed 4 to 8-fold lower molar absorptivity than NADH 
at 340 nm, allowing co-factor to be monitored for the characterization of the enzymatic 
reactions after baseline correction. The two furaldehydes, namely 5-HMF and 2,5-DMF, 
showed 300-fold and 50-fold lower molar absorptivity than NADH at 340 nm (Table 4.1).   
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Table 4.1. Molar absorptivity of AEH at λ of 340 nm. 
 Extinction Coefficient  
 [mM-1cm-1] 
5-HMF 0.017 





VZHE-039  1.1 
INN-310 1.5 





4.3.3. Optimization of Experimental Conditions 
All batches of HLC showed baseline metabolic rate (v0), probably due to the 
existence of endogenous substances. v0 were similar among all oxidative or reductive 
metabolism studies (Table 4.2, Table 4.3), indicating experimental runs were carried out 
under similar experimental conditions. The capacity of enzyme (vmax) depends on the 
total amount of enzyme in system (Etot) and the catalytic activity (kcat). Increased 
concentrations of enzyme result in higher vmax, but also v0, which may lead to saturation 
of detection limit. Due to the reasons listed above and results from previous studies, 0.2 
mg/mL of HLC was chosen for all test AEH (Parikh, 2013).  
Some of the selected AEH have solubility issues in Tris buffer. One of solution to 
this problem was to use solubilizing agent, for example DMSO. However, DMSO has 
been known to inhibit ADH and ALDH enzyme activities (Obied, 2010; Parikh, 2013). 2% 
DMSO showed completely inhibition of ALDH enzyme activity to acetaldehyde. 0.5% 
DMSO resulted in 30% decrease on vmax and 50% decrease on CLint of acetaldehyde, 
compared to enzyme with no DMSO (Figure 4.2). 0.5% DMSO was eventually 
determined to be optimal for studying one of the AEH, namely INN-310. We used an 
alternate solution to increase the solubility of other AEH by derivatizing the free acids of 
the following AEH (TD-7, TD-8, TD-9 and VZHE-039) into their corresponding HCl salt 
forms (provided by Dr.Zhang and Dr.Safo’s labs) for metabolism studies in HLC.  
The oxidative metabolism of AEH is facilitated by co-factor, i.e. NAD+, where 
reductive metabolism of AEH is facilitated by its reduced form NADH. Concentration of 
co-factor influence overall enzymatic reactions. An inadequate co-factor would result in 
rapid completion of reactions due to exhaustion of co-factor supply. However, high 
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concentration of co-factor, especially NADH, would increase the baseline interference 
and even saturate detection limit. Therefore, based on preliminary data and previous 
studies, 1.4 mM of NAD+ and 0.5 mM of NADH were chosen for oxidative and reductive 
metabolic studies, respectively (Parikh, 2013).  
Substrate concentration ranges of the acetaldehyde and ethanol were optimized 
according to the literature reported Km. In order to characterize the full MM profiles and 
estimate relative parameters (vmax, Km), concentrations of acetaldehyde and ethanol 
were chosen to cover at least 10-fold lower and higher than their Km (Table 4.2). 
Concentration ranges for tested AEH were limited due to different reasons. For most 
AEH, upper limits were due to the solubility issues, therefore only low millimolar 
concentrations of AEH were used in oxidative and reductive metabolism studies in HLC 
(Table 4.2). For 5-HMF, concentrations were studied up to 90 mM, where it approached 
to the saturation of detection limit (3 AU) due to baseline absorption of 5-HMF.  
4.3.4. Validation of ALDH and ADH Activity 
Acetaldehyde was used as substrate to verify ALDH activity for each batch of 
HLC. Because of the presence of the methyl alcohol, 5-HMF is also expected to subject 
to ADH, therefore ADH activity was also verified by using ethanol as substrate (Figure 
4.3). The studied concentrations of acetaldehyde and ethanol covered both first-order 
and zero-order enzyme kinetics. Plateau of MM curves were achieved. Km of 
acetaldehyde obtained from two different plates (0.012 mM, 0.016 mM) and vmax (1.4 
mM, 1.0 mM) were slightly different but comparable between two batches of HLC, 
indicating metabolic results obtained using these two batches of HLC can be compared 
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and interpreted among different AEH. Experimental Km value of acetaldehyde is smaller 
but still comparable (0.014 mM) to literature reported value (0.03 – 0.10 mM) (Vasiliou, 
Pappa, & Petersen, 2000). Similarly, ADH enzyme activity between two batches are 
comparable (Km = 1.4 mM, 1.9 mM; vmax = 2.5 mM, 1.9 mM), and are similar to literature 





Figure 4.2. Concentration-dependent oxidative metabolism of acetaldehyde in 
HLC with/without 0.5%DMSO. The modified MM model (lines) was fit to the 







































Figure 4.3. Concentration-dependent oxidative metabolism of ethanol in HLC. The 
modified MM model (line) was fit to the experimental data (symbols). Data are 








































4.3.5. Oxidative Metabolism of AEH in HLC 
For each experimental run, the baseline absorbance of each AEH at 340 nm in 
the well were comparable to the ε obtained during method validation procedure, 
indicating that AEH were well dissolved and achieved the designed concentrations in 
well.  
None of the tested AEH showed saturable metabolism in HLC. 5-HMF, TD-7 and 
INN-310 showed first-order enzymatic reactions with Km and vmax in millimolar range 
(Table 4.2, Figure 4.4, Figure 4.5). Compared to acetaldehyde, which has Km in 
micromolar range and vmax in low millimolar range, 5-HMF, TD-7 and INN-310 are 
considered as low affinity but high capacity substrates to ALDH, resulting in low in-vitro 
intrinsic clearance (CLintin-vitro). Though there is an additional aldehyde group that 
replaces the methyl hydroxy group of 5HMF on the furan ring, the initial reaction rates 
(vi) of 2,5-DMF only fluctuated around baseline v0, indicating no net oxidative 
metabolism evidence at the studied concentration range.  
TD-7 and INN-310 showed higher CLintin-vitro than 5-HMF in HLC. Among the TD 
isomers, TD-8 and TD-9, structurally featured with para-methoxy group instead of meta-
methoxy group in TD-7, showed no net oxidative metabolism in HLC.  Compared to TD-
7, the only structurally difference for VZHE-039 is the ortho-hydroxy group that protects 
aldehyde/AEH from ALDH enzymatic degradation (Figure 4.5). Structurally, the only 
difference between TD-7 and INN-310 is the methyl-hydroxy group on pyridine ring in 
TD-7. Due to solubility issue, INN-310 was tested in presence of 0.5% DMSO. Even this 
low DMSO concentration decreased ALDH enzyme activities in HLC by 50%, INN-310 
still showed faster CLintin-vitro than TD-7.  
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Figure 4.4. Concentration-dependent oxidative metabolism of 5-HMF in HLC. The 
linear regression (line) was fit to the experimental data (symbols). Data are 














































Figure 4.5. Concentration-dependent oxidative metabolism of TD-7 and VZHE-039 
in HLC. The linear regression (line) was fit to the experimental data (symbols). 
Data are presented as mean ± SD (n=3). 






































Table 4.2. Final parameter estimates of oxidative metabolism of AEH as well as 
acetaldehyde and ethanol (prototypical substrates of ALDH and ADH enzyme) in 
HLC, using linear regression for AEH and modified MM model. Data are presented 
as the mean from two separate experiment runs (except INN-310 and 
acetaldehyde in 0.5% DMSO with only one experiment run), where each 
experiment run as triplicates (n=3).  
Substrate 








5-HMF 1.4 - 90 >90 >90 0.036 0.5 
2,5-DMF 0.003 - 3 NA NA NA 0.5 
TD-8 0.02 – 0.6 NA NA NA 0.7 
TD-9 0.004 – 0.3 NA NA NA 0.6 
TD-7 0.01 – 0.5 > 0.53 >0.53 0.88 0.5 
VZHE-039 0.02 – 1.2 NA NA NA 0.4 
INN-310 
(0.5%DMSO) 
0.0003 – 0.3 > 0.30 >0.30 1.6 0.3 
Acetaldehyde 
(0.5% DSMO) 
0.001 – 0.9 0.019 0.85 44 0.2 
Acetaldehyde  0.001 – 0.9 0.014 1.2 89 0.4 







4.3.6. Reductive Metabolism of AEH in HLC  
Both 5-HMF and 2,5-DMF (furaldehydes) showed saturable reductive 
metabolism in HLC (Figure 4.6). A modified MM model were used to fit the 
experimental data (Equation 4.2 in section 4.2.7). Initial estimates were based on the 
visual inspection of experimental data. For 5-HMF, initial estimates were v0 = 2.5 
nmoles/min/mg, vmax = 3 nmoles/min/mg, and Km = 1.5 mM. For 2,5-DMF, initial 
estimates were v0 = 2.5 nmoles/min/mg, vmax = 16 nmoles/min/mg, and Km = 1.0 mM. 
Final estimates were listed in table 4.3. 5-HMF achieved plateau and showed more 
than 5-fold smaller enzyme capacity (vmax) than 2,5-DMF. Both of compounds showed 
similar affinity. However, 2,5-DMF with an additional aldehyde group on the furan ring 
(replaces the methyl hydroxyl group on 5-HMF) shows higher intrinsic clearance 
(CLintin-vitro) due to its larger vmax. Unlike furaldehydes, none of tested benzaldehydes (n 





Figure 4.6. Concentration-dependent reductive metabolism of 5-HMF and 2,5-DMF 
in HLC. The modified MM model (lines) were fit to the experimental data (symbols). 









































Table 4.3. Final parameter estimates of reductive metabolism of AEH in HLC, 
using the modified MM model. Data are presented as PE with (COV) (n = 3). 
Substrate 








5-HMF 0.06- 60 2.2 (40%) 3.4 (9%) 1.5 (49%) 2.7 (8%) 
2,5-DMF 0.003 - 3 2.0 (47%) 18.1 (22%) 9.0 (69%) 2.3 (16%) 
TD-8 0.02 – 0.6 No evidence 1.4 
TD-9 0.004 – 0.3 No evidence 1.8 
TD-7 0.001 – 0.5 No evidence 1.3 
VZHE-039 0.02 – 1.2 No evidence 1.5 
INN-310 
(0.5%DMSO) 




4.4.  Discussion and Conclusions 
The purpose of this part of research was to study the ALDH susceptibility of 
selected AEH (5-HMF, 2,5-DMF, TD-7, TD-8, TD-9, INN-310, and VZHE-039). By using 
a UV/Vis spectrophotometer assay method, their ALDH-mediated oxidation was 
successfully characterized in HLC. Key structure features that protect the aldehyde 
group from ALDH metabolism were identified. In addition, their reductive metabolism 
was also studied to understand their possible complication to the interpretation of 
ALDH-mediated oxidation results in HLC.  
5-HMF showed net oxidative metabolism in HLC. The methylhydroxyl group on the 
furan ring was also expected to undergo alcohol dehydrogenase (ADH)-mediated 
metabolism in HLC as well. Previous studies showed that in the presence of the ALDH 
and ADH enzymes inhibitor (i.e., 17.4 μM disulfiram), maximum inhibition of 59.9 % 
oxidative metabolism of 5-HMF in HLC was observed (Obied, 2010). When 273 μM of 
methylpyrazine, inhibitor of ADH, was added in HLC, maximum inhibition of oxidative 
metabolism for 5-HMF in HLC was 33.6% (Obied, 2010). These observations indicate 
that both ADH-mediated and ALDH-mediated metabolisms of 5-HMF occur in HLC.  
5-HMF also undergoes reductive metabolism in HLC by consuming NADH that 
competes with the oxidative metabolism (Scheme 4.1.a). Therefore, CLintin-vitro of ALDH-
mediated oxidative metabolism is expected to be underestimated in HLC. A possible 
responsible enzyme for this reductive reaction is ADH. Literature suggested that ADH is 
able to reduce aldehyde back to alcohol (Jelski et al., 2008). The influence from ADH-
mediated oxidative and reductive metabolism complicates the extrapolation from in-vitro 
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HLC results to intra-RBC metabolism, since ADH enzyme is absent in RBC. In addition, 
lack of the information of ALDH enzyme concentration in RBC, CLintin-vitro obtained from 
HLC cannot be quantitatively extrapolated into RBC. Though many factors listed above 
hindered the quantitative extrapolation for 5-HMF, qualitatively, 5-HMF is expected to be 
metabolized by ALDH enzyme in RBC. This is also supported by the previous in-vitro 
studies, where ALDH-oxidation of 5-HMF was observed in diluted human RBC(Obied, 
2010).  
5-HMF showed a first-order oxidative metabolism in HLC, because the studied 
substrate concentrations were lower than Km (> 90 mM). The dosing regimen of 5-HMF 
in phase II clinical trial was 1000 mg (4 times a day)(“ClinicalTrials.gov.,” 2020). 
Assuming a body fluid of 250 mL, the nominal concentration of a single dose (1000 mg) 
administration for 5-HMF would be 32 mM (MW = 126 g/mole), which is lower than Km. 
A non-saturable ALDH metabolism in RBC is expected for 5-HMF under physiological 
relevant concentrations.  
2,5-DMF with an additional aldehyde group that replaces the methyl hydroxy group 
of 5HMF showed no net oxidative metabolism. However, all previously and currently 
studied furaldehydes (n = 5) showed reductive metabolism evidences in HLC(Wohlford, 
Safo, & Venitz, 2015). One possible reason could be the ADH-mediated reductive 
metabolism balanced out the ALDH-mediated oxidative metabolism in HLC (Scheme 
4.1.b). Though 2,5-DMF showed no net oxidative metabolism in HLC, it might show 
ALDH-mediated metabolism in RBC, because of the missing ADH-mediated reductive 
metabolism pathway in RBC.  
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The competing reductive metabolism in HLC complicated the interpretation of the 
ALDH-mediated oxidative metabolism for 5-HMF and 2,5-DMF, which also applies to 
other previously studied furaldehydes studied by previously, namely 5-MMF, 5-EMF, 
and 5-PMF(Wohlford et al., 2015). Unlike the furaldehydes, the benzaldehydes (TD-7, 
TD-8, TD-9, INN-310, and VZHE-039) did not show evidence of reductive metabolism in 
HLC, indicating the furan ring is more susceptible to reductive enzymes than benzene 
ring, presumably and primarily due to ADH enzyme.  
RBC and HLC share the same isoform of ALDH enzyme (ALDH-1)(Mezey et al., 
1987). Reductive metabolism in HLC does not apply to the studied benzaldehydes. 
Therefore, a benzaldehyde with no in-vitro oxidative metabolism evidence in HLC are 



























By comparing the oxidative metabolism among the different benzaldehydes in 
HLC, it became obvious that certain structural features seem to protect AEH from ALDH 
enzymatic degradation (Figure 4.7). Meta-methoxy group (in TD-7 and INN-310) favors 
ALDH-mediated oxidative metabolism, while para-methoxy group (in TD-8 and TD-9) 
show no oxidative metabolism in HLC. Methoxy group is an electron-donating group 
that will affect the overall electric density of aromatic ring (“Reactions of 
Arenes.Electrophilic Aromatic Subsitution [online]. Accessed June-10,” 2020). Meta-
positioned methoxy may increase the electropositive nature of the carbon atom and 
electronegative of oxygen atom of the aldehyde group, which would favor conversion of 
the aldehyde moiety to the corresponding carboxylic acid by ALDH enzyme. It is also 
possible that para-methoxy group unlike meta-methoxy group sterically prevent the AEH 
from optimally binding to the ALDH. TD-7 and INN-310 are expected to undergo intra-
RBC metabolism in WB, while TD-8 and TD-9 are not. Time-dependent Hb modification 
studies in WB are consistent with this conclusion, where TD-7 and INN-310 showed 
modified Hb level to decrease after 2 hrs, while TD-8 and TD-9 sustained for at least 12 
hrs (Pagare et al., 2018). VZHE-039 is structurally similar to TD-7 but the former has a 
hydroxyl group ortho to the aldehyde, while the latter has a methoxy group meta to the 
aldehyde. The presence of the hydroxyl group led to VZHE-039 resistance to ALDH 
enzyme. The ortho-hydroxy forms an intra-hydrogen bond with the aldehyde group to 
protect the aldehyde from ALDH enzymatic degradation. Therefore, TD-8, TD-9 and 
VZHE-039 with certain unique structural features on the benzene ring are able to 
protect the aldehyde group from ALDH-mediated oxidative metabolism in HLC, which 
are expected to be resistance to intra-RBC metabolism in WB as well. 
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 GBT-440 (Voxelotor, Oxbryta®), structurally characterized with an ortho-hydroxy 
group like VZHE-039, is predicted to be resistance to ALDH-mediated metabolism in 
RBC. Phase I clinical studies showed that with 1000 mg single-oral dose (powder in 
capsule), GBT-440 concentration in RBC peaked with a median of 14 hrs and showed a 
terminal half-life of 50 hrs over 600 hrs measurements among 6 healthy volunteers 
(Hutchaleelaha et al., 2019). This slow RBC clearance supports our hypothesis of GBT-
440 resistance to ALDH-mediated metabolism in RBC. Clinical studies showed that 
GBT-440 primarily undergoes hepatic clearance metabolized by CYP-3A4, with minor 
contribution from CYP-2C19, CYP2B6 and CYP-2C9, and it also undergoes phase-2 
conjugation by UGT and SULT (Multi-Discipline Review of Voxelotor, 2019). GBT-440 is 
also a CYP-3A4 inhibitor, supported by clinical DDI studies(Multi-Discipline Review of 
Voxelotor, 2019). GBT-440 is expected to be low extraction ratio drug due to its highly 
PPB (99.8%, does-independent)(Multi-Discipline Review of Voxelotor, 2019), which is a 
favorable PK property to prolong its circulating time in body. 
Similar to GBT-440 (cLogP = 3.5), VZHE-039 also shows high in-vitro PPB (98% 
at 5 μM), presumably due to its lipophilicity (cLogP =1.8) (Safo, 2019), and therefore is 
expected to be a low extraction ratio substrate in liver as well. VZHE-039 does not show 
obvious in-vitro inhibition to CYP-3A4, CYP-2C9 and CYP-2C19 enzymes (IC50 > 100 
μM), with some inhibition to CPY1A2 (4.7 μM) and CYP2B6 (41.4 μM) (Safo, 2019). Our 
in-vitro HLC study suggested VZHE-039 is resistant to ALDH-mediated metabolism, and 
therefore, is expected to sustain in RBC (target site). These in-vitro metabolic and PPB 




In summary, this study provides fundamental structure-activity-relationship for 
AEH, including furaldehydes and benzaldehydes with respect to their ALDH-mediated 
metabolism in HLC. Since HLC and RBC express the same isoform of ALDH (ALDH-1), 
this HLC approach allows rational design of potential improved candidates with 
resistance to intra-RBC metabolism. This approach can be used as a critical tool to 
screen drug candidates for SCD therapy at early development stage with benefits of 
lower cost, lower risk and higher efficiency than in-vivo approaches.  Among the tested 
AEH, key molecular features that protect the aldehyde moiety from intra-RBC 
metabolism have been identified, namely the ortho-hydroxy group by forming intra 
molecular hydrogen bond and potentially para-methoxy group by enhancing 
electropositivity of the carbon atom in aldehyde group or increase steric hindrance.  
VZHE-039, TD-8 and TD-9 are selected as good candidates from the prospective of 





5. IN-VITRO DISPOSITION OF VZHE-039 AND 5-HMF IN WB 
5.1 Introduction 
This chapter addresses the specific aim 3: To integrate the underlying disposition 
mechanisms of WB (WB) using quantitative kinetic models for VZHE-039 and 5-HMF. 
WB (WB) is the target “tissue” for allosteric effectors of Hb (AEH), where they 
bind to Hb RBC) to elicit their anti-sickling effect.  In the WB environment, other 
processes may facilitate or hinder AEH penetrating into RBC and/or binding to Hb. 
These processes include ALDH-mediated metabolism in RBC, metabolism in plasma, 
plasma protein binding (PPB) and RBC membrane binding/crossing (Scheme 5.1). 
Therefore, their apparent binding affinity and binding kinetics of AEH to Hb in WB may 




Scheme 5.1. WB disposition of AEH 
 
  















As discussed in Chapter 3 and 4, the HbA binding kinetic properties and in-vitro 
ALDH-mediated metabolism of selected AEH have been characterized. Among the 
studied AEH, 5-HMF and VZHE-039 were chosen to further study their disposition in 
WB, based on their HbA binding properties and ALDH-mediated metabolism. 5-HMF is 
our previous lead compound with moderate anti-sickling potency, which underwent 
phase II clinical study until terminated due to apparent lack of efficacy in SCD. VZHE-
039, which is more potent than 5-HMF in inhibiting RBC sickling, is currently one of our 
top candidates, and undergoing preclinical studies for the treatment of SCD. 5-HMF 
behaves as a slow Hb binder (t1/2eq = 3.1 hrs) with relatively low affinity to Hb (KD = 0.37 
mM) in Hb solution, and undergoes significant ALDH-mediated oxidative metabolism in 
human liver cytosol (HLC). VZHE-039, on the other hand, exhibits faster Hb binding 
(t1/2eq = 0.058 hrs) and high affinity to Hb (KD = 0.10 mM), and is resistant to in-vitro 
ALDH-mediated oxidative metabolism. The physicochemical properties of these two 
compounds are also quite different:  While 5-HMF is hydrophilic (cLogP = -0.1), VZHE-
039 is lipophilic (cLogP = 1.8). 
Previous studies had shown that the in-vitro plasma clearance (CLplasmain-vitro) of 
5-HMF in WB was high, but decreased with increasing [5-HMF]0 (2 – 5 mM)(Parikh, 
2013). Two processes may be responsible for this non-linear behavior, namely 
saturable Hb binding and/or saturable ALDH-mediated metabolism in RBC. In-vitro HLC 
studies showed that 5-HMF – relative to acetaldehyde - behaves as a low affinity 
(Km >90 mM) and high-capacity (vmax > 90 nmoles/min/mg) substrate for ALDH (Chapter 
4). At the studied concentrations in WB, 5-HMF was expected to show first-order ALDH-
mediated metabolism in RBC. Therefore, saturable Hb binding was speculated to cause 
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the saturable clearance of 5-HMF in plasma. However, the lack of a validated generic 
analytical assay method on quantification of Hb-AEH adduct prevented the testing of 
this hypothesis in the original study (Parikh, 2013). In this chapter, we directly quantitate 
Hb-AEH adduct in WB to further characterize the disposition of 5-HMF. 
In this previous WB study, the p50-shift (pO2 at 50% oxygen saturation), i.e. the 
change of oxygen binding affinity of Hb, was used to indirectly characterize Hb binding 
properties of AEH, as it was assumed to reflect concentrations of HbA-5HMF adduct 
(Parikh, 2013). Kinetic profiles were characterized not directly from 5-HMF, Hb, or HbA-
AEH adduct concentrations in RBC, but indirectly based on plasma concentration (cp) of 
5-HMF and the corresponding p50-shift in WB which is the downstream effect of HbA-
AEH adduct(Parikh, 2013).  In this research, a generic “universal” analytical assay 
method allows direct characterization of the primary HbA binding profile of AEH by 
measuring HbA-AEH adduct concentrations. 
The objective in this chapter is to determine in-vitro disposition of 5-HMF and 
VZHE-039 in WB. To fulfill this objective under specific aim 3, the following research 
tasks were carried out: 1). Quantitate the HbA-AEH adduct concentrations for 5-HMF 
and VZHE-039 using a cation-exchange HPLC/UV assay method. 2). Apply non-
compartmental analysis (NCA) to estimate AUC from HbA-AEH adduct concentration – 
time profile. 3). Develop quantitative models to adequately fit the experimental data 
(HbA-AEH adduct concentrations) and to fully characterize their concentration and time-
dependent Hb binding properties. 4). Compare the Hb binding properties of VZHE-039 
and 5-HMF in WB and to their binding properties in isolated HbA solution. 5) Quantitate 
the plasma concentration of VZHE-039 using a reversed-phase HPLC/UV assay. 6) 
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Apply NCA to estimate relevant PK parameters for VZHE-039, assess dose-
proportionality and compare with the plasma disposition of 5-HMF from previous studies. 
7). Integrate the available experimental and literature information to analyze the 





5.2.1. Materials and Reagents 
1. NERL® high purity water (Fisher Scientific, Nazareth, PA) 
2. Bis-tris (Sigma-Aldrich, St.Louis, MO) (209.24 g/mol) 
3. Potassium cyanide (Sigma-Aldrich, St.Louis, MO) (KCN, 65.12 g/mol) 
4. Sodium chloride (Sigma-Aldrich, St.Louis, MO) (NaCl, 58.44 g/mol) 
5. HbA solution (purified by Dr. Martin Safo’s lab, Department of Medicinal 
Chemistry, VCU) (12.60 g/dL) 
6. Formic acid (Sigma-Aldrich, St.Louis, MO) (46.03 g/mol) 
7. Methanol, HPLC grade (Burdick and Jackson, Morristown, NJ) 
8. Hydrochloric acid, ACS 37% (Sigma-Aldrich, Milwaukee, WI) (HCl ,36.46 
g/mol) 
9. Sodium cyanoborohydride (sigma-aldrich, St.Louis, MO) (NaBH3CN, 62.84 
g/mol) 
10.  Sodium borohydride (sigma-aldrich, St.Louis, MO) (NaBH4, 37.84 g/mol) 
11. 5-Hydroxymethyl-2-furfural (5-HMF) (Sigma, St. Louis, MO) (126.11 g/mol) 
12. VZHE-039 (provided by Dr. Martin Safo, Dr. Yan Zhang, Department of 
Medicinal Chemistry, VCU) (259 g/mol) 
13. Dimethyl sulfoxide (DMSO), ≥ 99.9%, A.C.S. Reagent (Sigma-Aldrich, 
Milwaukee, WI) (78.13 g/mol) 
14. 0.5M EDTA.2Na, pH 8.0 (Quality Biological, Gaithersburg, MD) 




1. 96-well deep plate (Thermo Scientific, Nazareth, PA) 
2. Incubator (Thermo Fisher Scientific Inc., Pittsburgh PA) 
3. ABL800 FLEX blood gas analyzer (Radiometer America, Brea, CA) 
4. HPLC Water 2695 (Waters, Milford, MA) 
5. Photodiode array detector 2996 (Waters, Milford, MA) 
6. Poly CATA weak cation-exchange column, 30 mm x 4.6 mm (PolyLC, Inc., 
Columbia, MD)  
7. BDS HYPERSIL C18 column, 50 mm x 4.6 mm (Thermo Scientific, Nazareth, 
PA); 
8. Supelco® pre-column Filter 0.2 μm (Sigma-Aldrich, St.Louis, MO)  
9. Durapore® membrane filter, 0.22 μm (Sigma-Aldrich, St.Louis, MO) 
10. 9 mm autosampler Insert (VWR, West Chester, PA) 
11. 9 mm autosampler Insert (Thermo Fisher Scientific Inc., Pittsburgh PA) 
12. 9 mm autosampler vail (Waters, Milford, MA) 
13. 9 mm autosampler vail cap (Thermo Fisher Scientific Inc., Pittsburgh PA) 
14. Vacuum filtration apparatus (assembled, department of MedChem, VCU) 
15. Empower 2 software (Waters, Milford, MA) 
16. Scientist®, version 3.0 (Micromath Software) 
17. pH Meter (Fisher Scientific, Pittsburgh, PA) 
18. Vortex (Vortex-Genie, VWR, West Chester, PA) 
19. Balance (Fisher Scientific A 250, Pittsburgh, PA) 
20. Micro centrifuge (USA Scientific, Ocala, FL) 
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21. Centrifuge 5804R (Eppendorf, Hauppauge, NY) 
22. Thermo Sorvall Legend Micro 17 centrifuge (Thermo Scientific, Waltham, MA) 
23. 0.5-5 mL Finnpipette (Thermo Scientific, Waltham, MA) 
24. 30 – 300 µL multichannel pipette (Fisher Scientific, Hanover Park, IL) 
25. 3-25 µL positive displacement pipette and corresponding pipette tips (Rainin 
Instruments, Oakland, CA). 
26. 10-100 µL and 100-1000 µL VWR pipettes and corresponding pipette tips 





5.2.3. Preparation of Solutions 
1. NaBH3CN and NaBH4 solution (stopping solution)  
10 mg NaBH3CN was dissolved into 3 mL of water to make 50 mM NaBH3CN 
solution. 10 mg of NaBH4 was dissolved into 5 mL of water to make 50 mM NaBH4 
solution. NaBH3CN/NaBH4 mixture (1:1 v/v) stock solution was freshly made every day 
for the experiments. The mixture was used to stop the Schiff-base reaction between the 
AEH and Hb, and also to reduce unreacted aldehydes for kinetic measurement of HbA-
AEH adduct at specific time points (Deshpande et al., 2018).  
2. VZHE-039 and 5-HMF stock solution 
VZHE-039 or 5-HMF was dissolved in DMSO to make 100 mM stock solution. 
Different volume of stock solution was added to 96-well plate to achieve designed final 
initial nominal concentration of VZHE-039 or 5-HMF in the 96-well (see section 5.2.1 for 
concentration range). Final concentration of DMSO in 96-well was kept equal or less 
than 2%.  
3. Mobile phases for VZHE-039 quantification in plasma  
Aqueous phase was made using HPLC grade water with 0.1% FA. Organic 
phase was made using ACN with 0.1%FA. 
4. Mobile phases for HbA-AEH adduct quantification in WB 
Buffer A (20 mM Bis-Tris, 2 mM KCN, pH 6.5) and buffer B (20 mM Bis-Tris,2 
mM KCN, 200 mM NaCl, pH 6.6) were made using HPLC grade water, and adjusted pH 
with HCl. 8.37 g Bis-Tris, 0.26 g KCN were dissolved in 2000 mL water to make Buffer 
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A. 8.37 g Bis-Tris, 0.26 g KCN, and 23.38 g NaCl were dissolved in 2000 mL water to 
make Buffer B. The mobile phases were filtered through membrane filter (0.22 μm) 
under vacuum. 
5. VZHE-039 calibration curve in net solution 
Net solution was prepared with water and ACN (V:V = 1:1). Spike VZHE-039 
solution to net solution to achieve final concentration of 0.004 – 8 mM and injected 50 
μL into HPLC. 
6. VZHE-039 calibration curve in plasma 
Plasma was prepared from WB donated by healthy volunteer. WB was 
centrifuged at 3000 rpm for 8 mins to collect top plasma layer. Different volume of 
VZHE-039 stock solution was added into blank plasma sample to achieve a final 
concentration range of 0.004 – 8 mM. In order to deproteinize plasma proteins, 200 μL 
ACN (with 0.1%FA) was added to each plasma sample with VZHE-039 spiked (50 μL). 
Samples were well mixed, and left at 4°C for 30 mins for protein precipitation. Then 
samples were centrifuged at 13,000 rpm for 20 min. The top layer (supernatant) was 
collected and transferred to HLPC tube, which 50 μL was injected for HPLC analysis. 
7. HbA calibration curve in water 
Hb was purified from discarded normal blood samples using standard 
procedures(Safo & Abraham, 2003). Concentration of isolated HbA solution was 
measured using automated blood gas analyzer (Radiometer America, Inc., Westlake, 
OH), followed by dilution with HPLC grade water to the designed concentration range 
(0.0005 – 0.5 mM) of calibration curve.  
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5.2.4. Experimental Design  
5.2.4.1. HbA-AEH Adduct Quantification in WB 
Normal WB was collected from adult donors at the Virginia Commonwealth 
University after informed consent, in accordance with regulations of the IRB for 
Protection of Human Subjects. WB was used within 48 hrs to ensure the integrity of 
blood components including the enzyme activities.  %Hct was measured by blood gas 
analyzer (Radiometer America, Inc., Westlake, OH) (45%Hct, 2.3 mM HbA for VZHE-
039; 38%Hct, 2.0 mM HbA for 5-HMF). Varying initial concentrations of VZHE-039 or 5-
HMF were added to 2.25 mL WB in a 96-well plate and incubated at 37 ºC with mild 
shaking.  After compound addition, 30 μL aliquots were taken at different time points 
until 24 hrs. 150 μL (6-fold dilution) NaBH3CN/NaBH4 was added to and well mixed with 
each aliquot to terminate the Schiff-base reaction and to hemolyze WB(Deshpande et 
al., 2018).  Aliquots were immediately frozen and kept at -80 ºC. HbA-AEH adduct was 
measured in WB hemolysate instead of RBC to avoid additional Schiff-base reaction 
time during plasma separation process. For HPLC analysis, aliquots were thawed on ice, 
and centrifuged at 6000 rpm for 10 mins to separate HbA solution with cell membrane. 
10 μL of top supernatant was injected for HPLC analysis at 4 ºC.  
For VZHE-039, three pilot studies were performed to finalize experimental 
condition for definitive studies. The first pilot study was designed to determine proper 
dilution factor to quantify HbA-AEH adduct and HbA for HPLC analysis. According to the 
kinetic binding profile (KD = 0.1 mM, t1/2eq = 0.058 hrs) of VZHE-039 in isolated HbA 
solution, 0.03, 0.1, and 2 mM initial concentrations were prepared. 30 μL aliquot was 
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taken at 0.05, 0.5, and 1 hrs and mixed with 120 μL (5-fold dilution) NaBH3CN/NaBH4. 
After thawing (from -80ºC) aliquots were further diluted to 15-fold and 25-fold relative to 
the original WB concentrations. The second and third pilot studies were designed to 
determine concentration and time points for definitive studies.   Initial concentrations of 
0.25, 0.4, 0.5, 0.8, 1. 1.6, 2 mM were chosen and aliquots were taken at 0.1, 0.5, 1, 1.5, 
2, 5.5, 6.5, and 20 hrs for pilot 2 study. However due to the bad performance of 
analytical column, HbA-AEH adduct peak did not adequately separate from natural HbA 
peak for pilot 2 studies. For pilot 3 study, due to limitation by available WB volume, 
initial concentrations of 0.4, 0.5, 1, 2, 4, 8 mM were chosen and aliquots were taken at 0, 
2.5, and 17 hrs. For definitive study, 0.3, 0.5, 0.9, 1.4, 2.0, 2.7, 4.2, 7.8 mM of VZHE-
039 were studied with aliquots taken at 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 5, 8, 12, 15, and 24hrs.  
For 5-HMF, one definitive study was performed. The initial concentrations (0.5, 1, 
2, 3, 5 mM) were selected based on previous study (Parikh, 2013). Aliquots were taken 
at 0.1, 0.5, 1, 1.5, 2, 4, 8, 10, 12, 14, and 24 hrs, which is similar to the sampling 
schedule of VZHE-039 in order to compare their kinetic profiles. 
5.2.4.2. VZHE-039 Quantification in Plasma 
In the definitive study of VZHE-039, while preparing WB hemolysate, 150μL 
aliquots were taken at the same time point and centrifuged at 6000 rpm for 3 mins to 
separate plasma from RBC. 50 μL of top plasma was then collected and frozen at -80 
ºC. After plasma sample thaw on ice, 200 μL of ACN (with 0.1%FA) was added to 
plasma to deproteinize plasma proteins. Samples were well mixed, and left at 4°C for 30 
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mins for protein precipitation. Then samples were centrifuged at 13,000 rpm for 20 min. 
Top clear supernatant was collected and 50 μL was injected for HPLC analysis. 
5.2.5. HPLC-UV/Vis Conditions 
5.2.5.1. HbA-AEH Adduct Quantification in WB 
HbA and HbA-AEH adduct concentrations were quantitated by the same 
HPLC/UV assay method as for Hb quantification in isolated HbA solution, using a weak 
cation-exchange column (PolyCATA, 30 mm x 4.6 mm) and a detection wavelength of 
410 nm.  A precolumn filter (Supelco®, 2.0 μm) was used to protect column. A linear 
gradient wash was applied with buffer A (20 mM Bis-Tris, 2 mM KCN, pH 6.5) and 
buffer B (20 mM Bis-Tris,2 mM KCN, 200 mM NaCl, pH 6.6) over 20 minutes with flow 
rate of 1.5 mL/min (Table 5.1).    
5.2.5.2. VZHE-039 Quantification in Plasma  
Total VZHE-039 concentrations (free + PPB bound) were quantitated by a 
reversed-phase HPLC-UV/Vis assay, using a C18 column (Thermo, 50 mm x 4.6 mm) 
and a detection wavelength of 310 nm.  A precolumn filter (Supelco®, 2.0 μm) was used 
to protect column. A linear gradient wash was applied with an aqueous phase (water, 
0.1%FA) and organic phase (ACN, 0.1%FA) over 10 minutes with flow rate of 1.5 




Table 5.1. HPLC conditions for HbA and HbA-AEH adduct quantification in WB. 
LC System Waters 2695 separation model 
Detector Waters 2996 PDA  
Analytical Column  Poly CATA weak cation-exchange column, 30 mm x 4.6 mm  







Flow Rate 1.5 mL/min 
Injection Volume 10 μL 
Mobile Phases 
A (20 mM Bis-Tris, 2 mM 
KCN, pH 6.5) 
B (20 mM Bis-Tris, 2 mM 
KCN, 200 mM NaCl, pH 6.6) 
0 min 100 0 
10 min 60 40 
15 min 0 100 
16 min 100 0 
20 min 100 0 
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Table 5.2. HPLC conditions for VZHE-039 quantification in plasma. 
LC System Waters 2695 separation model 
Detector Waters 2996 PDA  
Analytical Column Thermo BDS HYPERSIL C18 column, 50 mm x 4.6 mm  







Flow Rate 1.5 mL/min 
Injection Volume 50 μL 
Mobile Phases 
Aqueous phase (water, 
0.1%FA) 
Organic phase (ACN, 
0.1%FA) 
0 min 90 10 
1 min 90 10 
5 min 10 90 
6 min 10 90 
7 min 90 10 





5.2.6. Partial Validation of HPLC-UV/Vis Assay Methods  
5.2.6.1 HbA-AEH Adduct Quantification in WB 
Selectivity was assessed by comparing blank WB hemolysate and WB with AEH 
added, i.e. comparing peaks of natural HbA and AEH-AEH adduct.  HbA calibration 
curves (n = 2) were prepared for each definitive study of VZHE-039 and 5-HMF. HbA 
concentrations ranged from 0.00125 – 0.325 mM, and 0.0005 – 0.5 mM. The peak area 
was used for quantification. Linearity was assessed using linear regression with 1/y 
weighting factor. Sensitivity, accuracy, and precision were evaluated. eLOQ was 
estimated as the lowest observed nominal concentration which has acceptable 
of %DFN and %RSD, and multiplied by dilution-factor (6-fold) of WB hemolysate. 
Concentrations below eLOQ were not included in the data set. 
Mass balance was assessed by adding HbA-AEH adduct and HbA 
concentrations quantified from HbA calibration curve and corrected with dilution factor 
(6-fold), and compared to the initial nominal concentration of HbA in blank WB.  
5.2.6.2 VZHE-039 Quantification in Plasma  
Selectivity was assessed by comparing blank plasma and plasma spiked with 
VZHE-039. Calibration curves (n=3) of VZHE-039 (0.004 - 8 mM) were prepared in net 
solution water/ACN (V:V = 1:1) and plasma. The peak area was used for quantification. 
Concentrations below eLOQ were not included in the data set. Linearity was assessed 
using linear regression with 1/y weighting factor. Sensitivity, accuracy, and precision 
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were evaluated. eLOQ was estimated as the lowest observed nominal concentration 
which has acceptable of precision, accuracy and absolute recovery.  
Absolute recovery was assessed by comparing HPLC response of VZHE-039 
calibration curves in net solution and VZHE-039 spike in plasma (Equation 5.1). 
Experimental amount on column for VZHE-039 in plasma was estimated by using 
VZHE-039 calibration curve in net solution. Calculated amount on column was 
determined by nominal concentration multiplied by injection volume (50 μL) and 
corrected from dilution factor (5-fold). Absolute recovery value within 80% - 120% range 
is acceptable.  
 
𝑨𝒃𝒔𝒐𝒍𝒖𝒕𝒆 𝑹𝒆𝒄𝒐𝒗𝒆𝒓𝒚  =  
𝑬𝒙𝒑𝒆𝒓𝒊𝒎𝒆𝒏𝒕𝒂𝒍 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒏 𝒄𝒐𝒍𝒖𝒎𝒏
𝑪𝒂𝒍𝒄𝒖𝒍𝒂𝒕𝒆𝒅 𝒂𝒎𝒐𝒖𝒏𝒕 𝒐𝒏 𝒄𝒐𝒍𝒖𝒎𝒏
∗ 𝟏𝟎𝟎% 





5.2.7. Data Analysis and Modeling 
5.2.7.1 Non-compartmental analysis (NCA) of cp -t and HbA-AEH adduct – t 
profiles for VZHE-039 and 5-HMF 
The NCA approach was used to characterize the cp -t profile of VZHE-039 and 
HbA-AEH adduct – t profiles for VZHE-039 and 5-HMF in WB, where the relevant 
exposure metrics were estimated. NCA does not have compartmental model-based 
assumptions, but it assumes a terminal log-linear portion sufficient for estimation of the 
extrapolated area based on the terminal slope. 
Area under the curve (AUCtrap) was calculated by the linear trapezoidal method 
(Equations 5.2).  
 
𝑨𝑼𝑪𝒕𝒓𝒂𝒑 =  ∑




∗ (𝒕𝒊+𝟏 − 𝒕𝒊) 
𝑨𝑼𝑪𝒆𝒙𝒕𝒓𝒂𝒑 =  
𝒄𝒏
𝝀
                    
 𝑨𝑼𝑪𝒕𝒐𝒕𝒂𝒍 =  𝑨𝑼𝑪𝒕𝒓𝒂𝒑 + 𝑨𝑼𝑪𝒆𝒙𝒕𝒓𝒂𝒑     
---- Equations 5.2 
 
The extrapolated area (AUCextrap) after the last measured concentration (cn) was 
calculated by using terminal slope from log-transformed cp -t or HbA-AEH adduct – t 
profiles. Traditionally, AUCextrap should be less than 20% of the total area, in order to 
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adequately estimate the AUCtotal based on the available experimental measurements. In 
this research, cp and HbA-AEH adduct were monitored until 24 hrs only, limited by the 
stability of in-vitro WB environment. Visual inspection on cp-t showed that VZHE-039 
concentrations decreased slowly after the peaks, while its HbA-AEH adduct levels were 
sustained in WB. Therefore, only AUCtrap was used for VZHE-039. For 5-HMF, HbA-
AEH adduct concentrations decreased below eLOQ after 4 hrs for the lowest [5-HMF]0 
(0.5 mM). In order to compare AUC fairly across [5-HMF]0, AUCtrap was calculated up to 
4 hrs. 
The highest observed plasma concentration (cmax) and the time it achieved peak 
concentration (tmax) were determined by visual inspection from cp-t profile. In-vitro 
plasma clearance (CLplasmain-vitro) was estimated from initial dose ([VZHE-039]0*0.6 mL 
plasma volume) and AUCtrap (Equation 5.3). 
 
𝑪𝑳𝒑𝒍𝒂𝒔𝒎𝒂
𝒊𝒏−𝒗𝒊𝒕𝒓𝒐 =  
𝑫𝒐𝒔𝒆
𝑨𝑼𝑪𝒕𝒓𝒂𝒑
                                                                       ---- Equation 5.3 
 
Dose-proportionality for VZHE-039 and 5-HMF were assessed by plotting AUCtrap, 
cmax, or CLplasmain-vitro against [VZHE-039]0 or [5-HMF]0 on linear scale and fitted with a 
power equation (y = a*Xb). The estimate for the exponent (b) from the power equation - 
representing the slope after log-log transformation - was then compared to 1. If the 
exponent is equal to or close to 1, exposure metrics increase proportionally with 
increasing [VZHE-039]0 or [5-HMF]0. When the exponent is less than 1, it represents 
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less than proportional (infra-proportional) kinetics. Vice versa, when the exponent is 
larger than 1, it represents more than proportional (super-proportional) kinetics. 
5.2.7.2 Modeling of SS Concentration-Dependency of HbA-AEH Adduct Profiles 
for VZHE-039 and 5-HMF  
For concentration-dependency studies, the same sigmodal Bmax-model and 
reverse sigmodal Bmax-model used for binding studies in HbA solution (Chapter 3) were 
applied to fit HbA-AEH adduct and HbA concentrations in WB, respectively. 
HbA-AEH adduct level of VZHE-039 in WB were sustained within 24 hrs, so that 
KD’ for VZHE-039 was estimated at equilibrium (24 hrs). For 5-HMF, because of the 
irreversible ALDH-mediated metabolism in RBC, equilibrium could not be achieved. KD’ 
of 5-HMF was estimated at peak (1.5 hrs). 
5.2.7.3 Modeling of Time-Dependency of HbA-AEH Adduct Profiles for VZHE-039  
Due to dissolution rate-limitations of VZHE-039 in WB, three modeling 
approaches were applied for the time-dependency studies. 1). Simple kinetic binding 
model fit of entire dataset to serve as a reference for the other two models; 2). Simple 
kinetic binding model fit with a subset, including HbA-AEH adduct concentrations only 
for low [VZHE-039]0, where dissolution may be assumed instantaneous; 3). Simple 
dissolution kinetic binding model, incorporating a zero-order input rate constant into WB 
(k0) to account for the dissolution step, and fit to the entire dataset. 
 Modeling approaches 1 and 2 were based on the same simple kinetic binding 






In WB kinetic model, kon’ and koff’ represent the apparent association and 
dissociation rate constants, respectively, which may be affected by PPB, RBC 
membrane binding/partitioning compared to the fundamental kon and koff in HbA solution. 
1)  Modeling approach 1: The entire dataset including 0.3 – 7.8 mM of [VZHE-039]0 
was used. 
2) Modeling approach 2: Subset including only 0.3, 0.4, 0.9 mM of [VZHE-039]0 was 
used. [VZHE-039]0 above 0.9 mM were excluded since cp peaked after time zero 
and tmax was found to increase with increasing [VZHE-039]0, presumably due to 
decreased dissolution rates/times with increasing [VZHE-039]0. 
3) Modeling approach 3: Initial slopes of cp -t and HbA-AEH adduct – t profiles 
appeared to be linear and parallel across higher [VZHE-039]0. A zero-order 
dissolution process is assumed to be responsible for the delayed cmax, as well as the 
slowing down of the formation of HbA-AEH adduct in WB. Therefore, a zero-order 
rate constant k0 was introduced to the simple binding kinetic binding model in WB 
(Scheme 5.3). In this model, VZHE-039 was assumed to directly dissolve into RBC, 
in order to simplify the overall model and minimize the possibility of 





AEH + HbA                   HbA-AEH adduct   ---------- Scheme 5.2 
k off
’    
 
k on
’    
AEH + HbA                   HbA-AEH adduct   ---------- Scheme 5.3 
k off
’    
 
k on
’    k 0   
 
AEH0    
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Due to dissolution limitations, VZHE-039 is assumed to dissolve in WB via a 
zero-order input rate. The time it takes for VZHE-039 to dissolve from time zero up to 
the time when all VZHE-039 fully dissolved in WB is defined as dissolution time (TE), 
which increases with increasing [VZHE-039]0.  After TE, VZHE-039 is completely 
dissolved and the input rate becomes 0. TE is determined by k0 and [VZHE-039]0, 
namely, TE = [VZHE-39]0/k0 where smaller k0 and/or higher [VZHE-039]0 results in 
longer TE. Equations used for modeling are listed below, 
 
𝑾𝒉𝒆𝒏 𝒕 < 𝑻𝑬, 𝑪𝑹𝑨𝑻𝑬 =  𝒌𝟎 ;  𝑾𝒉𝒆𝒏 𝒕 > 𝑻𝑬, 𝑪𝑹𝑨𝑻𝑬 =  𝟎         ----        Equations 5.4 
𝒅[𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]
𝒅𝒕
=  𝑪𝑹𝑨𝑻𝑬 + (𝒌𝒐𝒏
′ ∗  [𝑨𝑬𝑯]𝒕 ∗  [𝑯𝒃]𝒕) − (𝒌𝒐𝒇𝒇




′ ∗  [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]𝒕) −  (𝒌𝒐𝒏
′ ∗  [𝑨𝑬𝑯]𝒕 ∗  [𝑯𝒃𝑨]𝒕) 
----  Equations 5.5 
[𝑯𝒃𝑨]𝒕 = [𝑯𝒃𝑨]𝟎 −  [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]𝒕                ----      Equations 5.6 
 
Initial conditions: 
[𝐀𝐄𝐇]𝟎 = 𝟎 




Scientist® (version 3.0) was used for nonlinear-regression. Initial estimates of kon’ 
(61 mM-1hr-1) and koff’ (5.8 hr-1) for modeling approach 1 were obtained from the binding 
study of VHZE-039 in HbA solution (Chapter 3). For modeling approach 2, initial 
estimates of kon’ (0.085 mM-1hr-1) and koff’ (0.17 hr-1) were based on the modeling 
approach 1. For modeling approach 3, initial estimates of kon’ (0.16 mM-1hr-1) and koff’ 
(0.31 hr-1) were based on the modeling approach 2.  Initial estimate of k0 was obtained 
as the slope from cp-t profile of VZHE-039, corrected by the WB volume in well (0.75 
mL). Final parameters were optimized based on goodness-of-fit determined by r2, 
residuals, coefficient of variation (COV), and correlation matrix, and compared among 
different modeling approaches.  
To help interpret the apparent primary model parameters (kon’, koff’ and k0) and 
assess the rate limiting step in the WB environment, the following secondary model 
parameters were calculated as shown below (Equations 5.7):  
 
𝑲𝑫




′                      
𝒌𝒂𝒔𝒔′ =  𝒌𝒐𝒏
′ ∗  [𝑯𝒃𝑨]𝟎 
𝒌𝒅𝒊𝒔𝒔′ =  𝒌𝒐𝒇𝒇 
′                 
𝒕𝟏/𝟐
𝒆𝒒 =  
𝒍𝒏𝟐
𝒌𝒂𝒔𝒔′+ 𝒌𝒅𝒊𝒔𝒔′
     




 Assuming first-order association (kass’), and dissociation (kdiss’), half-lives (t1/2 = ln 
2 / k) were calculated to assess the rate limiting step for these processes.   
5.2.7.4 Modeling of Time-dependency of HbA-AEH Adduct Profiles for 5-HMF 
 Simple metabolism kinetic binding model 
The concentrations of HbA-AEH adduct for 5-HMF in WB were observed to peak 
at 1.5 hr, and decreased below eLOQ after 24hrs across all [5-HMF]0. Along with the 
evidence of in-vitro oxidative metabolism of 5-HMF in HLC, a first-order metabolism rate 
constant, i.e., kmet’, were introduced to the previously simple kinetic binding model 
(discussed in Chapter 3) to account for ALDH-mediated metabolism in RBC.  Since the 
studied concentration of 5-HMF in WB (0.5 – 5 mM) is much lower than the Km of 5-
HMF (>90 mM) in HLC, the metabolism in RBC was assumed to follow first-order 
reaction rate. Time-dependent profile was fit by the simple metabolism kinetic binding 





The following equations were used for modeling,  




′ ∗ [𝑨𝑬𝑯] ∗ [𝑯𝒃𝑨]) − (𝒌𝒐𝒇𝒇
′ ∗ [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]) −  (𝒌𝒎𝒆𝒕
′ ∗  [𝑨𝑬𝑯]) 
AEH + HbA                   HbA-AEH adduct                              ---- Scheme 5.4 
k off
’    
 
k on
’    
Metabolite 







′ ∗  [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]) − (𝒌𝒐𝒏




′ ∗  [𝑨𝑬𝑯])  
----  Equations 5.8 
[𝑯𝒃𝑨] = [𝑯𝒃𝑨]𝟎 −  [𝑯𝒃𝑨 − 𝑨𝑬𝑯 𝒂𝒅𝒅𝒖𝒄𝒕]                  ----       Equation 5.9 
 
Initial conditions: 
[𝐀𝐄𝐇]𝟎 = 𝐈𝐧𝐢𝐭𝐢𝐚𝐥 𝐜𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝒐𝒇 𝟓 − 𝑯𝑴𝑭 
[𝐇𝐛𝐀 − 𝐀𝐄𝐇 𝐚𝐝𝐝𝐮𝐜𝐭]𝟎 = 𝟎 
[𝐌𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐭𝐞]𝟎 = 𝟎 
 
Scientist® (version 3.0) was used for nonlinear-regression. Initial estimates of kon’ 
(0.46 mM-1hr-1) and koff’ (0.131hr-1) were obtained from the binding study of 5-HMF in 
HbA solution (Chapter 3). Due to the lack of experimental references for kmet’, two initial 
estimates were tested, including 0.3 hr-1 obtained from the previous studies (Parikh, 
2013) and a 10-fold larger value 3 hr-1. Final parameters were optimized based on 
goodness-of-fit determined by r2, residuals, COV, and correlation matrix.  
To help interpret the apparent primary model parameters (kon’, koff’, and kmet’) and 
assess the rate-limiting step in WB environment, secondary model parameters (KD’, kass’, 
kdiss’, t1/2) were calculated. Assuming first-order association (kass’), dissociation (kdiss’), 
173 
 
and metabolism (kmet’) rate constants, half-lives (t1/2 = ln 2 / k) were calculated to assess 
the rate limiting step for these processes.  kass’ depends on the initial HbA 
concentrations ([HbA]0), which were quite diluted in the HbA binding experiments (0.2 or 
0.1 mM, discussed in Chapter 3), but was speeded up by [HbA]0 (2.0 – 2.3 mM, within 
the physiological range) in WB study.  
 Post hoc sensitivity analyses of simple metabolism kinetic binding model 
kon and koff estimates for 5-HMF in HbA solution discussed in Chapter 3 can be 
used as a reference for WB kinetic profile. However, CLintin-vitro estimated in HLC 
(Chapter 4) cannot quantitatively be related to kmet’ in kinetic model due to the lack of 
information of ALDH enzyme concentrations in RBC. Besides, the COV of kmet’ is 48% 
from the final WB kinetic model, which is larger than the generally accepted cut-off 
value of 30%, indicating less confidence in the point estimate for kmet’. Goodness-of-fit 
results of WB kinetic model for 5-HMF showed a highly correlation between kon’ and koff’ 
(0.946), which increased the difficulties of independently estimating each of the three 
model parameters with the available experimental data. In order to better assess the 
reliability for kmet’ estimated from WB kinetic model, post-hoc sensitivity analyses were 
performed based on the final point estimates.  
2 mM initial concentration of 5-HMF is used for all simulations, which is higher 
than KD’ (0.2 mM). Since the HbA binding is a nonlinear process, different initial 5-HMF 
concentrations will result in a nonlinear fold-change for the corresponding exposure 
metrics. But the overall model sensitivity trend for kon’, koff’, and kmet’ should be the same. 
The initial HbA concertation is fixed to 2 mM, which is the experimental value from WB 
(38% Hct).  kon’, koff’, or kmet’ (scenario 1, 2, and 3) were increased or decreased 4-fold 
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relative to their final point estimate, leading to a 16-fold total change from upper limit 
(UL) to lower limit (LL) (Table 5.3). This 16-fold change was chosen to assess the 
change of exposure metrics under physiological relevant range. 
The change of the primary HbA-AEH adduct were assessed, using the metrics of 
AUC∞adduct, t1/2terminal, tmax, cmax. The change of 5-HMF exposures in RBC was also 
assessed, using the metrics of AUC∞5-HMF and t1/2terminal. To plot the 24 hrs profiles of 
exposure metrics in both linear and log scale, 0.01 to 24 hrs were simulated using 20 
time points with log scale interval to get smooth lines. Terminal half-lives were 
determined from the terminal log-linear slope from 24 hr simulation. AUC∞ was obtained 
by simulation from 0.01 to 1000 hrs with 2 time points to ensure the completion of 
reaction. tmax and cmax were determined by visual inspection from simulations of 1 to 3 
hrs with 100 time points with linear scale interval (every 0.03 hr). The fold-change was 
calculated by dividing the largest number by the smallest value obtained using 
parameter values from upper limit (UL) and lower limit (LL). If results from UL were 
smaller than results from LL, the fold-change is expressed as a negative number. A cut-
off of 4-fold change was set to determine if a parameter is sensitive to the change of 
exposure metrics (16-fold change).  
Non-compartmental analysis (NCA) was applied to estimate experimental AUC0.5-
14hr, cmax, tmax and t1/2terminal at 2 mM of [5-HMF]0 and compared to the simulation results 
from the final point estimate, to validate the simple metabolism kinetic binding model. 
AUC from 0.5 to 14 hrs were chosen instead of 24 hrs because HbA-AEH adduct 
concentrations were above eLOQ after 14 hrs.  
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Table 5.3. Post hoc sensitivity analyses for the simple metabolism kinetic binding 
model of 5-HMF.  













    LL PE UL FC 
kon’ [mM-1hr-1] 0.56 0.14 2.2 16 0.79 0.20 0.05 16 
koff’ [hr-1] 0.11 0.028 0.44 16 0.05 0.20 0.79 16 






5.3.1 Partial Validation of HPLC-UV/Vis Assay Methods  
5.3.1.1 HbA-AEH Adduct Quantification in WB 
5.3.1.1.1 Selectivity and Representative Chromatograms 
The chromatogram for blank WB sample (6-fold diluted) showed a single peak at 
similar retention time (11 – 11.5 mins) with isolated HbA solution (Figure 5.1).  The 
HbA-AEH adduct peak was well separated and eluted prior to HbA peak (Figure 5.2 – 
5.4). For 5-HMF, the HbA-AEH adduct peak was increased at early incubation time, and 





Figure 5.1. Representative chromatograms for blank WB sample (a) and 0.125 mM 












Figure 5.2. Representative chromatogram of HbA-AEH adduct and HbA 









Figure 5.3.  Representative chromatogram of HbA-AEH adduct and HbA 









HbA-AEH adduct  




Figure 5.4. Representative chromatogram of HbA-AEH adduct and HbA 














5.3.1.1.2 Linearity, Precision and Accuracy  
HbA calibration curves (n=2) were run every time before testing samples. All 
calibration curves (0.00125 – 0.325 mM or 0.0005 – 0.5 mM) were linear (1/y weighted) 
with r2 of 0.993 – 0.994 and slope of 1.07 * 108 and 1.24 * 108 (Figure 5.5). 0.0005 mM 
HbA showed acceptable precision (%RSD = 2%) and accuracy (%DFN = -4.4%). After 
corrected by the 6-fold dilution factor, eLOQ for HbA and HbA-AEH adduct 
quantification is 0.003 mM. Overall, the HbA calibration curves showed acceptable 
precision (%RSD of 0%-5%) and accuracy (%DFN of -9% to 16%). 
 
Figure 5.5. Representative calibration curve of HbA in water/stopping solution 
(V:V = 1:5). 1/y weighted linear regression (line) was fit to the experimental data 























5.3.1.1.3 Mass Balance 
With increasing [VZHE-039]0, more of free HbA were modified by AEH, reflected 
by a decrease in HbA concentration and corresponding increase in HbA-AEH adduct 
concentration in the SS concentration-dependency study (Figure 5.6 – 5.7). For [VZHE-
039]0, 0.3 -7.8 mM is a proper range that covered both low and high concentrations 
relative to KD. At [VZHE-039]0 of less than 4.2 mM, mass balance is acceptable (91% - 
120%) across tested [VZHE-039]0.  HbA concentrations decreased to zero at 7.8 mM of 
[VZHE-039]0, but only 63% converted to HbA-AEH adduct, resulting in 37% loss of 
mass balance. This trend in the loss of mass balance at high [VZHE-039]0 and long 
incubation times was previously observed when VZHE-039 was incubated in HbA 
solution (discussed in Chapter 3). 
For 5-HMF, mass balance was 79% at 0.5 mM of [5-HMF]0 caused by an 
unexpectedly lower HbA concentration, speculatively due to dilution error for that single 





Figure 5.6. Mass balance assessment for VZHE-039 in WB for 24 hrs. The 
sigmoidal Bmax-model and the reverse sigmoidal Bmax-model (lines) were fit with 
for HbA-AEH adduct and HbA (symbols), respectively. Linear regression (dashed 







































Figure 5.7. Mass balance assessment for 5-HMF in WB for 24 hrs. The sigmoidal 
Bmax-model and the reverse sigmoidal Bmax-model (lines) were fit with for HbA-
AEH adduct and HbA (symbols), respectively. Linear regression (dashed line) was 



































5.3.1.2 VZHE-039 Quantification in Plasma 
All chromatograms showed the same retention time (3.3 min) for VZHE-039 in 
neat solution and plasma (Figure 5.8). VZHE-039 peak was absent in blank neat 
solution and blank plasma sample (Figure 5.8). Precision is acceptable (<20%) for all 
measured concentrations in neat solution and plasma (Table 5.3 -5.4). Accuracy of low 
concentrations has been significantly improved by 1/y weighted factor. Therefore, all 
calibration curves were fitted with linear regression using 1/y weighting factor to put 
more strength on the lower concentration points in order to properly cover the large 
concentration range. Overall, %DNF was within -6% - 20% range. Concentrations below 
0.004 mM showed no detectable peak at 3.3 min. Calibration curves in both neat 
solution and plasma statistically showed the same slope, 5.65 * 106 (Figure 5.9). At the 
lowest concentration (0.004 mM), a o145% absolute recovery was observed due to its 
below the detection limit. After excluded the 0.004 mM concentration point, all other 
concentrations show acceptable absolute recovery (90 – 116%). 0.008 mM is the eLOQ 





Figure 5.8. Representative chromatograms for blank and 2 mM of [VZHE-039]0 in 
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Figure 5.9. Representative calibration curves of VZHE-039 in neat solution and 
plasma. 1/y weighted linear regression (lines) were fit to the experimental data 


























Table 5.4. Linearity, precision, and accuracy assessment for VZHE-039 in net 
solution (Water:ACN = 1:1) (n = 3).  
 




mM n=3 n=3 unweighted 1/y weighted nmoles 
0.004 28422 18%  NA -9% 0.04 
0.008 48518 6%  NA -12% 0.08 
0.015 95296 4% -51% 0% 0.15 
0.03 192616 6% -20% 5% 0.3 
0.06 380776 7% -6% 5% 0.6 
0.13 786180 7% 1% 5% 1.25 
0.25 1574212 8% 5% 6% 2.5 
0.5 3047747 7% 3% 3% 5 
1 5945746 6% 2% 1% 10 
2 11561330 7% -1% -2% 20 
4 23925389 5% 4% 4% 40 






Table 5.5. Linearity, precision, accuracy and absolute recovery assessment for 
VZHE-039 in plasma (n = 3).  
[VZHE-039]0 Response RSD DFN DFN 
mM n=3 n=3  unweighted  1/y weighted 
0.004 34975 2%  NA 20% 
0.008 55575 5% -94% 1% 
0.015 99053 5% -50% -6% 
0.03 197153 9% -17% 3% 
0.06 368570 6% -9% -3% 
0.13 718654 9% -4% -5% 
0.25 1537149 8% 2% -2% 
0.5 3060126 6% 4% -2% 
1 6022667 6% 3% -3% 
2 12816151 7% 10% 3% 
4 24627156 4% 11% 8% 









mM nmoles nmoles  
0.004 0.04 0.06 145%* 
0.008 0.08 0.09 116% 
0.015 0.15 0.17 111% 
0.03 0.3 0.33 111% 
0.06 0.6 0.62 104% 
0.13 1.25 1.21 97% 
0.25 2.5 2.6 104% 
0.5 5 5.18 104% 
1 10 10.19 102% 
2 20 21.68 108% 
4 40 41.67 108% 




5.3.2 WB disposition of VZHE-039 
5.3.2.1 NCA Analysis of cp – t Profile  
The cp of VZHE-039 peaked after t0 for high [VZHE-039]0 (>0.9 mM). On a log-
linear scale of cp - t profile, cp declined with parallel terminal slopes across all [VZHE-
039]0 studied (Figure 5.10). 
Table 5.9 summarizes the relevant exposure metrics for cp-t profiles, estimated 
by NCA. The t1/2terminal was similar across [VZHE-039]0, except for 7.8 mM where cp 
showed no obvious decline at 24 hrs. AUCtrap increased proportionally with increasing 
[VZHE-039]0 (Figure 5.11), indicating the extent of VZHE-039 dissolution in WB at 24 
hrs is proportional to [VZHE-039]0, i.e., ultimately ALL VZHE-039 is dissolved  However, 
with increasing [VZHE-039]0, cmax increased infra-proportionally and tmax was prolonger, 
indicating the rate of dissolution slowed down the overall kinetics of VZHE-039 in 
plasma, especially for high [VZHE-039]0. This dissolution rate limitation was also 
reflected by a constant c0 for high [VZHE-039]0 (Table 5.6).  
In summary, the in-vitro disposition of VZHE-039 in plasma and, by extension, in 
WB before reaching RBCs was impacted by its slow dissolution (despite DMSO 2%) 
due to its physicochemical properties.  However, ultimately, all of VZHE-039]0 was 
dissolved. Plasma clearance of VZHE-039 was found to be slow (0.0005 mL/min/12mL 
plasma) and was independent of [VZHE-039]0, i.e., consistent with reverse first-order 




Figure 5.10. cp-t profiles (linear and log-scale) for VZHE-039. Smooth lines 


































































Figure 5.11. Dose-proportionality assessment for VZHE-039 in plasma. A power 























































[mM] [mM] [mM] [mM*hr] 
mL/min/12 mL 
plasma [hr] [hr] 
7.8 0 3.4 66 0.0047 5.0 NA 
4.2 0.42 1.5 23 0.0073 2.5 21 
2.6 0.45 1.2 22 0.0047 1.5 21 
2.0 0.47 0.90 18 0.0044 2.0 18 
1.4 0.39 0.60 14 0.0040 2.0 18 
0.9 0.45 0.45 10 0.0036 0.09 22 
0.5 0.33 0.33 4 0.0050 0.09 19 





5.3.2.2 SS Concentration- and Time- Dependency of HbA-AEH Adduct Formation 
in WB 
In the pilot 1 study, no adduct peak was observed for 0.03 and 0.1 mM of VZHE-
0390 incubated with WB for 1 hr, indicating that the apparent KD in WB maybe larger 
than KD (0.1 mM) in HbA solution. Higher [VZHE-039]0 were needed for the definitive 
studies. A HbA-AEH adduct peak was observed for 2 mM VZHE-039 incubated in WB 
for 1 hr, and the peak height is about one-third of unmodified HbA peak. Both HbA and 
HbA-AEH adduct peaks were within concentration range (0.006 – 0.5 mM) of calibration 
curves with 5-fold dilution factor. For 25-fold dilution factor, HbA-AEH adduct was 
further diluted below eLOQ. To better quantitate HbA-AEH adduct when [VZHE-039]0 is 
below KD’, 5-fold dilution was therefore deemed to be a better dilution factor than 25-fold.  
[VZHE-039]0 range and sampling time for the definitive study were optimized 
according to pilot 2 and 3 studies. Although we were not able to adequately separate 
the HbA-AEH adduct peak because of performance problem of the analytical column, 
the trend of HbA-AEH adduct formation provided useful information. VZHE-039 showed 
time-dependent binding in WB but was slower in binding to Hb when compared to HbA 
solution. The sampling time used in pilot 2 study seems to give an optimal schedule. 
The concentration range in pilot 3 study covered the saturable binding condition, where 
HbA peak decreased below eLOQ with 8 mM of VZHE-0390 incubated in WB for 17 hrs. 
In definitive studies, 0.3 – 7.8 mM of VZHE-0390 was incubated in WB and aliquots 




5.3.2.2.1 NCA Analysis of HbA-AEH Adduct – t Profile  
HbA-AEH adduct concentrations increased from time zero, achieved equilibrium 
and were sustained over 24 hrs, for all [VZHE-039]0 studied in WB (Figure 5.12).  AUC 
for HbA-AEH adduct (AUC0-24adduct) was then calculated by the trapezoidal rule to 
estimate the extent of Hb-AEH adduct formed in RBC over 24 hrs and were used to 
assess dose-proportionality. At a physiological relevant [VZHE-039]0 range (0.3 – 7.8 
mM), AUC0-24adduct increased less than proportional, as described by an exponent of 
0.79 from the power equation fit (Figure 5.13). This is a conclusive evidence of 
saturable HbA binding, consistent with VZHE-039 being a high-affinity and low-capacity 





Figure 5.12. Time-dependency of HbA-AEH adduct formation for VZHE-039 in WB. 
Smooth lines connected the experimental data for visual inspection. 
 
Figure 5.13. Dose-proportionality assessment for HbA-AEH adduct of VZHE-039 in 
































































5.3.2.2.2 SS Concentration-Dependency of HbA-AEH Adduct Formation in WB 
Concentration-dependency HbA-AEH adduct profile was characterized at 
equilibrium (24 hrs). The sigmoidal Bmax-model fitted the concentration-dependent 
experimental well with an r2 value of 0.989. the Hill coefficient (n = 2.0 (22%)) was 
similar to “n” (1.9 (34%)) estimated from in HbA solution. However, the apparent 
binding affinity (KD’ = 1.5 (13%) mM) was 15-fold lower than the KD’ (0.1 (24%) mM) in 
HbA solution. Since VZHE-039 is resistant to ALDH-mediated metabolism in HLC (as 
discussed in Chapter 4), and the HbA-AEH adduct concentrations were sustained in 
WB until 24 hrs, there is no evidence of intra-RBC metabolism. The lower apparent 
binding affinity in WB reflects the high PPB (94%) of VZHE-039 and likely RBC 




Figure 5.14. SS concentration-dependency of HbA-AEH adduct formation for 
VZHE-039 in WB and the extrapolation (dashed line) using the final PE from the 
sigmoidal Bmax-model in HbA solution. The sigmoidal Bmax-model (solid line) was 





























VZHE-039 in WB Fit









5.3.2.2.3 Time-dependency of HbA-AEH Adduct Formation in WB 
The dissolution rate-limited cp-t profiles of VZHE-039 indicated that the HbA-AEH 
adduct formation in RBC was slowed down by the dissolution rate as well. In order to 
properly characterize VZHE-039 binding kinetic in WB, a subset of low [VZHE-039]0 was 
selected to reduce the influence of dissolution rate. Goodness-of-fit of using this subset 
was not as good as using the entire dataset fit by the simple kinetic binding model, 
reflected by a smaller r2 (0.880) and larger COV (35%) for parameter estimates (Table 
5.7). Initial ascending portion of HbA-AEH adduct – t profiles were constantly 
overestimated by the simple kinetic binding model. kon’ and koff’ estimates using subset 
data were both numerically larger than estimates using the entire dataset, which is 
indirect evidence of dissolution rate limitations for high [VZHE-039]0.  
To improve the goodness-of-fit and incorporate a dissolution step in the model, 
the simple dissolution kinetic binding model was established and the entire dataset was 
included. VZHE-039 was dissolved in WB with the same rate, characterized by k0. As 
expected, with higher [VZHE-039]0, it took longer for VZHE-039 to be completely 
dissolved in WB (Figure 5.15). The estimated dissolution times (TE) for each [VZHE-
039]0 were similar to the observed tmax from cp – t profile, indicating ko was properly 
estimated. Final point estimates of kon’ and koff’ are almost identical to results using 
simple kinetic binding model with subset data, indicating both approaches successfully 
circumvent the “nuisance” dissolution problem in the parameter estimation (Table 5.7). 
Moreover, the goodness-of-fit using the simple dissolution kinetic binding model was 
significantly improved, as reflected by r2 (0.956), and more precise point estimates 
(COV 16% - 25%) (Table 5.7). The simple dissolution kinetic binding model introduced 
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sigmoidicity at the initial ascending portions of HbA-AEH adduct – t profiles, and the 
experimental data were well fitted (Figure 5.16b). The model also captured well the 
HbA-AEH adduct level after equilibrium (Figure 5.17b). Though high correlation 
between kon’ and koff’ (0.960) were observed using the dissolution kinetic binding model, 
precision on point estimates (COV) were improved compared to using simple kinetic 
binding model (Table 5.7). Therefore, the simple dissolution kinetic binding model was 
deemed the best among the tested modeling approaches (Table 5.7).  
Both kon’ and koff’ estimates were significantly smaller than kon (~300-fold) and koff 
(~10-fold) in HbA solution, resulting in a slowing down of the overall Hb binding kinetics 
(prolonged t1/2eq) and lowering the apparent binding affinity (larger KD’) of VZHE-039 in 
WB (Table 5.7).  The value for KD’ (2.3 mM) of VZHE-039 in WB was approximately 20-
fold larger than it KD (0.1 mM) in HbA solution, primarily due to significantly slower 
association (smaller kon’), indicating that processes like PPB (94%) and/or RBC 




Table 5.7. Final parameter estimates of time-dependency of HbA-AEH adduct 
formation for VZHE-039 in WB, using different kinetic binding models, and 
compared to the PE in HbA solution. The primary rate constants were presented 
as PE with (COV). 









    Simple kinetic binding model 
Dissolution kinetic 
binding model 
[HbA]0 [mM] 0.1 2.3 2.3 2.3 
r2   0.983 0.938 0.880 0.956 
Correlation between 
kon’ and koff’ 
0.888 0.823 0.894 0.960 
k0 [mmole*hr-1] NA NA NA 0.0019 (16%) 
kon’  [mM-1*hr-1] 61 (9%) 0.085 (10%) 0.16 (24%) 0.20 (21%) 
koff’  [hr-1] 5.8 (13%) 0.17 (17%) 0.31 (35%) 0.46 (25%) 
KD’  [mM] 0.095 2.0 2.0 2.3 






Figure 5.15. Simulation of the zero-order dissolution process using the final k0 

















































Figure 5.16. Initial portion of the time-dependency of HbA-AEH adduct formation 
for VZHE-039 in WB, using the simple kinetic binding model (Figure 5.16a) and 
the simple dissolution kinetic binding model (Figure 5.16b). Models (lines) were fit 















































































Figure 5.17. Full time-dependency of HbA-AEH adduct formation for VZHE-039 in 
WB, using the simple kinetic binding model (Figure 5.16a) and the simple 
dissolution kinetic binding model (Figure 5.16b). Models (lines) were fit to the 















































































5.3.2.3 Disposition of VZHE-039 between Plasma and RBC 
Plasma concentrations, cp, of VZHE-039 and HbA-AEH adduct concentrations in 
WB are plotted together against time to compare the disposition of VZHE-039 in plasma 
and RBC. 
Figure 5.18a is an example of a low [VZHE-039]0 (0.3 mM). cp rapidly decreased 
from time zero with a concurrent increase of HbA-AEH adduct. With time, HbA-AEH 
adduct concentrations surpassed cp and achieved equilibrium within an hour, indicating 
rapid RBC uptake and subsequent binding to HbA. 
Figure 5.18b is an example of a high [VZHE-039]0 (7.8 mM). Both cp and HbA-
AEH adduct concentrations slowly increased until 5 hrs, indicating dissolution-rate 
limitations. In the ascending portion, VZHE-039 was dissolving into plasma and 
penetrating into RBC to bind Hb. After 5 hrs, cp and HbA-AEH adduct concentrations 
achieved their plateaus, indicating that HbA binding achieved equilibrium, as the 
dissolution and distribution processes were completed, and VZHE-039 concentrations in 
both plasma and RBC remained constant. 
Disposition of VZHE-039 at equilibrium was assessed across [VZHE-039]0 
concentrations (Figure 5.19). cp increased at lower [VZHE-39]0 and achieved a plateau 
at around 2 mM. After plateauing, cp increased again and surpassed HbA-AEH adduct 
concentrations because of saturation of HbA binding sites, while the extra VZHE-039 
remained in plasma. When [VZHE-039]0 concentrations were lower than the maximal 
HbA binding capacity, cp was lower than HbA-AEH adduct concentrations, indicating 
205 
 
extensive RBC partitioning, where most VZHE-039 was cleared from plasma and 




Figure 5.18. Time-dependent VZHE-039 disposition in plasma and RBC for low 
and high [VZHE-039]0 (Figure a, 0.3 mM; Figure b, 7.8 mM). Smooth lines 













































































































Figure 5.19. Disposition of VZHE-039 in plasma and RBC at equilibrium (at 24 hrs). 
The sigmoidal Bmax-model (lines) were fit to HbA-AEH adduct in WB. Smooth 





5.3.3 WB Disposition of 5-HMF 
5.3.3.1 NCA Analysis of HbA-AEH adduct – t Profile  
HbA-AEH adduct concentrations of 5-HMF in WB increased from time zero, 
peaked around 1.5 hrs and declined below eLOQ by 24 hrs (Figure 5.22).  For the 
lowest [5-HMF]0 (0.5 mM), HbA-AEH adduct was not detectable after 4 hrs. 
To assess dose-proportionality using all [5-HMF]0 (0.5 – 5 mM), AUC0-4adduct were 
calculated. AUC0-4adduct increased less than proportionally with [5-HMF]0, described by 
an exponent from the power model fit of 0.73, i.e., less than 1 (Figure 5.20). AUC is a 
metric that describes the extent of HbA-AEH adduct formation in WB. cmax is a hybrid 
metric, describing both extent and rate of HbA-AEH adduct formation. cmax increased 
less than proportionally with [5-HMF]0, and the proportionality constant was almost 
identical to the proportionality constant of AUC0-4adduct, indicating this nonlinearity of 
HbA-AEH adduct in WB caused by the extent of HbA-AEH adduct, rather than its rate 




Figure 5.20. Dose-proportionality assessment for HbA-AEH adduct of 5-HMF in 






































5.3.3.2 Apparent SS Concentration- and Time-dependency of HbA-AEH Adduct 
Formation in WB 
5.3.3.2.1 Apparent SS Concentration-Dependency of HbA-AEH Adduct Formation 
in WB 
Due to the intra-RBC metabolism of 5-HMF, equilibrium cannot be achieved in 
WB. Thus, the apparent SS binding affinity KD’ was estimated at tmax (1.5 hrs). In the 
previous 5-HMF binding studies in HbA solution (as discussed in Chapter 3), equilibrium 
was achieved at high [5-HMF]0 (4 mM) relative to KD (0.37 mM). In WB, saturation is 
expected to be achieved as well with higher [5-HMF]0 (>5 mM). Therefore, for 
comparison sake, Bmax was fixed to 2.0 mM, i.e., [HbA]0 to mimic saturable conditions. 
The sigmoidal-Bmax-model fitted the concentration-dependent experimental well with an 
r2 value of 0.999. The Hill coefficient (n = 1.2 (7%)) was almost identical to the point 
estimate in HbA solution (n = 1.1 (36%)). However, the apparent binding affinity (KD’ = 
3.0 (4%)) in WB was 8-fold lower than the binding affinity in HbA solution (Figure 5.21), 
as a result of rapid intra-RBC metabolism within 1.5 hrs, reducing intra-RBC 5-HMF 




Figure 5.21. Apparent SS concentration-dependency HbA-AEH adduct of 5-HMF in 
WB and the extrapolation (dashed line) from HbA solution. A sigmoidal Bmax-
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5.3.3.2.2 Time-dependency of HbA-AEH Adduct Formation in WB 
Across the studied [5-HMF]0 in WB, HbA-AEH adduct concentrations increased 
from time zero, peaked at 1.5 hrs and decreased below eLOQ at 24hrs (Figure 5.10).  
Unlike the time-dependent profile of 5-HMF in WB, HbA-AEH adduct concentrations 
were sustained in HbA solution at least for 24 hrs. Intra-RBC metabolism is the likely 
reason behind this major difference in time-dependency of HbA-AEH adduct profiles. 5-
HMF is a substrate of ALDH enzyme, present in RBC but not in HbA solution. The 
simple metabolism kinetic binding model captured the overall HbA-AEH adduct 
changing trend with time. Goodness-of-fit of the simple metabolism kinetic binding 
model used in WB is less optimal than the simple kinetic binding model used for 5-HMF 
in HbA solution, with a smaller r2, larger COV and high correlation of kon’ and koff’ 
estimates (Table 5.8). 
Point estimates of kon’ and koff’ from WB are 15 – 20%, similar to kon and koff 
estimated from HbA solution, resulting in about 30% estimate of similar kinetic binding 
affinity (KDkinetic’ = kon / koff) (Table 5.8). This suggests that the primary Hb binding 
mechanism for 5-HMF is not affected by WB constituents.  However, due to much 
higher initial HbA concentrations ([HbA]0 = 2 mM) in WB, the association rate in WB was 
significantly faster than observed with the low [HbA]0 (0.2 mM) in HbA solution. The 
apparent half-lives of HbA association and metabolism in were less than hour in WB, 
while in HbA solution, the association half-life was longer than 7 hrs. On the other hand, 
the dissociation rate is independent of [HbA]0, and therefore is almost identical (~ 6hrs) 
between WB and HbA solution. 
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In HbA solution, both association and dissociation processes are equally slow 
(Table 5.8). However, in WB, the dissociation process has become the rate-limiting step 
due to rapid metabolism in RBC and the increased [HbA]0 speeding up the association 
rate. 
kmet’ was introduced to account for and characterize the intra-RBC metabolism of 
5-HMF in WB. Final fit from the simple metabolism binding model showed a large COV 
(48%) for kmet’, indicating less confidence in the precision of the PE. In addition, due to 
lack of experimental reference for kmet’, and high correlation among model parameters, 
assessing the stability and sensitivity of the parameter kmet’ is necessary for better 
validation of this simple metabolism kinetic binding model (discussed in the following 





Figure 5.22. Time -dependency of HbA-AEH adduct formation for 5-HMF in WB. 
The simple metabolism kinetic binding model (lines) was fit to the experimental 








































Table 5.8. Final parameter estimates of time-dependency of HbA-AEH adduct 
formation for 5-HMF in WB and in HbA solution, using the simple metabolism 
kinetic binding model and the simple kinetic binding model, respectively. The 
primary rate constants are presented as PE with (COV). 
 5-HMF   HbA Solution WB 
[HbA]
0
 [mM] 0.2 2.0 
r
2
  0.957 0.918 



















































5.3.3.2.3 Post-hoc sensitivity analyses 
The reference scenario (Figure 5.23) is based on the final point estimates from 
the simple metabolism kinetic binding model of 5-HMF in WB. 
In this reference scenario, HbA-AEH adduct is rapidly formed in RBC and peaks 
at 0.54 mM at 1.2 hrs, followed by a slower and parallel decline of 5-HMF concentration 
in RBC. The terminal half-life is 9 hr (Figure 5.23). After 24 hrs, the metabolic reaction, 
i.e., metabolic conversion of 5-HMF to HMFA, is close to completion, with 
metabolite/HMFA concentrations close to 2 mM, i.e., [5-HMF]0. HbA-AEH adduct and 5-
HMF concentrations are close to zero at 24 hrs. Similar results were also observed in 
the experimental data, where HbA-AEH adduct peaked at 0.75 mM after 1.5 hrs and 
declined to zero by 24 hrs (Table 5.9). 
When kon’ or koff’ was changed within their LL and UL, KD’ (which is equal to koff’ 
divided by kon’) was changed accordingly. On the other hand, kmet’ does not influence 




Figure 5.23. Reference case: Simulation of the disposition of 5-HMF (2 mM) in WB 
([HbA]0 of 2.0 mM) from the simple metabolism kinetic binding model using the 



































































Table 5.9. Assessment of the outcome metrics for HbA-AEH adduct in RBC from 
sensitivity analysis of the simple metabolism kinetic binding model. 
Abbreviations: LL, lower limit; ST, simulation from final point estimates; EX, 




Table 5.10. Assessment of the outcome metrics of 5-HMF in RBC from sensitivity 
analysis of the simple metabolism kinetic binding model. 
  AUC∞ [mM*hr] t1/2 
terminal [hr] 
  LL ST UL FC LL ST UL FC 
kon’ 0.9 0.9 0.9 1.0 7.1 9.1 12.5 1.8 
koff’ 0.9 0.9 0.9 1.0 33 9.1 2.5 -13 
kmet’ 3.6 0.9 0.2 -16 12 9.1 7.1 -1.7 
 
  






UL FC LL ST EX UL FC 
kon’ 2.2 5.0 4.5 26 12 7.1 9.4 17 16 2.2 
koff’ 31 5.0 4.5 2.0 -16 35 9.4 17 2.5 -14 
kmet’ 27 5.0 4.5 2.2 -12 16 9.4 17 7.1 -2.3 
  tmax [hr] cmax [mM] 
  LL ST EX UL FC LL ST EX UL FC 
kon’ 1.4 1.2 1.5 0.88 -0.65 0.19 0.54 0.75 1.1 5.8 
koff’ 1.6 1.2 1.5 0.8 -2.1 0.58 0.54 0.75 0.46 -1.3 
kmet’ 2.4 1.2 1.5 0.46 -5.2 0.98 0.54 0.75 0.20 -4.8 
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Scenario 1 shows model predictions with the change of kon’ only (Figures 5.24 
and 5.25). When kon’ is decreased, the association rate (binding to HbA) is reduced 
(Figure 5.24). Therefore, the initial decrease of 5-HMF is shallower on log-scale, where 
HbA-AEH adduct peaks slighter later (at 1.4 hr) with 5.8-fold lower concentrations than 
kon’ at UL (Table 5.9). AUC∞adduct is dramatically decreased (12-fold), because the 
binding affinity is decreased, where less HbA-AEH adduct is formed and more of free 5-
HMF is available for the rapid metabolism in RBC. The reaction is complete at 24 hrs, 
where all 5-HMF is converted to metabolite (2 mM). When kon’ is increased, more HbA-
AEH adduct is formed due to enhanced binding affinity (Figure 5.25). HbA-AEH adduct 
peaks earlier, and less 5-HMF is available to undergo metabolism. The terminal slopes 
of HbA-AEH adduct and 5-HMF are shallower and the (metabolic) reaction is not 
completed after 24 hrs. AUC∞5-HMF for both cases (increase or decrease of kon’) remains 
the same, because binding to Hb is reversible and the irreversible removal of 5-HMF 
only depends on metabolism (kmet’) (Table 5.10). Overall, cmax and AUC∞adduct are quite 




Figure 5.24. Scenario 1a: Simulation of the disposition of 5-HMF (2 mM) in WB 
([HbA]0 of 2.0 mM) from the simple metabolism kinetic binding model by changing 




































































Figure 5.25. Scenario 1b: Simulation of the disposition of 5-HMF (2 mM) in WB 
([HbA]0 of 2.0 mM) from the simple metabolism kinetic binding model by changing 



































































Scenario 2 are the model predictions with the change of koff’ only (Figure 5.26 
and 5.27).  Dissociation from HbA is the rate-limiting step for all simulated scenarios, 
where koff’ is the smallest among kon’*HbA0 and kmet’. Thus, the terminal slopes of HbA-
AEH adduct and 5-HMF are predominantly driven by koff’ and are parallel on a log-scale 
in all cases. When koff’ is decreased, the dissociation rate (5-HMF release from HbA) is 
reduced (Figure 5.26). The terminal decline of HbA-AEH adduct and 5-HMF are 
significantly slower, characterized by 14-fold longer t1/2terminal than it is of koff’ at upper 
limit (UL), and the (metabolic) reaction is incomplete at 24 hrs (Table 5.9 and 5.10). 
HbA-AEH adduct peaks slightly later (at 1.6 hr) with a small increase in peak level (at 
0.58 mM). AUC∞adduct is dramatically increased (16-fold) due to the 16-fold increase in 
binding affinity. Vice versa, when koff’ is increased, less HbA-AEH adduct is formed, 
more 5-HMF becomes available for metabolism, and AUC∞adduct is decreases 16-fold 
(Figure 5.27). Dissociation from HbA is faster, where 5-HMF undergoes more rapid 
metabolism. The terminal slopes of HbA-AEH adduct and 5-HMF are steeper, and the 
(metabolic) reaction is completed at 24 hrs. Overall, t1/2terminal and AUC∞adduct are quite 




Figure 5.26. Scenario 2a: Simulation of the disposition of 5-HMF (2 mM) in WB 
([HbA]0 of 2.0 mM) from the simple metabolism kinetic binding model by changing 



































































Figure 5.27. Scenario 2b: Simulation of the disposition of 5-HMF (2 mM) in WB 
([HbA]0 of 2.0 mM) from the simple metabolism kinetic binding model by changing 



































































Scenario 3 includes the model predictions with a change of kmet only (Figure 5.28 
and 5.29).  When the ALDH activity is reduced, kmet’ is decreased, resulting in a slower 
formation of metabolite from 5-HMF (Figure 5.28). Therefore, more HbA-AEH adduct is 
formed and remains in WB. The reaction is incomplete at 24 hrs. Although HbA binding 
affinity remains the same, AUC∞adduct is dramatically increased (by 12-fold) due to the 
slow metabolism in RBC. AUC∞5-HMF is 16-fold decreased when kmet’ is increased 16-fold, 
because the metabolism of 5-HMF is an irreversible process. The initial decrease of 5-
HMF is shallower on log-scale, but the terminal decrease of HbA-AEH adduct and 5-
HMF are only slightly slower due to the dissociation from HbA remains as the rate-
limiting step. When kmet’ is increased, less HbA-AEH adduct is formed since 5-HMF is 
rapidly metabolized by ALDH (Figure 5.29). HbA-AEH adduct peaks much earlier (0.46 
hrs) compared to kmet’ at LL (2.4 hrs), and to a lower level (0.20 mM compared to 0.98 
mM). Terminal slopes of HbA-AEH adduct and 5-HMF are steeper and the reaction is 
complete at 24 hrs. Overall, AUC∞adduct and AUC∞5-HMF, as well as cmax and tmax are 




Figure 5.28. Scenario 3a: Simulation of the disposition of 5-HMF (2 mM) in WB 
([HbA]0 of 2.0 mM) from the simple metabolism kinetic binding model by changing 



































































Figure 5.29. Scenario 3b: Simulation of the disposition of 5-HMF (2 mM) in WB 
([HbA]0 of 2.0 mM) from the simple metabolism kinetic binding model by changing 




































































Table 5.9 and 5.10 summarize the results for sensitive analyses. The exposure 
of 5-HMF in RBC (AUC∞5-HMF) remains the same with the changes of kon’ and koff’, but 
sensitive to kmet’.  The exposure of HbA-AEH adduct in RBC (AUC∞adduct), which drives 
the pharmacological effect, is greatly affected by all parameters, i.e., kon’, koff’, and kmet’. 
The estimate for kon’ and kmet’ has an effect on peak of HbA-AEH adduct (cmax), because 
the formation of HbA-AEH adduct competes with metabolism by ALDH.  koff’ determines 
the duration of HbA-AEH adduct, since the dissociation from HbA is the rate-limiting 
step. Onset time (tmax) is not sensitive to either kon’ nor koff’, but affected by kmet’. The 
experimental AUC0-14adduct, cmax and tmax are similar to the simulation results using the 
final point estimates, which is a validation of the sensitivity analysis for the simple 
metabolism kinetic binding model (Table 5.9). t1/2terminal was determined by the rate-
limiting step, which characterized by koff’ for these simulated scenarios. The duration of 
the circulating HbA-AEH adduct and 5-HMF are similar to their reference scenarios, as 
koff’ remains the same as the rate-limiting step. 
For this simple metabolism kinetic binding model, most metrics of HbA adduct 
exposure (including onset, duration and extent) and (intra-RBC) 5-HMF exposure are 
very sensitive to changes in kmet’. In addition, there is no external quantitative 
experimental reference for kmet’, which further decreases the reliability of kmet’ estimate. 
For kon’ and koff’, though high correlation and less precision (large COV) were observed 
for the final point estimates; both of them were similar to the external references from 5-
HMF binding study in HbA solution (Table 5.8). In conclusion, kon’ and koff’ estimates 
from the final simple metabolism kinetic binding model of 5-HMF in WB are reliable, 
whereas kmet’ is less reliable.  
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5.4 Discussion and Conclusions 
This chapter presents studies to gain insight into in-vitro disposition of 5-HMF 
and VZHE-039 in WB, and compare the results with those obtained under similar 
studies conducted in HbA solution (discussed in Chapter 3) in order to explore how 
blood components may affect formation of HbA-AEH adduct. 
For VZHE-039, no evidence of intra-RBC metabolism was observed, as the HbA-
AEH adduct concentrations were sustained in WB for 24 hrs. KD’ estimated from both 
kinetic and SS concentration-dependent model are similar and were 15- to 20-fold 
larger than KD values estimated from HbA solution, primarily due to a dramatic decrease 
of association rate constant to Hb. High degree of PPB (94%) and/or RBC membrane 
binding (non-specific binding) are believed to be responsible for the slowdown of overall 
kinetic binding and lower apparent binding affinity of VZHE-039 in WB, mostly by 
affecting kon’. Due to its lipophilicity, VZHE-039 is extensively plasma protein ound and 
expected to bind to RBC membranes as well.  These reversible binding processes are 
competing with its specific binding to Hb via Schiff base.  They are NOT expected to 
irreversibly remove VZHE-039 (as is the case for 5-HMF metabolism inside RBC). 
Given the dramatic reduction in kon’ and KD’ relative to kon and KD, one or both of these 
binding processes are of low affinity and high capacity relative to HbA binding. This is 
supported by a constant, i.e., dose-invariant, and low in-vitro plasma clearance (0.005 
mL/min/ 12 mL plasma), seemingly dose-proportional plasma exposures and long 
plasma t1/2terminal (~20 hr). On the other hand, VZHE-039 is considered as a high affinity 
and low capacity Hb binder, as reflected by an infra-proportional increase of AUCadduct 
with [VZHE-039]0. This saturable Hb binding is essential for VZHE-039 to elicit its 
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pharmacological effects at its target site, and prolonged persistence in WB may be 
advantageous in-vivo. 
For 5-HMF, it quickly binds to HbA, but in its unbound form in RBC, it is rapidly 
metabolized by ALDH enzyme, leading to a quick onset, short duration and lower extent 
of action/HbA adduct formation as shown by the irreversible decrease of HbA-AEH 
adduct and cp of 5-HMF.  The reduction in apparent binding affinity relative to HbA 
solution results from the rapid intra-RBC metabolism reducing its availability for HbA 
binding. After incorporating this irreversible removal of 5-HMF by ALDH metabolism by 
using simple metabolism binding model of 5-HMF, however, the kinetic apparent 
binding affinity (KD’kinetic=0.28 mm) is similar to KD (0.20 mM) in HbA.  Given its 
hydrophilic nature, it is not expected to bind to plasma and proteins or RBC membranes 
in any significant way. Previous studies showed that PPB of 5-HMF and metabolism in 
plasma are negligible(Parikh, 2013). RBC membrane binding is most likely negligible as 
well due to the hydrophilicity of 5-HMF (cLogP = 0.4). The final point estimate for kon’ in 
WB is almost identical to the kon in HbA solution, indicating PPB/RBC membrane 
binding do not hinder 5-HMF transport into RBC and binding to Hb. Using a modified 
kinetic binding model, incorporating first-order metabolism for 5-HMF, both apparent 
association and metabolic processes are fast, while the terminal decrease of HbA-AEH 




Table 5.11. Summary table of VZHE-039 and 5-HMF disposition in WB. 










   [mM] 
[mM-1 
hr-1] 
[hr-1] [hr-1] [mM]  [mM] 
VZHE-
039 
0.79 1.5 0.20 0.46 0 2.0 0.93 NA 
5-HMF 0.73 3.0 0.56 0.11 2.2 0.20 2.05 0.54 
 
 
Previous studies have showed that the majority of 5-HMF was cleared from 
plasma at 10 hrs across [5-HMF]0 (0.5 – 5 mM)(Parikh, 2013). The plasma clearance, 
however, decreased from 1.36 mL/min/12 mL plasma to 0.12 mL/min/12 mL plasma as 
[5-HMF]0 increased from 0.5 mM to 5 mM(Parikh, 2013). The decreasing plasma 
clearance results in a supra-proportional increase of AUC5-HMF, characterized by an 
power model exponent of greater than 1 (Table 5.11). This nonlinear in-vitro plasma 
kinetics of 5-HMF suggest saturable ALDH metabolism and/or saturable Hb binding. As 
discussed in Chapter 4, 5-HMF undergoes in-vitro metabolism in HLC and expected to 
show similar metabolism in RBC, because of the same isoform of ALDH enzymes in 
HLC and RBC. Only first-order metabolism was observed in HLC with a km larger than 
90 mM, the highest studied [5-HMF]0. In WB maximum [5-HMF]0 of 5 mM was studied, 
which is much lower than the estimated km. Metabolic clearance by ALDH is expected to 
be constant within 0.5 – 5 mM of [5-HMF]0. Previous plasma disposition results showed 
that the cp at half-maximal clearance (Kmapp = 0.54 mM) was similar to HbA binding 
affinity of 5-HMF characterized in HbA solution (KD=0.37 mM), indicating that the 
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saturable clearance from plasma is due to the saturable Hb binding (Parikh, 2013).  
These plasma disposition results match to the current findings from HbA-AEH 
adduct profiles in WB. AUCadduct of HbA-AEH adduct increased less than proportional to 
increasing [5-HMF]0, due to the saturation of Hb binding.   Along with the findings from 
previous cp-t profile, the current HbA binding properties in WB provide conclusive 
evidence that the saturable Hb binding lead to the nonlinear plasma disposition of 5-
HMF rather than saturable ALDH-mediated metabolism in RBC.  
The anti-sickling effect of 5-HMF and VZHE-039 were previously tested by 
incubating 5-HMF or VZHE-039 in SCD blood for 2 hrs. 2 mM of 5-HMF showed 22% 
sickling inhibition, whereas VZHE-039 showed ~100% inhibition(Abdulmalik, 2018; Safo 
& Kato, 2014). After thoroughly studying their HbA binding properties, ALDH-mediated 
metabolism and WB disposition, we conclude that the different anti-sickling effect of 5-
HMF and VZHE-039 in SCD blood is predominantly due to the ALDH-mediated 
metabolism. 
The lower apparent binding affinity of VZHE-039 and 5-HMF in WB may require 
larger in-vivo dose for future drug development than the extrapolation from binding 
affinity in HbA solution, to achieve similar HbA modification level for desirable anti-
sickling effect. Though both VZHE-039 and 5-HMF showed similar apparent binding 
affinity in WB, the WB disposition VZHE-039 favors better PK/PD properties than 5-
HMF, where a linear PK and longer half-life are expected and its reversible PPB would 






6. OVERALL CONCLUSIONS AND FUTURE DIRECTIONS 
 
SCD is characterized primarily by chronic, severe hemolytic anemia, leading to 
vascular occlusion, tissue infection, painful “crises” and, eventually, chronic organ 
damage that ultimately results in poor quality of life and decreased life expectancy (Piel 
et al., 2017). Common clinical management includes temporary administration of 
analgesics and blood transfusions for symptom relief. Four F.D.A.-approved drug 
treatment options are available for SCD, including hydroxyurea, voxelotor (GBT-440), 
crizanlizumab and L-glutamine. 
AEH have been studied for several years and have demonstrated dramatic in-
vitro and in-vivo anti-sickling effects by forming Schiff-base adducts with Hb, increasing 
its O2-binding affinity and inhibiting polymerization of HbS (Safo & Kato, 2014). GBT-
440 is the first AEH to be approved in 2019 by the U.S. F.D.A. for SCD treatment, 
confirming the clinical benefits of this novel MOA (Blair, 2020b; Vichinsky et al., 2019).  
The marketing approval of GBT-440 for SCD was based mainly on increased Hb levels and 
reduced hemolysis in SCD patients, considered to be clinically relevant benefits, rather than 
pertinent long-term clinical outcomes (Multi-Discipline Review of Voxelotor, 2019; Vichinsky 
et al., 2019). Regardless, the clinical studies supporting approval of GBT-440 provide 
encouraging evidence that AEH have SCD disease-modifying potential, mitigating the 
downstream adverse consequences of RBC sickling (Vichinsky et al., 2019). To aid future 
development of potentially more effective AEH drug candidates with better PK/PD 
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properties, this research encompasses a series of rationally-designed in-vitro studies 
that were conducted to screen novel synthetic AEH. 
This research had the following overall objectives: 1). To fully characterize 
concentration- and time-dependent Hb binding of AEH (their primary MOA); 2). To 
investigate their ALDH susceptibility; and 3). To integrate the underlying disposition 
mechanisms in WB using quantitative kinetic models. 
Since the rate and extent of Hb-AEH adduct formation at the target site (RBC) 
are expected to correlate directly with anti-sickling effect of AEH, a “universal” LC-
UV/Vis assay method was developed to quantitate Hb-AEH adduct concentrations in 
relevant matrices, e.g., HbA solution and WB. Liquid chromatography using a weak 
cation-exchange column (PolyCAT A) with a linear mobile phase gradient was 
employed to separate the HbA-AEH adducts from free HbA, based on their differences 
in pI and detection of the heme part at 410 nm allowed quantitation. The assay was 
validated indirectly with external (free) HbA calibration curves, where a single HbA peak 
was observed for blank HbA solution and blank WB hemolysate at retention times of 
11.0–11.5 min. Using this indirect validation, HbA calibration curves (0.0005–0.5 mM) 
were found to be linear (1/y weighted) with r2 values of 0.993–0.999, with acceptable 
precision (RSD) and accuracy (DFN). This universal assay method was subsequently 
applied to AEH with different chemical structures and physicochemical properties. It 
successfully allowed to fully characterize HbA binding kinetics for the selected AEH as 
part of this research and can also be used to screen other AEH in future drug discovery. 
235 
 
Using HbA solutions (0.1 or 0.2 mM), experiments with an optimized sampling 
schedule and optimized AEH concentration ranges (based on pilot studies) showed that 
all AEH bind to HbA in a concentration- and time-dependent manner. The HbA-AEH 
adduct levels were sustained in HbA solution for most of the tested AEH (TDs, INN-310, 
PP-14, VZHE-039, 5-HMF), due to the absence of chemical and/or metabolic 
degradation in HbA solution; however, they achieved SS binding at different rates. A SS 
sigmoidal Bmax-model was used to characterize the SS binding affinity (equivalent to 
1/KD) as well as the capacity of HbA binding sites (Bmax); it also captured potential 
cooperativity of HbA binding sites using the Hill coefficient (n) as measure of 
sigmoidicity. Furthermore, a simple kinetic binding model was used to characterize time-
dependent binding profiles with association and dissociation processes (characterized 
by kon and koff) across the initial AEH concentrations, [AEH]0. Using nonlinear regression 
methods, both models estimated relevant HbA binding properties with acceptable 
goodness-of-fit and parameter estimates (r2, COV, correlation matrix, residuals); it 
resulted in similar KD (from SS concentration-dependent) and KDkinetic (from time-
dependent) estimates. 
All vanillin-derived benzaldehydes exhibited enhanced binding affinity in HbA 
solution - relative to their parent vanillin, primarily due to their faster kon - indicating that 
the additional pyridinyl-methoxy side chains do increase HbA interactions (Table 6.1).  
In addition, the position of the pyridinyl-methoxy group alters HbA binding affinity and 
kinetics as demonstrated by comparing the three TD isomers: KD and t1/2eq: TD-7 (0.15 
hr) <TD-9 (0.23 hr) <TD-8 (0.55 hr) (Table 6.1).  5-HMF and 2,5-DMF, the two 
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furaldehydes studied, exhibited smaller KD, i.e., higher HbA affinity, than vanillin, but 
larger than VZHE-039 – due to the changes on koff and kon (Table 6.1). 
Table 6.1. Summary table of HbA binding kinetics of AEH in HbA solution and 
their oxidative metabolism in HLC. 
  Binding in HbA Solution Metabolism in HLC 
AEH  KD KDkinetic kon koff CLintin-vitro Km 
  [mM] [mM] [mM-1hr-1] [hr-1] [μL/min/mg] [mM] 
5-HMF 0.37 0.28  0.46 0.13 0.036 >90 
2,5-DMF 0.19 0.12  0.54 0.07 0 0 
Vanillin 1.72 4.3  0.16 0.69 NA 
TD-8 0.58 0.55  0.18 0.10 0 0 
TD-9 0.25 0.23  0.76 0.18 0 0 
TD-7 0.19 0.15  9.8 1.5 0.88 >0.4 
INN-310 0.19 0.14  5.0 0.70 1.6 >0.3 
PP-14 0.16 0.10  16 2.2 NA 
VZHE-039 0.10 0.10 61 5.8 0 0 
GBT-440 0.11 Faster than VZHE-039 NA 
 
 
A strong (log-log) correlation (r=0.993, n=7) was found between the kon and koff 
values among most of the tested AEH, suggesting that the current molecular design 
approach did accomplish (deliberately) enhancing HbA association while (inadvertently) 
increasing Hb dissociation as well. The chemical reaction kinetics for both formation and 
hydrolysis of Schiff-base involve several intermediates, and the rate-limiting step 
(reflected in kon or koff) may be determined by any of these intermediate steps (Scheme 
6.1) (Kallen, 1971). The electron density on the carbon atom of the aldehyde on the 
AEH, and the nitrogen atom of the primary amine of Val1 on the α-chain of HbA may 
affect the association kinetics of AEH to Hb (kon), whereas the oxygen atom of the water 
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molecule, the carbon  and nitrogen atom of Schiff-base HbA-AEH adduct may affect the 




Two deviations from this relationship, namely 2,5-DMF and vanillin, were 
observed: 2,5-DMF has two aldehyde moieties on the furan ring (rather than one for 5-
HMF) and showed a slower koff than 5-HMF. Vanillin, however, being the smallest 
benzaldehyde with fewer molecular interactions with Hb, consistently showed the 
slowest kon. In X-ray crystallographic structural studies with benzaldehydes, key 
molecular features, i.e., the methoxy-pyridine ring, the ortho-hydroxyl moiety (relative to 
the aldehyde group) on the aromatic ring and the methyl-hydroxyl group on the pyridine 
ring, have been identified as key features in enhancing Hb interactions and affinity - 
which was confirmed by the results of the kinetic HbA binding studies - by speeding up 
binding kinetics, however, in both directions, i.e., by changing kon and koff 
simultaneously. 
Due to their aldehyde functionality, AEH can be subject to ALDH-mediated 
metabolism; however, not all AEH were found to undergo oxidation in HLC, which 
contains the ALDH1 isoform (that is present in RBCs as well). ALDH1 is the major 
ALDH isoform to catalyze the oxidation of retinal (a form of vitamin A) and is efficient at 
oxidizing long-chain alkanals (O’Brien et al., 2005). It can also oxidize a rather broad 
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spectrum of both aliphatic and aromatic aldehydes with varying efficiency, including 
aldophosphamide, naphthalene, phenanthrene, and coumarin (Inoue et al., 1979; 
O’Brien et al., 2005; Vasiliou et al., 2000; Yoshida et al., 1998). The influence of side 
chains relative to the aldehyde group on ALDH oxidation has not been systemically 
studied.  5-HMF, TD-7 and INN-310 showed much lower affinity to, but a larger 
capacity/catalytic efficiency of the ALDH enzyme in HLC, compared to its prototypical 
substrate, i.e., acetaldehyde (Table 6.1). SAR studies showed that the ALDH enzyme 
favors TD-7 (with a meta-methoxy group) as substrate rather than its two isomers, i.e., 
TD-8 and TD-9 (with para-methoxy group). Interestingly, VZHE-039 did not exhibit any 
measurable oxidative metabolism, presumably due to the ortho-hydroxyl group on the 
aromatic ring, forming an intra-molecular hydrogen bond interaction with the aldehyde 
group, thus reducing its catalytic efficiency of ALDH. Electron density on the aromatic 
ring and steric hindrance may also play a role in AEH binding to and catalytic efficiency 
of ALDH. These metabolic findings in HLC are expected to be translatable to RBC, the 
site of action for AEH containing ALDH1 isoform, as demonstrated below for the 
disposition of AEH in WB. 
To quantitatively integrate the results from HbA binding and HLC metabolism 
studies, apparent SS concentration- and time-dependent studies in WB (with RBC and 
other blood components, reflecting the physiologically relevant milieu for AEH) were 
designed. Normal WB (collected from healthy volunteers, Hct: 38-45%, [HbA]0: 2.0-2.3 
mM) was equilibrated with two prototypical AEH individually, 5-HMF (a polar 
furaldehyde, subject to ALDH-mediated metabolism) and VZHE-039 (a lipophilic 
239 
 
benzaldehyde, not subject to ALDH-mediated metabolism). [AEH]0 ranges and sampling 
times were optimized from pilot experiments. 
Protection from ALDH-mediated metabolism was found to be pivotal in sustaining 
HbA-AEH adduct levels in RBC, and extending the PD effects of AEH: VZHE-039 
consistently showed sustained HbA-AEH adduct levels in WB for 24 hrs (Figure 6.1). 
On the other hand, the HbA-AEH adduct concentrations of 5-HMF in WB decreased 
after 1.5 hrs due to rapid metabolism in the RBC, consistent with the metabolic results 
in HLC (Figure 6.2, Table 6.1). Using a modified kinetic binding model, incorporating 
first-order metabolism for 5-HMF, both apparent association and metabolic processes 
are fast – as shown for 5-HMF in HbA solutions -, while the terminal decrease of HbA-
AEH adduct is determined by the slow dissociation of 5-HMF from HbA (Table 6.2). 
Previous studies had shown that the in-vitro plasma clearance (CLplasmain-vitro) of 
5-HMF was high, but it decreased with increasing [5-HMF]0, presumably due to 
saturable Hb binding and/or saturable metabolism (Parikh, 2013). In the current 
research, the observed saturable HbA-AEH adduct formation provides conclusive 
evidence that the cause of super-proportional increase for AUC of 5-HMF in plasma and 
the corresponding decrease in CLplasmain-vitro with increasing [5-HMF]0 is the saturable 




Figure 6.1. Time-dependency of HbA-AEH adduct formation for VZHE-039 in WB.  
The simple dissolution kinetic binding model (lines) was fit to the experimental 
data (symbols), as discussed in Chapter 5. 
 
Figure 6.2. Time-dependent HbA-AEH adduct formation for 5-HMF in WB. The 
simple metabolic kinetic binding model (lines) was fit to experimental data 



















































































































































































































































































































































































































Binding affinity and binding capacity of AEH to HbA, as well as to other blood 
components - such as PPB and RBC membranes - together determine the disposition 
of AEH in WB: Both 5-HMF and VZHE-039 exhibited an infra-proportional increase of 
HbA-AEH adduct exposures (AUC) with increasing [AEH]0, due to their saturable HbA 
binding (with high affinity and low capacity relative to other WB components). 
Furthermore - different from 5-HMF -, CLplasmain-vitro of VZHE-039 was low and remained 
constant across [VZHE-039]0 due to its high PPB and likely RBC membrane binding, 
which appears characterized by high capacity and low affinity (i.e., reversible first-order 
binding)  and competes with HbA binding. 
In HbA solution, the HbA binding affinity for VZHE-039 was four-fold higher 
(smaller KD) than for 5-HMF (Figure 6.3). However, the apparent WB binding affinity 
values (1/KD’) for VZHE-039 and 5-HMF - characterized from SS concentration-
dependency binding curves - are quite similar.  However, the underlying mechanisms 
are quite different: 
VZHE-039, due to its lipophilicity, is subject to extensive reversible PPB/RBC 
membrane binding, which slows down and reduces VZHE-039 available for intra-RBC 
HbA binding. This is reflected in a dramatically decreased value for kon’ in WB compared 
to kon in HbA solution, and to a lesser extent, by a decreased koff’ value (Table 6.2).  
Similar properties are expected for GBT-440, due to its higher lipophilicity compared to 
VZHE-039. 
On the other hand, 5-HMF, a hydrophilic compound, is not likely to bind 
significantly to plasma proteins and/or RBC membranes.  However, as opposed to 
VZHE-039, it is subject to ALDH-mediated metabolism inside the RBC. Using the 
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metabolism binding kinetic model to account for this concurrent metabolism, the HbA 
association and dissociation rate constants for 5-HMF in WB and HbA solution are quite 
similar (Table 6.2).  This demonstrates that its loss of HbA binding affinity in WB over 




Figure 6.3. Simulation of SS concentration-dependency of HbA-AEH adduct 
formation for VZHE-039 (solid line) and 5-HMF (dashed line) in HbA solution (red 
lines) and in WB (blue lines), using the final PE from the sigmoidal Bmax-model (as 








































Among the tested AEH, VZHE-039 has been selected as our top candidate for 
further preclinical development. In HbA solution, VZHE-039 is characterized by high 
HbA binding affinity (KD = 0.1 mM) and rapid binding kinetics, similar to the clinical 
reference compound, GBT-440 (Table 6.1). In HLC studies, VZHE-039 was also found 
to be resistant to ALDH-mediated metabolism – properties expected to be beneficial for 
sustaining its PD effect in blood, which was confirmed in the WB studies. However, the 
observed WB potency (KD’ of 1.5 mM) was reduced quite significantly due to 
nonspecific binding to plasma proteins and/or RBC membranes. 
Both VZHE-039 and GBT-440 are highly bound to plasma protein, with a fraction 
bound in human plasma of 94% for VZHE-039 experimentally obtained from a rapid 
equilibrium dialysis method at a concentration of 5 μM, and 99.8% for GBT-440 
measured by ultracentrifugation at concentrations of 5 and 50 μM (Abdulmalik, 2018; 
Multi-Discipline Review of Voxelotor, 2019). This high degree of PPB lowers their 
apparent potency in WB by competing with Hb binding (target site), but - along with the 
HbA binding - it also retains both compounds in the intravascular space, which is 
expected to lead to a reduction of their extravascular tissue distribution (small Vdss) and 
clearance (small CLtot) as well, as will be discussed below. 
Depending on the oral dose requirements, GI solubility of VZHE-039 is expected 
to be low: Our in-vitro studies showed that the maximal concentration of VZHE-039 that 
can be dissolved in 0.5 M Tris buffer (pH = 7.5) is 1.3 mM (i.e., 0.35 mg/mL). Assuming 
a human GI fluid volume of 250 mL, the predicted maximal dissolvable P.O. dose would 
be 87 mg, which is likely below its therapeutic oral doses, expected to exceed 10-20 
mg/kg, i.e., 750-1500 mg. Appropriate formulation for adequate Foral would be 
246 
 
necessary, as is the case for GBT-440 which was formulated as a 500 mg immediate-
release solid oral dosage form (Multi-Discipline Review of Voxelotor, 2019). 
GBT-440 has low solubility (0.032 mg/mL = 8 mg/250 mL, i.e., ~10 times lower 
than VZHE-039) in water and aqueous buffers at pH 7.0, relative to its therapeutic oral 
doses (1500 mg) (Product Quality Review(s) of Voxelotor, 2019). 
VZHE-039 has shown high in-vitro Caco2 cell permeability and is not a substrate 
of efflux transporters (efflux ratio [Re] > 0.85), consistent with trans-epithelial diffusion 
due to its high lipophilicity (cLog = 1.7) (Safo, 2019). 
GBT-440, another lipophilic compound (cLog = 3.5), also appears to be a high 
permeability drug with Papp(B-to-A) / Papp(A-to-B) ratio of 1.31 in a polarized monolayer 
of Madin Darcy Canine Kidney MDR1 (MDCK-MDR1) cells system, indicating it is not a 
substrate of P-gp (Product Quality Review(s) of Voxelotor, 2019).GBT-440 is classified 
by F.D.A. as a BCS Class 2 drug (Multi-Discipline Review of Voxelotor, 2019). In a 
human mass balance study with a single radio-labeled dose of 400 mg of GBT-440 to 
healthy volunteers, 63% of radioactivity dose was recovered in feces, including 33% as 
parent drug (Multi-Discipline Review of Voxelotor, 2019). In-vivo radiolabeled studies in 
rats (I.V.: 2 mg/kg) showed that only approximately 6.6% of GBT-440 was excreted as 
unchanged form into bile and most of the dose was excreted as metabolites (77% of the 
dose) (Multi-Discipline Review of Voxelotor, 2019). These findings suggest that GBT-
440 was not well absorbed from the GI tract and not subject to significant biliary 
excretion; about one third of the oral dose in humans does not get absorbed. A low-fat 
breakfast showed no significant effect on GBT-440 exposures, whereas a high-fat meal 
did not affect tmax significantly, but increased AUC by 42% and cmax by 45%, 
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demonstrating enhancement of the extent, rather than the rate of absorption 
(Hutchaleelaha et al., 2019; Multi-Discipline Review of Voxelotor, 2019). A high-fat meal 
is expected to stimulate bile acid secretion into the GI tract, where they help solubilizing 
lipophilic molecules, including GBT-440, thus increasing its GI solubility and Foral. The 
results from both mass balance and food effect studies are consistent with its BCS class 
2 designation as a poor GI solubility/high GI permeability drug. 
VZHE-039 and GBT-440 are expected to be low hepatic extraction ratio 
compounds, as both of them are highly PPB; therefore, low first-pass metabolism is 
expected for both. However, their Foral may be limited by GI solubility - as discussed 
above. In-vitro studies in mice showed that after oral administration of 100-200 mg/kg 
(non-optimized suspension), VZHE-039 exhibited a low Foral of 11%-13%, whereas 
GBT-440 (P.O., 30 mg/kg, presumably the patented suspension) showed moderate Foral 
of 71%, likely due to differences in their GI solubility and formulation (Table 6.3) (US 
2016/0206604 A1, 2016; “Datasets obtained from Abdulmalik, Osheiza,” 2018; 
Oksenberg et al., 2016). 
 
Table 6.3. PK parameters for VZHE-039 and GBT-440 in mice (n = 2-3). 
AEH  Dose CLtot Vdss t1/2 Foral RBC/plasma 
ratio  [mg/kg] [mL/min/kg] [L/kg] [hr] % 
VZHE-039 
I.V.,12.5 - 25;  
P.O. 100 - 200  
0.13 0.10 12 18  NA 




Based on the results of the in-vitro WB disposition studies, VZHE-039 showed a 
constant low CLplasmain-vitro (0.005 mL/min/12mL plasma), independent of [VZHE-039]0 
(0.3 – 8 mM) – reflecting non-saturable PPB/RBC membrane binding- as well as 
saturable HbA binding at the target site. In-vivo PK studies with VZHE-039 (12.5-25 
mg/kg) and GBT-440 (70 mg/kg) in mice after I.V. administration showed a small Vdss of 
0.1 ml/kg for both (Table 6.3), which is consistent with their in-vitro PPB/RBC 
membrane and Hb binding, reducing their extravascular tissue distribution (Dufu, Patel, 
Oksenberg, & Cabrales, 2018). GBT-440 is the main circulating moiety in human 
plasma and in WB accounting for 48.8% and 95% of the total radioactivity, respectively, 
indicating despite the high PPB of GBT-440 (99.8%), the blood-to-plasma ratio is 
approximately 2:1 - which further confirms its non-specific binding to RBC membranes 
and specific binding to Hb (target) (Multi-Discipline Review of Voxelotor, 2019). 
GBT-440 is metabolized by CYP-450, UGT and SULT(Multi-Discipline Review of 
Voxelotor, 2019). In-vitro metabolism studies using recombinant isozymes indicate that 
the contribution of CYP3A4, CYP2C9, CYP2C19, and CYP2B6 to overall metabolism of 
GBT-440 was 56%, 7%, 5%, 7%, respectively (Multi-Discipline Review of Voxelotor, 
2019). Phase 2 conjugation by UGT1A1 and UGT1A9 accounted for 8% of the overall 
metabolism of GBT-440 (Multi-Discipline Review of Voxelotor, 2019). In-vivo studies 
showed the major circulating metabolite in human plasma (as in mouse, rat and dog) is 
an (inactive, phase 2) O-dealkylation-sulfate metabolite that is formed by oxidation and 
subsequent conjugation with sulfate, accounting for 16.8% of total radioactivity in WB 
(Multi-Discipline Review of Voxelotor, 2019). A human mass balance study also showed 
that CYP-mediated oxidation, reduction and direct conjugation accounted for 16.9%, 
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11.4%, and 4.6% of the GBT-440 dose recovered in feces and urine, where 3.1% of 
GBT-440 was oxidized to the carboxylic acid, presumably due to ALDH-mediated 
metabolism (Multi-Discipline Review of Voxelotor, 2019). 
Preliminary in-vitro studies with VZHE-039 (0.1 – 100 μM) in HLM showed no 
inhibition of several major isoforms of CYP-450 (3A4, 2C8, 2C9, 2C19, 2D6), with 
exception of CYP1A2 (4.7 μM) and CYP2B6 (41.4 μM). GBT-440, on the other hand, 
showed inhibition of major CYP-450 isozymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, and 
3A4) in HLM with IC50 values ranging from 7.9 to 148 μM, where CYP3A4, in particular 
showed a IC50 of 12.5 – 81.9 μM (Metcalf et al., 2017). In an in-vivo cocktail DDI study 
using different CYP-450 substrate drugs, exposure of midazolam (substrate of CYP3A4) 
increased by 63% in presence of GBT-440, indicating that GBT-440 is an inhibitor of 
CYP3A4 at clinically relevant doses (Multi-Discipline Review of Voxelotor, 2019). This 
study also showed a less than 1.12-fold change in exposure of caffeine (CYP1A2), 
warfarin (CYP2C9), and omeprazole (CYP2C19) (Multi-Discipline Review of Voxelotor, 
2019). As GBT-440 is a known substrate of CYP3A4, which is its major metabolic 
elimination pathway, a reduced dose from 1,500 to 1,000 mg/daily of GBT-440 is 
recommended by F.D.A in concomitant use of strong CYP3A4 inhibitors (Multi-
Discipline Review of Voxelotor, 2019).  
In-vivo PK studies in mice after I.V. administration of VZHE-039 (12.5-25 mg/kg) 
consistently showed a low, dose-independent in-vivo clearance (CLtot) of 0.12-0.14 
mL/min/kg and a long terminal half-life (t1/2) of 10 -13 hrs (“Datasets obtained from 
Abdulmalik, Osheiza,” 2018). GBT-440 (I.V. 70 mg/kg) also showed a low CLtot of 0.11 
mL/min/kg and a long t1/2 of 12 hrs in mice (Table 6.3) (Oksenberg et al., 2016). In-vivo 
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radiolabeled studies in rats (I.V.: 2 mg/kg) showed that metabolism is the main 
elimination route of GBT-440, accounting for 93% of the administered dose, while only 
approximately 6.6% of GBT-440 was excreted as unchanged parent drug into bile and 
<1% in urine (Multi-Discipline Review of Voxelotor, 2019).   
In a human mass balance study, a single radio-labeled dose of 400 mg of GBT-
440 was administrated to healthy volunteers (n = 7) on day 5 after SS was achieved 
with pre-administrated non-radioactive GBT-440 (Rademacher, Hutchaleelaha, 
Washington, Lehrer, & Ramos, 2016). 98.0% radioactivity was recovered over 23 days 
(Multi-Discipline Review of Voxelotor, 2019). 35% of radioactivity was recovered in urine 
and 63% in feces, where most excreted as metabolites (Multi-Discipline Review of 
Voxelotor, 2019). Only 0.08% was excreted renally unchanged (Multi-Discipline Review 
of Voxelotor, 2019), suggesting that renal elimination of parent drug is negligible and 
GBT-440 is almost exclusively metabolized. Low renal clearance is expected due to the 
high PPB (99.8%) preventing GBT-440 from being filtered in the glomeruli and any drug 
reaching the tubuli being reabsorbed due to its high lipophilicity. 
In humans, GBT-440 followed dose-proportional PK for doses up to 2,800 mg 
(i.e., 37 mg/kg) (Hutchaleelaha et al., 2019). The terminal plasma t1/2 in healthy 
volunteers was around 61–85 hrs, while, in SCD patients, it was shorter (~36 hrs), most 
likely due to low Hb level and less RBC in SCD patients, resulting in less GBT-440 
bound to Hb and RBC membranes, resulting in more free drug in blood available for 
hepatic clearance (Hutchaleelaha et al., 2019).  
Upon once daily dosing of therapeutic doses, SS concentrations of GBT-440 in 
plasma and blood were reached by day 8 in SCD patients. The accumulation ratio of 
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AUC0-24h at SS was approximately 3-fold, suggesting an accumulation half-life 
exceeding 24 hrs, consistent with the terminal half-life after single doses, as mentioned 
above (Multi-Discipline Review of Voxelotor, 2019). At steady-state after 1,000 mg/day 
in SCD patients (n=6), average cmaxSS of GBT-440 were measured to be 483 μg/mL 
(1.43 mM), 8.1 μg/mL (0.024 mM), and 221 μg/mL (0.66 mM) in RBC, plasma, and WB, 
respectively (Howard et al., 2019) – clearly demonstrating the preference of GBT-440 
for RBC accumulation. Compared to its KD (0.11 mM) from the in-vitro HbA binding 
study in HbA solution, these in-vivo SS peak concentrations in RBC (1.43 mM) are 
much larger. However, this doesn’t account for the non-specific binding to RBC 
membranes, which are high for lipophilic compounds such as GBT-440, nor PPB (fb of 
99.6% for GBT-440 and 94% for VZHE-039).  Comparing the in-vivo SS peak WB 
concentrations (0.66 mM) to the apparent KD’ in WB HbA binding studies of 2.3 mM, 
which includes nonspecific binding, (see Table 6.2) suggests that less than 50% of Hb 
had bound GBT-440 in-vivo.  This is consistent with ex-vivo measurements of “modified 
HbS” concentrations at therapeutic doses in SCD patients, which suggests that only 25-
30% of HbS was modified in achieving clinical efficacy. (Multi-Discipline Review of 
Voxelotor, 2019) 
In summary, both VZHE-039 and GBT-440 exhibit or are expected to exhibit high 
GI permeability and presumably low hepatic first-pass metabolism due to high PPB. 
Their Foral, however, is limited by poor GI solubility at therapeutic doses. Small Vdss and 
low CLtot were observed for both VZHE-039 and GBT-440 in mice, due to their high 
PPB/RBC membrane binding and Hb binding, retaining them in blood. Due to the low 
CLren of GBT-440, hepatic CYP-mediated oxidative metabolism (with secondary 
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conjugation) was the main route of elimination. Overall, in muine PK studies, the 
systemic PK properties (after I.V. administration) of VZHE-039 and GBT-440 are quite 
similar. 
Observed MOA-related differences between VZHE-039 and GBT-440 in 
preclinical development include: In HbA solution, at saturating concentrations, VZHE-
039 exhibited 100% HbA modification whereas GBT-440 modified only ~50% of HbA - 
consistent with one molecule of HbA binding two molecules of VZHE-039, but only one 
molecule of GBT-440, as discussed in Chapter 3. In addition, VZHE-039 has a 
secondary, O2-independent anti-sickling MOA over GBT-440 due to interactions with the 
surface-located αF-helix of Hb to directly weaken HbS polymer interactions (Ahmed et 
al., 2020; Oder et al., 2016; Pagare et al., 2018). It is expected that GBT-440-modified 
HbS tetramers may still transition to the DeoxyHb T-state in areas of severe regional 
hypoxia with GBT-440 incorporated into fibers, leading to local sickling. On the other hand, 
VZHE-039-bound to the DeoxyHb T-state of HbS would destabilize fiber formation and 
prevent sickling, which may be clinically advantageous (Ahmed et al., 2020; Oder et al., 
2016; Pagare et al., 2018). 
For future discovery of novel AEH, enhanced HbA binding affinity and kinetics as 
well as resistance to ALDH-mediated metabolism are pivotal criteria to improve their 
potency and PK/PD properties and meet dose requirement for the intended sustained 
PD effects. To increase Hb binding affinity (KD = koff/kon), increasing kon and/or 
decreasing koff is desirable. Current molecular modifications of vanillin to identify and 
investigate novel AEH successfully increased their kon (deliberately) but also 
(inadvertently) increased their koff.  There is a need to keep koff small while increasing kon. 
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Keeping koff small will also slow down the overall Hb binding kinetics (t1/2eq= 
ln(2)/(HbA0*kon+koff)). This slow dissociation from HbA is desirable and makes RBC 
(target site) into deep compartment, which will be beneficial to hold AEH on Hb and 
prolong its PD effect.  Lipophilicity in general is expected to decrease the apparent 
binding affinity of AEH (e.g. VZHE-039, GBT-440) in WB due to non-specific binding to 
PPB and RBC membranes. However, a possible benefit of this off-target, nonspecific, 
high capacity binding is drug retention in the blood, prolonging the in-vivo persistence of 
AEH in blood. Poor GI solubility can be a problem for lipophilic AEH (e.g. VZHE-039, 
GBT-440), reducing their Foral, which can be overcome by appropriate formulations 
and/or improving dose potency. Other druggability issues, including PPB, other 
metabolic routes, and DDI liabilities also need to be considered to meet dose 
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1. Michaelis-Menten Kinetics Model 
 
// Michaelis-Menten Kinetics Model 
// AP/JV XX 2018 









2. Sigmoidal-Bmax Model 
 
// Sigmoidal-Bmax Model 
// AP/JV XX 2018  










3. Reversed Sigmoidal-Bmax Model 
 
// Reversed Sigmoidal-Bmax Model 
// AP/JV XX 2018  










4. Simple Kinetic Binding Model 
 
// Simple Kinetic Binding Model 
// JV, AP, TO, XX, Jun 25, 2018 
// 
// Assuming bimolecular, reversible interaction between AEH and Hb 
// concentrations unit in mM 
// kon, forward rate constant in mM-1*hr-1 
// koff, backward rate constant in hr-1 
// 
IndVars: T, AEH0 
DepVars: HbAEH 
Params: kon, koff, Hb0 













5. Simple Metabolism Kinetic Binding Model 
 
// Simple metabolism kinetic binding model 
// JV, AP, TO, XX, Mar 10, 2020 
// 
// Assuming bimolecular, reversible interaction between HMF and Hb, irreversible 
metabolism from HMF to HMFA 
// concentrations in mM 
// kon in mM-1*hr-1 
// koff in hr-1 
// kmet in hr-1 
// 
IndVars: T, HMF0 
DepVars: HMF, Hb, HbHMF, HMFA 
Params: kon, koff, Hb0, kmet 










HMFA = 0 




6. Simple Dissolution Kinetic Binding Model 
// Simple Dissolution Kinetic Binding Model 
// Version 3.0 
// JV, XX, June.14, 2020 
// 
// Assuming zero-order input/dissolution of AEH, reversible interaction between 
AEH in and Hb  
// concentrations in mM 
// kon in mM-1*hr-1 
// koff is first-order backward rate constant in hr-1 
// V is WB volume in L 
// k0 is zero order dissolution rate constant in mmole*hr-1 
// TE is dissolution time in hr 
//CRATE dissolution rate in mM 
// Adiss the amount dissolved up to time t in mmole 
//// 
IndVars: T, AEH0 
DepVars: HbAEH 
Params:  k0, V, kon, koff, Hb0 
// 









// Differential equation 

















Experimental Data for in-vitro Concentration- and Time-Dependency HbA-AEH adduct 
of AEH in HbA Solution 
 























Figure B.3.4. Representative chromatogram for vanillin.  
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Figure B.3.10. Representative chromatogram for GBT-440 after 0.03 hrs.  
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Table B.3.1. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
5-HMF in HbA solution. 
[5-HMF]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.06 0.027 0.18 
0.13 0.041 0.19 
0.25 0.076 0.17 
0.5 0.12 0.13 
1 0.15 0.066 
2 0.18 0.050 





Table B.3.2. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
2,5-DMF in HbA solution. 
[2,5-DMF]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.025 0.011 0.20 
0.05 0.024 0.21 
0.1 0.041 0.20 
0.25 0.12 0.18 
0.5 0.16 0.085 






Table B.3.3. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
vanillin in HbA solution. 
[Vanillin]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.44 0.006 0.16 
0.74 0.024 0.18 
1.5 0.069 0.11 
2.9 0.07 0.067 
3.5 0.11 0.068 
4.4 0.12 0.055 
4.9 0.13 0.046 
5.8 0.14 0.038 
7.1 0.13 0.029 
11 0.12 0.013 
21 0.13 Below eLOQ 
 
 
Table B.3.4. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
TD-8 in HbA solution. 
[TD-8]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.1 0.027 0.21 
0.2 0.032 0.20 
0.4 0.063 0.17 
1 0.13 0.10 
2 0.16 0.045 






Table B.3.5. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
TD-9 in HbA solution. 
[TD-9]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.1 0.030 0.18 
0.2 0.068 0.15 
0.4 0.128 0.10 
1 0.18 0.02 
2 0.17 0.017 
4 0.18 0.023 
 
 
Table B.3.6. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
TD-7 in HbA solution. 
[TD-7]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.025 0.012 0.19 
0.05 0.021 0.17 
0.10 0.037 0.14 
0.2 0.08 0.11 
0.4 0.14 0.046 
0.8 0.17 Below eLOQ 






Table B.3.7. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
INN-310 in HbA solution. 
[INN-310]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.027 0.014 0.16 
0.046 0.019 0.15 
0.09 0.033 0.13 
0.11 0.03 0.110 
0.18 0.06 0.102 
0.36 0.13 0.032 
0.57 0.16 Below eLOQ 
0.9 0.12 Below eLOQ 
1.8 0.13 Below eLOQ 
3 0.13 Below eLOQ 
5 0.14 Below eLOQ 
 
 
Table B.3.8. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
PP-14 in HbA solution. 
[PP-14]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.05 0.022 0.18 
0.1 0.043 0.16 
0.2 0.079 0.10 
0.25 0.14 0.080 
0.3 0.16 0.059 
0.4 0.16 0.024 
0.5 0.17 0.054 
0.6 0.16 Below eLOQ 
1 0.15 Below eLOQ 





Table B.3.9. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
VZHE-039 in HbA solution. 
[VZHE-039]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.03 0.009 0.066 
0.04 0.016 0.064 
0.06 0.020 0.058 
0.08 0.027 0.044 
0.12 0.046 0.041 
0.25 0.071 0.010 





Table B.3.10. Dataset for concentration-dependency HbA-AEH adduct and HbA of 
GBT-440 in HbA solution. 
[GBT-440]0 [HbA-AEH adduct] [HbA] 
[mM] [mM] [mM] 
0.02 0.028 0.22 
0.04 0.025 0.19 
0.06 0.032 0.17 
0.08 0.043 0.16 
0.10 0.061 0.15 
0.12 0.064 0.15 
0.14 0.070 0.14 
0.16 0.078 0.13 
0.20 0.096 0.12 
0.39 0.096 0.10 
0.40 0.13 0.11 
0.52 0.12 0.11 
0.65 0.13 0.10 
0.77 0.13 0.10 
0.90 0.13 0.10 
1.00 0.13 0.10 
1.65 0.13 0.11 
3.28 0.12 0.11 
6.45 0.13 0.097 








Table B.3.11. Dataset for time-dependency HbA-AEH adduct of 5-HMF in HbA 
solution. 
T [5-HMF]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.03 0.0625 0.022 
0.3 0.0625 0.022 
1.0 0.0625 0.022 
3.0 0.0625 0.024 
5.0 0.0625 0.033 
6.0 0.0625 0.028 
7.0 0.0625 0.029 
23.0 0.0625 0.030 
24.0 0.0625 0.027 
0.0 0.125 0.020 
0.3 0.125 0.023 
1.0 0.125 0.024 
3.0 0.125 0.031 
5.0 0.125 0.037 
6.0 0.125 0.041 
7.0 0.125 0.038 
23.0 0.125 0.048 
24.0 0.125 0.041 
0.03 0.25 0.018 
0.3 0.25 0.023 
1.0 0.25 0.033 
3.0 0.25 0.047 
5.0 0.25 0.054 
6.0 0.25 0.069 
7.0 0.25 0.061 
23.0 0.25 0.075 
24.0 0.25 0.076 
0.03 0.5 0.020 
0.3 0.5 0.028 
1.0 0.5 0.029 
3.0 0.5 0.058 
5.0 0.5 0.065 
6.0 0.5 0.109 
7.0 0.5 0.101 
23.0 0.5 0.097 
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24.0 0.5 0.124 
0.0 1 0.021 
0.3 1 0.035 
1.0 1 0.050 
1.5 1 0.083 
2.0 1 0.110 
3.0 1 0.119 
4.0 1 0.126 
5.0 1 0.143 
6.0 1 0.141 
24.0 1 0.147 
0.03 2 0.025 
0.3 2 0.047 
1.0 2 0.111 
1.5 2 0.112 
2.0 2 0.187 
3.0 2 0.137 
4.0 2 0.196 
5.0 2 0.207 
6.0 2 0.183 
0.0 4 0.024 
0.3 4 0.079 
0.7 4 0.136 
1.0 4 0.146 
1.5 4 0.182 
2.0 4 0.306 
3.0 4 0.223 
4.0 4 0.169 





Table B.3.12. Dataset for time-dependency HbA-AEH adduct of 2,5-DMF in HbA 
solution. 
T [2,5-DMF]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
6.0 0.025 0.013 
24.5 0.025 0.020 
25.5 0.025 0.011 
1.0 0.05 0.012 
2.0 0.05 0.016 
4.0 0.05 0.020 
6.0 0.05 0.021 
24.5 0.05 0.031 
25.5 0.05 0.024 
0.5 0.1 0.009 
1.0 0.1 0.015 
2.0 0.1 0.023 
4.0 0.1 0.031 
6.0 0.1 0.036 
24.5 0.1 0.052 
25.5 0.1 0.041 
0.2 0.25 0.008 
0.3 0.25 0.020 
0.5 0.25 0.024 
1.0 0.25 0.035 
2.0 0.25 0.046 
4.0 0.25 0.066 
6.0 0.25 0.079 
24.5 0.25 0.120 
0.1 0.5 0.017 
0.2 0.5 0.020 
0.3 0.5 0.021 
0.5 0.5 0.030 
1.0 0.5 0.047 
2.0 0.5 0.072 
4.0 0.5 0.094 
6.0 0.5 0.113 




Table B.3.13. Dataset for time-dependency HbA-AEH adduct of vanillin in HbA 
solution. 
T [Vanillin]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
2.0 0.44 0.004 
3.0 0.44 0.004 
4.5 0.44 0.006 
1.0 0.74 0.007 
2.0 0.74 0.016 
3.0 0.74 0.013 
4.5 0.74 0.024 
0.5 1.5 0.006 
1.0 1.5 0.011 
2.0 1.5 0.026 
3.0 1.5 0.032 
4.5 1.5 0.069 
0.5 2.1 0.010 
1.0 2.1 0.015 
2.0 2.1 0.038 
3.0 2.1 0.043 
0.5 2.9 0.022 
1.0 2.9 0.047 
2.0 2.9 0.068 
3.0 2.9 0.065 
4.5 2.9 0.075 
0.5 3.5 0.037 
1.0 3.5 0.062 
2.0 3.5 0.094 
3.0 3.5 0.099 
4.5 3.5 0.106 
0.5 4.4 0.049 
1.0 4.4 0.098 
2.0 4.4 0.119 
3.0 4.4 0.120 
4.5 4.4 0.123 
0.5 4.9 0.075 
1.0 4.9 0.103 
2.0 4.9 0.125 
3.0 4.9 0.123 
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4.5 4.9 0.126 
0.5 5.8 0.095 
1.0 5.8 0.124 
2.0 5.8 0.120 
3.0 5.8 0.129 
4.5 5.8 0.138 
0.1 7.1 0.014 
0.3 7.1 0.076 
1.0 7.1 0.135 
0.1 10.5 0.028 
0.3 10.5 0.125 
1.0 10.5 0.102 
0.1 20.8 0.033 
0.3 20.8 0.108 






Table B.3.14. Dataset for time-dependency HbA-AEH adduct of TD-8 in HbA 
solution. 
T [TD-8]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.1 0.1 0.009 
0.5 0.1 0.013 
1.0 0.1 0.015 
2.0 0.1 0.017 
4.0 0.1 0.020 
6.0 0.1 0.023 
24.0 0.1 0.027 
0.1 0.2 0.013 
0.5 0.2 0.016 
1.0 0.2 0.017 
2.0 0.2 0.021 
4.0 0.2 0.029 
6.0 0.2 0.031 
24.0 0.2 0.032 
0.1 0.4 0.012 
0.5 0.4 0.018 
1.0 0.4 0.021 
2.0 0.4 0.030 
4.0 0.4 0.048 
6.0 0.4 0.060 
24.0 0.4 0.063 
0.1 1 0.011 
0.5 1 0.020 
1.0 1 0.030 
2.0 1 0.063 
4.0 1 0.096 
6.0 1 0.115 
24.0 1 0.129 
0.1 2 0.010 
0.5 2 0.027 
1.0 2 0.050 
2.0 2 0.094 
4.0 2 0.132 
6.0 2 0.154 
24.0 2 0.159 
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0.1 4 0.010 
0.5 4 0.035 
1.0 4 0.078 
2.0 4 0.123 
4.0 4 0.154 
6.0 4 0.182 





Table B.3.15. Dataset for time-dependency HbA-AEH adduct of TD-9 in HbA 
solution. 
T [TD-9]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.1 0.1 0.012 
0.5 0.1 0.009 
1.0 0.1 0.015 
4.5 0.1 0.027 
5.0 0.1 0.029 
6.0 0.1 0.029 
24.0 0.1 0.030 
27.0 0.1 0.030 
0.1 0.2 0.011 
0.5 0.2 0.017 
1.0 0.2 0.029 
4.5 0.2 0.064 
5.0 0.2 0.063 
6.0 0.2 0.065 
24.0 0.2 0.065 
27.0 0.2 0.068 
0.1 0.4 0.010 
0.5 0.4 0.034 
1.0 0.4 0.059 
4.5 0.4 0.116 
5.0 0.4 0.117 
6.0 0.4 0.115 
24.0 0.4 0.122 
27.0 0.4 0.128 
0.1 1 0.010 
0.5 1 0.059 
1.0 1 0.108 
4.5 1 0.172 
5.0 1 0.172 
6.0 1 0.169 
24.0 1 0.175 
27.0 1 0.179 
0.1 2 0.009 
0.5 2 0.093 
0.5 2 0.093 
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1.0 2 0.153 
4.5 2 0.172 
4.5 2 0.172 
5.0 2 0.167 
6.0 2 0.165 
24.0 2 0.166 
27.0 2 0.175 
0.5 4 0.109 
1.0 4 0.154 
4.5 4 0.171 
5.0 4 0.173 
6.0 4 0.171 
24.0 4 0.167 





Table B.3.16. Dataset for time-dependency HbA-AEH adduct of TD-7 in HbA 
solution. 
T [TD-7]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.1 0.025 0.006 
0.2 0.025 0.007 
0.3 0.025 0.011 
0.4 0.025 0.013 
0.5 0.025 0.012 
0.6 0.025 0.016 
0.8 0.025 0.014 
1.0 0.025 0.013 
1.1 0.025 0.015 
2.1 0.025 0.014 
5.1 0.025 0.012 
0.1 0.05 0.008 
0.2 0.05 0.016 
0.3 0.05 0.015 
0.4 0.05 0.018 
0.5 0.05 0.022 
0.6 0.05 0.026 
0.8 0.05 0.022 
1.0 0.05 0.025 
1.1 0.05 0.024 
2.1 0.05 0.022 
5.1 0.05 0.021 
0.1 0.1 0.015 
0.2 0.1 0.023 
0.3 0.1 0.029 
0.4 0.1 0.035 
0.5 0.1 0.034 
0.6 0.1 0.042 
0.8 0.1 0.040 
1.0 0.1 0.043 
1.1 0.1 0.045 
2.1 0.1 0.043 
5.1 0.1 0.037 
0.1 0.2 0.026 
0.2 0.2 0.053 
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0.3 0.2 0.062 
0.4 0.2 0.066 
0.5 0.2 0.077 
0.6 0.2 0.084 
0.6 0.2 0.083 
0.7 0.2 0.085 
0.8 0.2 0.078 
1.0 0.2 0.087 
1.1 0.2 0.085 
0.1 0.4 0.059 
0.2 0.4 0.087 
0.3 0.4 0.103 
0.4 0.4 0.117 
0.5 0.4 0.125 
0.6 0.4 0.129 
0.6 0.4 0.131 
0.7 0.4 0.136 
0.8 0.4 0.139 
1.0 0.4 0.146 
1.1 0.4 0.140 
0.1 0.8 0.104 
0.2 0.8 0.137 
0.3 0.8 0.153 
0.4 0.8 0.174 
0.5 0.8 0.171 
0.6 0.8 0.164 
0.6 0.8 0.166 
0.7 0.8 0.166 
0.1 1.6 0.130 
0.2 1.6 0.155 
0.3 1.6 0.162 





Table B.3.17. Dataset for time-dependency HbA-AEH adduct of INN-310 in HbA 
solution. 
T [INN-310]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.1 0.046 0.005 
0.2 0.046 0.008 
0.3 0.046 0.015 
0.4 0.046 0.016 
1.0 0.046 0.022 
1.5 0.046 0.016 
2.0 0.046 0.018 
4.0 0.046 0.015 
6.0 0.046 0.014 
0.0 0.09 0.004 
0.1 0.09 0.010 
0.2 0.09 0.024 
0.3 0.09 0.024 
0.4 0.09 0.026 
1.0 0.09 0.030 
1.5 0.09 0.028 
2.0 0.09 0.028 
4.0 0.09 0.025 
6.0 0.09 0.026 
0.0 0.11 0.004 
0.1 0.11 0.012 
0.2 0.11 0.021 
0.3 0.11 0.027 
0.4 0.11 0.030 
1.0 0.11 0.039 
1.5 0.11 0.041 
2.0 0.11 0.041 
4.0 0.11 0.031 
6.0 0.11 0.026 
0.0 0.18 0.013 
0.1 0.18 0.023 
0.2 0.18 0.037 
0.3 0.18 0.044 
0.4 0.18 0.044 
1.0 0.18 0.061 
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1.5 0.18 0.058 
2.0 0.18 0.063 
4.0 0.18 0.054 
6.0 0.18 0.054 
0.0 0.36 0.022 
0.1 0.36 0.044 
0.2 0.36 0.054 
0.3 0.36 0.079 
0.4 0.36 0.087 
1.0 0.36 0.117 
1.5 0.36 0.106 
2.0 0.36 0.113 
4.0 0.36 0.106 
6.0 0.36 0.109 
0.0 0.6 0.034 
0.1 0.6 0.068 
0.2 0.6 0.103 
0.3 0.6 0.105 
0.4 0.6 0.113 
1.0 0.6 0.137 
6.0 0.6 0.136 
0.0 0.9 0.024 
0.1 0.9 0.042 
0.2 0.9 0.072 
0.3 0.9 0.087 
0.4 0.9 0.101 
1.0 0.9 0.130 
6.0 0.9 0.103 
0.0 1.8 0.027 
0.1 1.8 0.056 
0.2 1.8 0.079 
0.3 1.8 0.079 
0.4 1.8 0.110 
1.0 1.8 0.120 
6.0 1.8 0.112 
0.0 2.9 0.032 
0.1 2.9 0.063 
0.2 2.9 0.099 
0.3 2.9 0.109 
0.4 2.9 0.122 
1.0 2.9 0.120 
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6.0 2.9 0.116 
0.0 5.2 0.024 
0.1 5.2 0.067 
0.2 5.2 0.109 
0.3 5.2 0.116 
0.4 5.2 0.132 
1.0 5.2 0.130 





Table B.3.18. Dataset for time-dependency HbA-AEH adduct of PP-14 in HbA 
solution. 
T [PP-14]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.1 0.05 0.016 
0.2 0.05 0.017 
0.2 0.05 0.016 
0.3 0.05 0.021 
0.4 0.05 0.019 
0.5 0.05 0.018 
0.6 0.05 0.019 
0.7 0.05 0.021 
1.0 0.05 0.019 
4.0 0.05 0.022 
0.0 0.1 0.017 
0.1 0.1 0.031 
0.2 0.1 0.028 
0.2 0.1 0.030 
0.3 0.1 0.034 
0.4 0.1 0.034 
0.5 0.1 0.033 
0.6 0.1 0.033 
0.7 0.1 0.039 
1.0 0.1 0.040 
4.0 0.1 0.043 
0.0 0.2 0.036 
0.1 0.2 0.058 
0.2 0.2 0.058 
0.2 0.2 0.055 
0.3 0.2 0.065 
0.4 0.2 0.063 
0.5 0.2 0.065 
0.6 0.2 0.065 
0.7 0.2 0.076 
1.0 0.2 0.076 
4.0 0.2 0.079 
0.1 0.25 0.061 
0.2 0.25 0.077 
0.3 0.25 0.100 
302 
 
0.5 0.25 0.087 
1.0 0.25 0.103 
2.0 0.25 0.101 
4.0 0.25 0.138 
0.1 0.3 0.059 
0.2 0.3 0.093 
0.3 0.3 0.092 
0.5 0.3 0.133 
1.0 0.3 0.117 
2.0 0.3 0.141 
4.0 0.3 0.162 
0.1 0.4 0.101 
0.2 0.4 0.118 
0.3 0.4 0.142 
0.5 0.4 0.145 
1.0 0.4 0.156 
2.0 0.4 0.194 
0.0 0.5 0.071 
0.1 0.5 0.114 
0.2 0.5 0.140 
0.2 0.5 0.131 
0.3 0.5 0.148 
0.4 0.5 0.157 
0.5 0.5 0.153 
0.6 0.5 0.157 
0.7 0.5 0.100 
1.0 0.5 0.158 
4.0 0.5 0.172 
0.1 0.6 0.085 
0.3 0.6 0.155 
0.5 0.6 0.150 
1.0 0.6 0.123 
2.0 0.6 0.151 
4.0 0.6 0.162 
0.0 1.0 0.072 
0.1 1.0 0.118 
0.2 1.0 0.128 
0.2 1.0 0.151 
0.3 1.0 0.142 
0.4 1.0 0.129 
0.5 1.0 0.141 
303 
 
0.6 1.0 0.146 
0.0 2.0 0.073 
0.1 2.0 0.112 
0.2 2.0 0.135 
0.3 2.0 0.151 
0.4 2.0 0.165 
0.5 2.0 0.164 





Table B.3.19. Dataset for time-dependency HbA-AEH adduct of VZHE-039 in HbA 
solution. 
T [VZHE-039]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.03 0.026 0.005 
0.05 0.026 0.010 
0.10 0.026 0.009 
0.15 0.026 0.008 
0.20 0.026 0.010 
0.25 0.026 0.007 
0.30 0.026 0.008 
0.35 0.026 0.007 
0.40 0.026 0.009 
0.03 0.04 0.009 
0.05 0.04 0.013 
0.10 0.04 0.021 
0.15 0.04 0.018 
0.20 0.04 0.018 
0.25 0.04 0.018 
0.30 0.04 0.019 
0.35 0.04 0.017 
0.03 0.06 0.011 
0.05 0.06 0.015 
0.10 0.06 0.018 
0.15 0.06 0.020 
0.20 0.06 0.020 
0.25 0.06 0.021 
0.30 0.06 0.020 
0.35 0.06 0.020 
0.03 0.083 0.011 
0.05 0.083 0.020 
0.10 0.083 0.020 
0.15 0.083 0.025 
0.20 0.083 0.026 
0.25 0.083 0.027 
0.30 0.083 0.027 
0.35 0.083 0.028 
0.40 0.083 0.027 
0.03 0.124 0.018 
305 
 
0.05 0.124 0.031 
0.10 0.124 0.037 
0.15 0.124 0.036 
0.20 0.124 0.040 
0.25 0.124 0.046 
0.30 0.124 0.044 
0.35 0.124 0.046 
0.40 0.124 0.046 
0.03 0.25 0.029 
0.05 0.25 0.046 
0.10 0.25 0.058 
0.15 0.25 0.057 
0.20 0.25 0.061 
0.25 0.25 0.065 
0.30 0.3 0.060 
0.35 0.3 0.068 
0.40 0.3 0.071 
0.03 0.3 0.014 
0.05 0.3 0.056 
0.10 0.3 0.076 
0.15 0.3 0.076 
0.20 0.3 0.081 
0.25 0.3 0.072 
0.30 0.3 0.077 
0.35 0.3 0.083 






























































































































































































































































































































































































































































































































































































































































































































































































































































































8. APPENDIX C 
 
Experimental Data for in-vitro Metabolism of AEH in Human Liver Cytosol (HLC) 
 
Table C.4.1. Concentration-dependent oxidative metabolism of acetaldehyde in 
HLC 
[Acetaldehyde]0 Initial Reaction Rate (vi) SD 
[mM [nmole/min/mg]   
0 0.38 0.003 
0.001 0.64 0.17 
0.002 0.60 0.08 
0.004 0.67 0.04 
0.007 0.88 0.13 
0.014 0.95 0.10 
0.028 1.05 0.07 
0.056 1.32 0.18 
0.113 1.39 0.22 
0.450 1.54 0.17 





Table C.4.2. Concentration-dependent oxidative metabolism of acetaldehyde 
(0.5%DMSO) in HLC 
[Acetaldehyde]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.24 0.008 
0.001 0.25 0.04 
0.002 0.28 0.00 
0.004 0.33 0.05 
0.007 0.45 0.03 
0.014 0.58 0.02 
0.028 0.76 0.01 
0.056 0.84 0.02 
0.11 0.93 0.02 
0.23 0.97 0.02 
0.45 1.03 0.03 
0.90 1.09 0.02 
 
Table C.4.3. Concentration-dependent oxidative metabolism of ethanol in HLC 
[Ethanol]0 Initial Reaction Rate (vi) SD 
[mM [nmole/min/mg]   
0 0.47 0.06 
0.1 0.64 0.12 
0.2 0.68 0.02 
0.4 0.80 0.02 
0.7 1.07 0.03 
1.4 1.35 0.05 
2.8 1.60 0.01 
5.6 1.87 0.05 
11 2.06 0.03 
23 2.26 0.02 
45 2.26 0.15 




Table C.4.4. Concentration-dependent oxidative metabolism of 5-HMF in HLC 
[5-HMF]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.47 0.03 
1.4 0.59 0.02 
2.8 0.67 0.05 
4.2 0.74 0.03 
5.6 0.77 0.03 
11 0.90 0.05 
17 1.01 0.06 
23 1.14 0.05 
45 1.58 0.20 
68 2.08 0.16 
90 3.00 0.32 
 
Table C.4.5. Concentration-dependent oxidative metabolism of 2,5-DMF in HLC 
[2,5-DMF]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.47 0.04 
0.003 0.54 0.01 
0.007 0.66 0.14 
0.013 0.83 0.26 
0.026 0.80 0.05 
0.052 0.95 0.04 
0.104 0.69 0.02 
0.208 0.69 0.18 
0.420 0.53 0.06 
0.830 0.65 0.24 
1.670 0.47 0.01 





Table C.4.6. Concentration-dependent oxidative metabolism of TD-8 in HLC 
[TD-8]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.65 0.08 
0.02 0.70 0.07 
0.04 0.60 0.14 
0.08 0.64 0.10 
0.12 0.58 0.07 
0.15 0.60 0.09 
0.18 0.55 0.06 
0.24 0.54 0.12 
0.30 0.52 0.10 
0.36 0.48 0.09 
0.48 0.41 0.05 
0.60 0.46 0.09 
 
Table C.4.7. Concentration-dependent oxidative metabolism of TD-9 in HLC 
[TD-9]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.62 0.07 
0.004 0.64 0.00 
0.01 0.70 0.03 
0.02 0.58 0.09 
0.03 0.64 0.07 
0.05 0.64 0.20 
0.09 0.54 0.02 
0.18 0.46 0.05 





Table C.4.8. Concentration-dependent oxidative metabolism of TD-7 in HLC 
[TD-7]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.44 0.05 
0.01 0.47 0.04 
0.02 0.51 0.03 
0.04 0.51 0.05 
0.08 0.56 0.07 
0.14 0.59 0.07 
0.18 0.67 0.04 
0.37 0.79 0.09 
 
Table C.4.9. Concentration-dependent oxidative metabolism of VZHE-039 in HLC 
[VZHE-039]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.55 0.02 
0.21 0.53 0.04 
0.38 0.45 0.03 
0.41 0.54 0.00 
0.53 0.47 0.02 





Table C.4.10. Concentration-dependent oxidative metabolism of INN-310 
(0.5%DMSO) in HLC 
[INN-310]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.27 0.01 
0.0003 0.25 0.01 
0.0006 0.26 0.01 
0.001 0.25 0.01 
0.002 0.27 0.01 
0.005 0.26 0.01 
0.009 0.26 0.03 
0.02 0.30 0.01 
0.04 0.33 0.03 
0.08 0.38 0.03 
0.15 0.49 0.03 
0.30 0.75 0.04 
 
Table C.4.11. Concentration-dependent reductive metabolism of 5-HMF in HLC 
[5-HMF]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 2.93 0.37 
0.06 2.20 1.69 
0.12 3.23 2.34 
0.23 2.55 1.00 
0.47 3.76 0.70 
0.94 4.01 0.91 
1.9 4.28 0.83 
3.8 4.76 0.89 
7.5 4.96 1.57 
15 5.55 1.71 
30 6.02 1.27 




Table C.4.12. Concentration-dependent reductive metabolism of 2,5-DMF in HLC 
[2,5-DMF]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 1.84 0.41 
0.003 1.36 1.82 
0.007 1.81 1.83 
0.013 3.64 0.53 
0.026 3.67 0.15 
0.052 3.87 0.75 
0.104 3.20 1.46 
0.208 2.76 3.22 
0.42 5.18 2.83 
0.83 7.65 0.59 
1.67 11.35 1.11 
3.33 13.26 1.15 
 
Table C.4.13. Concentration-dependent reductive metabolism of TD-8 in HLC 
[TD-8]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 1.38 1.01 
0.02 0.42 0.44 
0.04 1.69 0.02 
0.08 0.58 0.31 
0.12 0.63 0.59 
0.15 1.53 0.32 
0.18 1.00 0.09 
0.24 1.43 0.44 
0.30 2.06 0.58 
0.36 0.63 0.53 
0.48 1.29 1.29 





Table C.4.14. Concentration-dependent reductive metabolism of TD-9 in HLC 
[TD-9]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 1.84 0.87 
0.004 1.44 0.37 
0.01 1.92 0.55 
0.02 0.87 0.03 
0.03 0.83 0.20 
0.05 1.03 0.27 
0.09 1.26 0.28 
0.18 1.34 0.62 
0.30 0.93 0.43 
 
Table C.4.15. Concentration-dependent reductive metabolism of TD-7 in HLC 
[TD-7]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 1.40 0.06 
0.001 1.33 0.57 
0.016 0.89 0.07 
0.033 1.03 1.63 
0.066 1.52 0.93 
0.13 1.13 0.77 
0.20 1.20 0.24 
0.26 1.74 1.90 
0.35 2.14 0.36 
0.40 1.77 1.22 
0.46 2.42 1.45 





Table C.4.16. Concentration-dependent reductive metabolism of VZHE-039 in HLC 
[VZHE-039]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 1.52 0.67 
0.019 1.42 0.76 
0.038 2.12 1.13 
0.075 1.33 1.38 
0.15 1.27 0.72 
0.30 1.31 1.46 
0.45 1.96 1.43 
0.6 1.57 1.05 
0.8 2.12 1.43 
0.9 2.23 0.82 
1.0 2.34 1.02 
1.2 1.67 1.06 
 
Table C.4.17. Concentration-dependent reductive metabolism of INN-310 
(0.5%DMSO) in HLC 
[INN-310]0 Initial Reaction Rate (vi) SD 
[mM] [nmole/min/mg]   
0 0.27 0.03 
0.0003 0.28 0.03 
0.0006 0.32 0.04 
0.001 0.26 0.05 
0.002 0.26 0.02 
0.005 0.29 0.05 
0.009 0.24 0.05 
0.02 0.27 0.03 
0.04 0.22 0.04 
0.08 0.19 0.10 
0.15 0.20 0.04 






Experimental Data for in-vitro Disposition of VZHE-039 and 5-HMF in WB 
 
 
Table D.5.1. Dataset for VZHE-039 plasma – t profile. 
 
T [VZHE-039]0 cp 
[hr] [mM] [mM] 
0.09 0.27 0.20 
0.5 0.27 0.21 
1 0.27 0.07 
1.5 0.27 0.08 
2 0.27 0.12 
2.5 0.27 0.09 
3 0.27 0.09 
5 0.27 0.08 
8 0.27 0.07 
15 0.27 0.05 
24 0.27 0.04 
0.09 0.46 0.33 
1.5 0.46 0.16 
2 0.46 0.28 
2.5 0.46 0.26 
3 0.46 0.19 
5 0.46 0.22 
8 0.46 0.11 
12 0.46 0.09 
15 0.46 0.07 
24 0.46 0.06 
0.09 0.92 0.45 
0.5 0.92 0.32 
1 0.92 0.25 
1.5 0.92 0.26 
2 0.92 0.29 
2.5 0.92 0.31 
5 0.92 0.34 
317 
 
8 0.92 0.25 
12 0.92 0.22 
15 0.92 0.16 
24 0.92 0.18 
0.09 1.44 0.39 
0.5 1.44 0.56 
1 1.44 0.32 
1.5 1.44 0.44 
2 1.44 0.57 
3 1.44 0.50 
5 1.44 0.46 
8 1.44 0.42 
12 1.44 0.34 
15 1.44 0.30 
24 1.44 0.22 
0.09 1.96 0.47 
0.5 1.96 0.59 
1 1.96 0.37 
1.5 1.96 0.53 
2 1.96 0.87 
2.5 1.96 0.75 
3 1.96 0.76 
5 1.96 0.67 
8 1.96 0.51 
12 1.96 0.41 
15 1.96 0.31 
24 1.96 0.27 
0.09 2.65 0.45 
0.5 2.65 0.78 
1 2.65 0.75 
1.5 2.65 1.22 
2 2.65 1.02 
2.5 2.65 0.97 
3 2.65 0.93 
5 2.65 0.71 
8 2.65 0.44 
12 2.65 0.46 
15 2.65 0.40 
24 2.65 0.31 
0.09 4.2 0.42 
0.5 4.2 0.62 
318 
 
1 4.2 0.46 
1.5 4.2 0.97 
2 4.2 1.11 
2.5 4.2 1.50 
3 4.2 1.35 
5 4.2 1.24 
8 4.2 1.16 
12 4.2 1.05 
15 4.2 0.76 
24 4.2 0.69 
0.5 7.8 0.24 
1 7.8 1.06 
1.5 7.8 1.48 
2 7.8 1.85 
2.5 7.8 2.85 
3 7.8 3.00 
5 7.8 3.41 
8 7.8 3.08 
12 7.8 2.98 
15 7.8 2.90 







Table D.5.2. Dataset for concentration-dependency HbA and HbA-AEH adduct of 
VZHE-039 in WB. 
[VZHE-039]0 [HbA-AEH Adduct]  [HbA] 
[mM] [mM] [mM] 
0.27 0.19 2.61 
0.46 0.21 2.24 
0.92 0.36 1.86 
1.44 0.76 1.57 
1.96 0.93 1.31 
2.65 1.23 1.45 
4.2 1.57 0.53 
7.8 1.44 Below eLOQ 
 
 
Table D.5.3. Dataset for concentration-dependency HbA and HbA-AEH adduct of 





[mM] [mM] [mM] 
0.5 0.18 1.62 
1 0.40 1.53 
2 0.75 1.25 
3 0.98 1.05 





Table D.5.4. Dataset for time-dependency HbA-AEH adduct of VZHE-039 in WB. 
 
T [VZHE-039]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.09 0.27 0.09 
0.5 0.27 0.13 
1 0.27 0.25 
1.5 0.27 0.21 
2 0.27 0.20 
2.5 0.27 0.13 
3 0.27 0.24 
5 0.27 0.23 
8 0.27 0.23 
12 0.27 0.26 
15 0.27 0.27 
24 0.27 0.19 
0.09 0.46 0.12 
1.5 0.46 0.14 
2 0.46 0.16 
2.5 0.46 0.15 
3 0.46 0.12 
5 0.46 0.14 
8 0.46 0.18 
12 0.46 0.25 
15 0.46 0.25 
24 0.46 0.21 
0.09 0.92 0.09 
0.5 0.92 0.13 
1 0.92 0.24 
1.5 0.92 0.24 
2 0.92 0.20 
2.5 0.92 0.19 
3 0.92 0.35 
5 0.92 0.42 
8 0.92 0.33 
12 0.92 0.41 
15 0.92 0.44 
24 0.92 0.36 
0.09 1.44 0.09 
0.5 1.44 0.17 
321 
 
1 1.44 0.40 
1.5 1.44 0.36 
2 1.44 0.36 
2.5 1.44 0.36 
3 1.44 0.53 
5 1.44 0.75 
8 1.44 0.57 
12 1.44 0.52 
15 1.44 0.55 
24 1.44 0.76 
0.09 1.96 0.09 
0.5 1.96 0.17 
1 1.96 0.30 
1.5 1.96 0.49 
2 1.96 0.60 
2.5 1.96 0.58 
3 1.96 0.74 
5 1.96 0.85 
8 1.96 0.70 
12 1.96 0.70 
15 1.96 0.53 
24 1.96 0.93 
0.09 2.65 0.07 
0.5 2.65 0.24 
1 2.65 0.42 
1.5 2.65 0.36 
2 2.65 0.70 
2.5 2.65 0.94 
3 2.65 1.09 
5 2.65 1.32 
8 2.65 0.99 
12 2.65 1.09 
15 2.65 0.91 
24 2.65 1.23 
0.09 4.2 0.11 
0.5 4.2 0.37 
1 4.2 0.31 
1.5 4.2 0.97 
2 4.2 1.08 
2.5 4.2 1.31 
3 4.2 1.24 
322 
 
5 4.2 1.68 
8 4.2 1.14 
12 4.2 1.45 
15 4.2 1.37 
24 4.2 1.57 
0.09 7.8 0.20 
0.5 7.8 0.26 
1 7.8 0.46 
1.5 7.8 0.79 
2 7.8 1.01 
2.5 7.8 1.14 
3 7.8 1.29 
5 7.8 1.33 
8 7.8 1.03 
12 7.8 1.54 
15 7.8 1.42 
























T [5-HMF]0 [HbA-AEH adduct] 
[hr] [mM] [mM] 
0.5 0.5 0.20 
1 0.5 0.24 
1.5 0.5 0.18 
2 0.5 0.20 
4 0.5 0.09 
0.5 1 0.15 
1 1 0.43 
1.5 1 0.40 
2 1 0.15 
4 1 0.14 
8 1 0.14 
0.5 2 0.39 
1 2 0.54 
1.5 2 0.75 
2 2 0.33 
4 2 0.29 
8 2 0.26 
10 2 0.26 
12 2 0.29 
14.1 2 0.34 
0.1 3 0.21 
0.5 3 0.61 
1 3 0.81 
1.5 3 0.98 
2 3 0.50 
4 3 0.39 
8 3 0.37 
14 3 0.40 
0.5 5 0.68 
1 5 1.04 
1.5 5 1.17 
2 5 0.77 
4 5 0.81 
4 5 0.77 
6 5 1.19 
8 5 0.85 
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